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ABSTRACT OF THE DISSERTATION 
 
Engineering Multifunctional Mesoporous Silica Nanoparticles 
for Stimuli-Responsive Drug Delivery and Bioimaging 
 
by 
 
Chi-An Cheng 
Doctor of Philosophy in Bioengineering 
University of California, Los Angeles, 2020 
Professor Benjamin M. Wu, Co-Chair 
Professor Jeffrey I. Zink, Co-Chair 
 
This dissertation makes contributions to the fields of formulation and delivery of anticancer 
drugs, antibiotics, and imaging agents, primarily focused on engineering mesoporous silica 
nanoparticles (MSNs) for stimuli-responsive drug delivery. The strategies and techniques 
developed in this dissertation will be especially useful for achieving precision medicine or 
personalized medicine, which is defined as the “right drug, right dosage at right timing to right 
patient”. Although various emerging approaches for personalized disease treatment that take 
individual variability into account have been developed, the necessity of delivering the desired 
therapeutics at the desired time to the specific site of the disease and with accurate dosage remains 
a challenge. Here we first review the previously reported stimuli-responsive MSNs controlled by 
supramolecular nanomachines for antibiotic and drug delivery. In the second part of the 
 iii 
dissertation, we report novel MSNs-based nanoparticles engineered to be responsive to 
noninvasive stimuli, such as alternating magnetic field (AMF) or high-intensity focused ultrasound 
(HIFU). AMF-responsive drug delivery demonstrates the controlled therapeutic efficacy for 
pancreatic cancer cells in vitro by adjusting different lengths of AMF exposure time. The HIFU-
responsive MSNs provide a promising platform for magnetic resonance imaging (MRI)-guided 
HIFU (MRgHIFU)-stimulated cargo delivery. The change of T1 reports on the amount of released 
cargo which is imageable by MRI ex vivo. Both AMF-and MRgHIFU-stimulation strategies offer 
the potential for the spatial, temporal, and dosage control of drug delivery. In the last part, we 
develop an approach to achieve both high loading and high release amount of a water-insoluble 
antibiotic clofazimine (CFZ) carried by MSNs by using acetophenone (AP) as a chaperone 
molecule, solving the water insolubility problem faced when treating multidrug-resistant 
tuberculosis. The treatment of Mycobacterium tuberculosis infected macrophages with optimized 
CFZ-loaded MSNs shows good therapeutic efficacy in vitro. Finally, we develop a hollow 
mesoporous silica nanoparticle (HMSN) formulated near infrared (NIR) fluorophore IR-140, to 
realize a novel biocompatible shortwave infrared (SWIR) optical imaging contrast agent for 
bioimaging with a higher tissue penetration depth. The J-aggregates of IR-140 stabilized inside 
HMSNs showed the potential to overcome the stability, toxicity, and brightness challenges faced 
by common SWIR contrast agents. 
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CHAPTER 1 
Introduction 
This introduction consists of two parts. In section 1.1, I provide a background of the field 
adapted and reprinted with permission from a review book chapter (Navnita Kumar, Wei Chen, 
Chi-An Cheng, Tian Deng, Ruining Wang, Jeffrey I. Zink Enzymes 2018, 43, 31–65). Copyright 
2018 Elsevier. Co-author contributions: Kumar, N., Chen, W., Cheng, C. A.; Deng, T., and Wang, 
R. reviewed the literature and drafted the manuscript of this book chapter. Jeffrey I. Zink was the 
P.I.  
In section 1.2, I introduce and give an overview of the research work in Chapter 3 to 6 of my 
dissertation.  
 
1.1 Background of Stimuli-Responsive Nanomachines and Caps for Drug Delivery 
Major objectives in nanomedicine and nanotherapy include: the ability to trap therapeutic 
molecules inside of nano-carriers; carry therapeutics to the site of the disease with no leakage; 
release high local concentrations of drug; release only on demand—either autonomous or external; 
and kill the cancer or an infectious organism. In this section we focus on mesoporous silica 
nanoparticles (MSNs) as the nano-carriers and nanomachines or related capping agents to trap, 
carry and release therapeutic molecules. Localized release of high concentrations of therapeutics 
produce low concentrations when diluted in the total volume of blood and reduce off-target side 
effects. Nanomachines that carry out the stimuli-responsive local release of drugs consist of a solid 
support (the MSN) and moving parts (molecules that undergo large amplitude motion) that respond 
to either external spatial and temporal control, or to internal chemical stimuli specific to the site of 
the disease.  
The MSNs that are the backbone of the drug delivery platforms are the result of two key 
discoveries: the sol–gel synthesis of silica and self-assembling surfactant templates of the pores. 
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Silica, SiO2, is one of the most abundant minerals on earth. A solution-based synthesis was first 
reported in 1847 by Ebelmen who discovered that alkoxysilanes formed an amorphous form of 
silica when exposed to moisture.1 This reaction is now known as a sol–gel synthesis.2 The initially 
formed gel can be dried to produce a xerogel under mild conditions, and organic or biomolecules 
that are dissolved in the initial solution can be trapped in the forming glass.3 Trapped enzymes can 
be stabilized in the amorphous glass, retain their enzymatic reactive properties, and be used as 
biosensors.4,5 
The second key discovery, independently discovered by several groups, was that liquid 
crystalline phases of surfactant molecules can be used as templates to form highly structured pores 
in sol–gel glass. The structure that is primarily discussed in this section involves rod-shaped 
surfactant structures that are encapsulated in glass and upon removal by extraction or calcination 
leave behind empty tubular pores. The most famous example involved a cetylammonium halide 
template (CTAB) that was first reported in the patent literature in 1971, independently reported in 
1990, then again in 1991 by Beck et al. and now known as “MCM41”.6-8 The as-synthesized 
materials were multi-sized aggregates, but further refinements by many groups ultimately led to 
controllable synthesis of both nanofilms9-13 and nanospheres. The latter structures containing 
mesopores (between 2 and 8 nm) are shown in Figure 1.1 and discussed in this section.  
MSNs have remarkable properties. Typical particles discussed in this section are spheres 
about 100nm in diameter with tubular pores about 2.5 nm in diameter. One gram of particles has a 
surface area of about 1000 m2 and a pore volume of about 1 cm3. Because typical anticancer drugs 
have a density of about 1 g/cm3, the carrying capacity can be 100 wt% (although this upper limit 
is rarely achieved because of imperfect molecular packing).  
Are mesostructured silica nanoparticles safe? The answer is generally yes. It is beyond the 
scope of this discussion to go into detail, but it is important to note that “not all silica is created 
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equal”; some forms such as “fumed” silica made at very high temperatures have very different 
properties from those of solution-based sol–gel silica.2,14 Many in vivo studies have been carried 
out with the latter with no adverse effects from the nanoparticles. It is also important to note that 
silica dissolves in water; ocean water contains enough silicic acid that diatoms form bio-
mineralized silica structures. Silica is excreted by mammals in the feces and urine. 
Methods of chemically derivatizing silica surfaces are well established and can be applied to 
MSNs. The molecules to be attached can be added to the initial preparation solution (co-synthesis) 
or after formation of the MSNs (post-synthesis grafting). Pure MSNs aggregate in aqueous solution, 
but chemically attaching charged molecules to the outer surfaces stabilizes colloidal suspensions. 
Fluorescent molecules are attached in order to use the particles for imaging applications; 
biomolecules are attached to actively target cancer cells. 
The diverse capping systems can be broadly categorized into three main groups as seen in 
Figure 1.2. Reusable caps are based on reversible binding constants of a bulky capping molecule. 
Completely reversible caps work on the principle of reversal of affinity of a bulky ring shaped 
molecule threaded on a stalk containing two or more binding sites after stimulation. Irreversible 
caps function via chemical bond cleavage of the bulky capping molecule, thus permanently 
detaching them from the nanomachines. Caps based on supramolecular systems such as rotaxanes 
and pseudorotaxanes that consist of a long chain-like molecule threaded through a cyclic molecule 
are discussed in Chapter 2.  
Stimuli-responsive drug delivery in general, and nanomachines in particular, require a 
biocompatible stimulus and/or power supply. How can the delivery system be activated when the 
particles are deep in the body? Two categories of stimuli are being used: external and autonomous. 
External activation has the desirable property of being under control by the operator; it can be 
turned on or off as desired and it can be localized to the site of the disease. Examples using external 
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activation by alternating magnetic fields (AMFs) and high-intensity focused ultrasound (HIFU) 
will be discussed respectively in Chapter 3 and Chapter 4 of this dissertation. One can be used 
depending on the need— AMFs penetrate tissue better than HIFU without suffering from blockage 
by bone and air; HIFU obtains a more precise spatial focus on the order of 10 mm3. The second 
category, autonomous activation, takes advantage of chemical properties that are as specific as 
possible to the site of the disease. The most widely used properties include pH change (from pH 
7.4 in blood to 6 or below in tumors or lysosomes of cells), redox change (antioxidants such as 
glutathione in the cytosols of cells), enzymes over expressed by tumor cells or antigens, or 
antibodies specific to tumor cells. These subjects have been reviewed extensively.15-24 In Chapter 
2, the design, synthesis and operation of several stimuli-responsive supramolecular caps for 
therapeutic or imaging applications are discussed.25  
 
1.2 Introduction of The Dissertation 
The research included in this dissertation makes the most of the MSN’s preeminent properties 
and focus on biomedical applications, primarily stimuli-responsive drug delivery and bioimaging, 
aiming to provide alternative approaches to achieving precision medicine. We exploited the high 
surface area and large pore volume of MSNs to carry and deliver large amounts of anticancer drugs, 
antibiotics, and imaging agents. We functionalized the surface of MSNs for different purposes 
based on their easy surface functionalization. Of particular importance, MSN’s low toxicity 
allowed us to fearlessly introduce them to bio-systems. The questions I am specifically interested 
in during my PhD research include: (1) how to precisely deliver drugs at the desired time to the 
specific site of the disease and with accurate dosage; (2) how to deliver water-insoluble drugs to 
improve the treatment to specific diseases; (3) how to create a new shortwave infrared (SWIR) 
optical imaging contrast agent that is easy to deliver and use (good stability and water solubility, 
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biocompatible). The following paragraphs provide a brief introduction of the work in each chapter 
that is able to address the above questions.  
In Chapter 3, I discussed the first approach to controlling the drug release location, time, and 
dose.26 We synthesized monodispersed superparamagnetic nanoparticles with a high 
magnetization and high specific loss power that efficiently generates localized heating under an 
AMF. We engineered core@shell nanoparticles that have mesoporous silica shell “drug containers” 
around the magnetic core with a thermos-responsive cap. Released drug dosage as well as killing 
of cancer cells were shown controllable by the AMF exposure time. On the basis of the inherent 
nature of AMF, the AMF-stimulated drug delivery offers the potential to noninvasively and 
precisely control the location, time and dosage of the released drugs, avoiding the risk of 
overheating the surrounding tissues. 
In Chapter 4, I discussed the second approach that used magnetic resonance imaging-guided 
high-intensity focused ultrasound (MRgHIFU) to precisely control the drug release location, time, 
and dose.27 Compared to AMF, HIFU has a more precise energy-focusing ability which may be 
favored to treat rather delicate tissue. We engineered MSNs with a widely used polymer, 
polyethylene glycol (PEG), which we found to be ultrasound-sensitive. Via the guidance of MRI, 
the cargo release was shown pinpointed at the HIFU focal point in three-dimensional space. Cargo 
released amount and the correlated MRI contrast change were shown controllable by the HIFU 
stimulation time. This technology was demonstrated ex vivo, opening up an opportunity for future 
image-guided theranostic applications. 
In Chapter 5, I presented a “chaperone-assisted” delivery strategy to approach the problem of 
water-insoluble drug delivery.28 Acetophenone (AP) was found as the promising chaperone that 
helped improve both loading and release of clofazimine (CFZ), an antibiotic used to treat 
tuberculosis, using MSNs.28 The antibacterial effect to the intracellular M. tuberculosis using this 
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delivery strategy further validate their potential use in biomedical applications. This is the first 
work that examines an appropriate chaperone for CFZ and to actually integrate the strategy with 
nanoparticles. This novel “chaperone-assisted” delivery strategy could also be applied to other 
hydrophobic drugs with their suitable loading solvents (chaperone), broadening the type of 
diseases to be treated with this approach. 
In Chapter 6, I presented a design of a new SWIR optical imaging contrast agent that fulfilled 
the need of good stability, good water solubility as well as biocompatibility.29 We employed the 
photophysical consequences including bathochromically-shifted absorption and emission spectra 
caused by J-aggregation to reach SWIR region, a compelling region of the electromagnetic 
spectrum. The J-aggregates of a near infrared (NIR) fluorophore IR-140 inside PEG conjugated 
hollow mesoporous silica nanoparticles (HMSNs-PEG) are stable for multiple weeks in phosphate-
buffered saline and enable high resolution imaging in vivo with 980 nm excitation. The use of this 
new SWIR optical imaging contrast agent has the potential to overcome the stability, toxicity, and 
brightness challenges faced by normal SWIR contrast agents. 
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1.3 Figures 
 
 
Figure 1.1. TEM images of (A) typical mesoporous silica nanoparticles, (B) large pore silica nanoparticles, 
and (C) core@shell nanoparticles. 
 
 
 
 
Figure 1.2. Sketch of the three major modes of operation of pore uncapping. (1) Reusable valve where a 
bulky cyclic molecule has a binding constant to the attached thread-like “stalk” that decreases when 
stimulated. (2) Reversible valve where the bulky cyclic molecule has a binding constant at a position close 
to the pore opening that decreases allowing it to slide away from the pore opening but not leave the stalk. 
(3) A bulky molecule is chemically bonded to the pore opening and the bond is broken when stimulated. 
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CHAPTER 2 
Supramolecular Nanomachines as Stimuli-Responsive 
Gatekeepers on Mesoporous Silica Nanoparticles for 
Antibiotic and Cancer Drug Delivery 
This chapter of the dissertation was adapted and reprinted with permission from Chi-An Cheng, 
Tian Deng, Fang-Chu Lin, Yao Cai, Jeffrey I. Zink Theranostics 2019, 9, 3341–3364. Copyright 
2019 Ivyspring. Co-author contributions: Cheng C. A., Deng T., Lin F. C. and Cai Y. reviewed the 
literature and drafted the manuscript of this review article. Jeffrey I. Zink was the P.I. 
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2.1 Abstract 
Major objectives in nanomedicine and nanotherapy include the ability to trap therapeutic 
molecules inside of nano-carriers, carry therapeutics to the site of the disease with no leakage, 
release high local concentrations of drug, release only on demand – either autonomous or external, 
and kill the cancer or an infectious organism. This review will focus on mesoporous silica 
nanoparticle carriers with a large internal pore volume suitable for carrying anticancer and 
antibiotic drugs, and supramolecular components that function as caps that can both trap and 
release the drugs on-command. 
Caps that are especially relevant to this review are rotaxanes and pseudorotaxanes that consist 
of a long chain-like molecule threaded through a cyclic molecule. Under certain conditions 
discussed throughout this review, the cyclic molecule can be attracted to one end of the rotaxane 
and in the presence of a stimulus can slide to the other end. When the thread is attached near the 
pore opening on MSNs, the sliding cyclic molecule can block the pore when it is near the particle 
or open it when it slides away. 
The design, synthesis and operation of supramolecular systems that act as stimuli-responsive 
pore capping devices that trap and release molecules for therapeutic or imaging applications are 
discussed. Uncapping can either be irreversible because the cap comes off, or irreversable when 
the cyclic molecule is prevented from sliding off by a steric barrier. In the latter case the amount 
of cargo released (the dose) can be controlled. These nanomachines act as valves. 
Examples of supramolecular systems stimulated by chemical signals (pH, redox, enzymes, 
antibodies) or by external physical signals (light, heat, magnetism, ultrasound) are presented. 
Many of the systems have been studied in vitro proving that they are taken up by cancer cells and 
release drugs and kill the cells when stimulated. Some have been studied in mouse models; after 
IV injection they shrink tumors or kill intracellular pathogens after stimulation. Supramolecular 
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constructs offer fascinating, highly controllable and biologically compatible platforms for drug 
delivery. 
 
2.2 Introduction 
Supramolecular constructs on mesoporous silica nanoparticles (MSNs) for drug delivery, the 
subject of this review, resulted from the convergence of two fields: sol-gel synthesis of metal oxide 
solids,1 and organic syntheses of supramolecular rotaxanes and pseudorotaxanes.2 The primary 
current goal is to use porous sol-gel nanomaterials to carry cargo molecules such as drugs, and 
supramolecular constructs to hold the cargo in place until stimulated to release it on command. 
Success in this venture would result in the decrease in off-target effects of the drugs by carrying 
them with no leakage to the site of the disease, and releasing high local concentrations of them 
where and when desired.  
 Sol-gel chemistry had a resurgence in popularity a decade ago because it is a solution-based 
synthesis for making metal oxide solids. Silica (silicon dioxide) was one of the favorites because 
of its optical transparency, the ability to synthesize the glass around organic and biomolecules 
(including enzymes),3-6 the ability to use molds to make monoliths in desired shapes, and the ability 
to synthesize films7-9 fibers and nanoparticles in amazing varieties of shapes and sizes. 
 Especially interesting was the syntheses of glass around liquid crystalline phases of surfactant 
molecules to template mesoporous glass. After the hydrolysis and condensation of the precursor 
molecules tetraalkoxysilanes around rod-shaped two-dimensional hexagonal phases of 
cetyltammonium chloride, the templating surfactant was removed by solvent extraction or 
calcination to make silica materials with uniform sized and well-ordered pores. This procedure 
was patented and the material named MSM-41 even though the same material had been patented 
16 years earlier10 and rediscovered prior to the second patent. Further research led to controllable 
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synthesis of nanospheres. Typical MSNs discussed in this review are spheres about 100 nm in 
diameter with tubular pores about 2.5 nm in diameter. The size of supramolecular nanomachines 
should be comparable to that of the pores of MSNs in order to trap the cargo inside. The majority 
of supramolecular nanomachines discussed in this article are capable of capping pores of this size 
(2.5 nm). The biocompatibility of these materials has been reviewed11,12 and many examples of in 
vitro and in vivo studies are shown in this review (Tables 2.1 and 2.2). One gram of particles has 
a surface area of about 1000 m2 and a pore volume of about 1 cm3. Because typical anticancer 
drugs have a density of about 1g/cm3, the carrying capacity can be 100 wt% (although this upper 
limit is rarely achieved because of imperfect molecular packing). 
 During the same period, supramolecular organic molecule-based structures were being 
synthesized. Especially relevant to this review are the now famous rotaxanes consisting of a long 
chain-like molecule threaded through a cyclic molecule (known as a pseudo-rotaxane).2 When 
large “blocking” molecules were attached to the ends of the chain, the cyclic molecule could not 
slide off and was held in place by “mechanical bonds”. Under certain conditions discussed 
throughout this review, the cyclic molecule could be attracted to one end of the rotaxane and in the 
presence of a stimulus could slide to the other end. The bonding of one end of this organic structure 
to mesoporous sol-gel glass was the key to unlock and open the door to an amazing variety of 
drug-delivery vehicles. 
 The ground-breaking paper that reported the system is shown in Figure 2.1A.13 A thread 
containing a dioxynaphthalene was attached to a silica surface and a cyclic ring molecule 
containing two bipyridinium units was threaded on to it. Chemical reduction of the ring weakened 
the attraction to the thread thus releasing the ring. Oxidation caused it to re-attach, and the 
threading/dethreading was monitored by the quenching and reappearance of the naphthalene 
fluorescence. This rotaxane system worked on the solid support. 
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 The next advance was the attachment of the organic component to the regions around the pore 
openings on silica particles (Figure 2.1B).14 Ir(PPY)3 was chosen as the cargo molecule because 
it is brightly fluorescent and stable in the presence of the oxidizing and reducing agents required 
to trigger the trapping and release. When the paraquat was attracted to the dioxynapthalene near 
the pore opening, the cargo molecules were trapped in the pore. When the reducing agent CNBH3- 
was added, the pseudorotaxane disassembled releasing the fluorophore into the solution. The 
fluorescence of the naphthalene component that had been partially quenched by the paraquat 
increased in intensity. This supramolecular nanovalve is an example of a molecular machine 
consisting of a solid framework with movable parts capable of doing work. 
 Continuing studies further refined and enhanced the new nanomachine. A more complicated 
stalk containing two different binding sites for the paraquat enabled the system to be switched back 
and forth as a result of sequential oxidation and reduction steps (Figure 2.1C).15 One end of the 
stalk was attached to the pore openings on the silica and a bulky group was attached on the other 
end to prevent escape of the ring. This rotaxane was the first example of a truly reversible 
nanovalve. The positioning of the rotaxane on the particle was refined,16 and the system was 
reconfigured such that it could be stimulated by light energy via a photoredox transducers.17,18  
The focus of these pioneering studies was to prove that the rotaxane actually moved when 
attached to a silica surface, and then to prove that it could actually trap molecules in pores and 
release them on command. When it became clear that the supramolecular concept of a controllable 
cap on a pore was a reality, attention turned to potential applications. A challenging one was to 
improve on nanomaterials as drug delivery vehicles. Liposomes were being used, but drug release 
from them was not controllable. Rotaxane caps are, but they only operated in non-aqueous media. 
Attention turned to water-based supramolecular systems, and the results of those investigations, 
including operation in vitro and in vivo, are described in this review and summarized in Table 2.1 
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and 2.2, respectively. 
 
2.3 Supramolecular Nanovalves for Stimuli Responsive Cargo Delivery 
Macrocyclic molecules such as cucurbit[n]urils (n=5-10, CB[n]), cyclodextrins (CDs), crown 
ethers, and pillararenes tend to form inclusion complexes with guests and can be dissociated 
reversibly or irreversibly in response to external stimuli in aqueous solution. Therefore, these 
families of polymacrocycles have been used as the biologically friendly rings on the nanovalves 
for drug delivery applications.19 In this section, two categories of supramolecular capping systems 
will be discussed based on their reversibility of capping and uncapping. First, pseudorotaxane 
nanovalves are discussed. In the closed position the cyclic molecules are on a binding site on the 
stalks that is close to the pore openings. Upon activation they slide away from and off of the stalk. 
The system is reusable because the cyclic molecules can be rethreaded, but they are irreversible 
because in biological conditions the cyclic molecules diffuse away from the particles and have 
such low concentrations that the rate of rebinding is very low. Next, reversible rotaxane nanovalves 
are discussed. These nanovalves, in contrast, are reversible because a bulky group at the end of the 
stalk prevents the cyclic molecules from leaving the stalk. At the end of this section, we will also 
describe “inactive supramolecular systems”. Different from the pseudorotaxane and rotaxane 
nanovalves, the active parts of this inactive system are not the supramolecular inclusion complexes, 
but bond breaking between the bulky inclusion complexes and the nanoparticles occurs. 
2.3.1 Irreversible Pseudorotaxane Based Nanovalves 
2.3.1.1 Cucurbit[n]urils 
CB[n] are pumpkin-shaped cyclic methylene-bridged glycoluril oligomers that were named 
cucurbituril because of their resemblance to pumpkins, the most prominent member of the 
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cucurbitaceae plant family.20,21 CB[n] analogues have a common depth (9.1 Å), but their widths 
and volumes vary. Their shape of the narrower portals to the entry with the wider cavity produces 
significant steric barriers to guest association and dissociation.22 To have biological applications, 
water solubility is an essential property. The three members of the cucurbiturils CB[5], CB[6], and 
CB[7] possess modest solubility in water. Among these CB[n] analogues, CB[6] was the first and 
the most widely studied cucurbituril, with greater than a one hundred year history.  
CB[6] Rings and Bisammonium Stalks  
Angelos et al. synthesized pseudorotaxanes consisting of CB[6] rings and bisammonium 
stalks bonded to mesoporous silica nanoparticles (MSNs) (Figure 2.2).23 Alkyne-functionalized 
MSNs were synthesized and the particles were loaded with rhodamine B (RhB) cargo molecules 
by soaking the MSNs in a RhB solution (0.5 mM) for 5 h at room temperature. Then an excess of 
CB[6] was added to the above mixture and thus capping the pore. The release of RhB was carried 
out by raising the pH. The binding of CB[6] with the bisammonium stalks is pH-dependent; at 
neutral and acidic pH the CB[6] rings encircle the stalks tightly and thus block the pores. At basic 
pH, deprotonation of the stalks switch off the ion-dipole interactions between the CB[6] rings and 
the stalks resulting in dethreading of CB[6]. The subsequent release of the RhB cargo was 
monitored as a function of time by fluorescence spectroscopy.   
CB[6] Rings and Dialkyl-4,4-bipyridinium (Viologen) Stalks 
Khashab et al. designed another pH-controlled CB[6] - based pseudorotaxane nanoparticle 
system.24 In this case, dialkyl-4,4-bipyridinium (viologen) dicationic guests form highly stable 
inclusion complexes with CB[6] hosts, giving rise to a well-known [2]pseudorotaxane (Figure 
2.3). The internal cavity of CB[6] forms strong complexes with the alkyl chains in the stalk by 
means of hydrophobic interactions and electrostatic interactions between the positive charge on 
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viologen and carbonyl oxygens on CB[6]. Under acidic conditions (pH 4), the carboxylate end 
group becomes protonated attracting the CB[6] macrocycle away from the pore towards the end 
of the stalk and thus releases the cargo.  
CB[6] Rings and N-(6-aminohexyl) Aminomethyltriethoxysilane Stalks 
The CB[6] valve can be stimulated by means other than pH. Thomas et al. expanded the use 
of CB[6] by constructing a thermosensitive nanovalve that is operable by oscillating magnetic 
fields (OMFs) (Figure 2.4).25 This system was also the first study exploring the possibility of 
OMF-triggered cargo release. The carrier, a core-shell nanoparticle with a superparamagnetic iron 
oxide core and a mesoporous silica shell, was synthesized by phase-transferring the iron oxide 
nanoparticle into the water phase and forming an outer silica shell. The resulted core-shell MSN 
was then grafted with N-(6-aminohexyl) aminomethyltriethoxysilane (stalk) by refluxing the 
nanoparticles with the stalks in toluene overnight. RhB and doxorubicin (DOX) were used as the 
cargos. The loading of the cargo was done by soaking the stalk-mechanized core-shell MSNs in 
RhB or DOX solution overnight. Finally, the cargo-loaded nanoparticles were capped with CB[6] 
rings and the whole system was ready to use. The hydrophobic cavity of CB[6] encircles the alkyl 
chain of the stalk through non-covalent London force, ion-dipole interactions and hydrogen 
bonding. The binding constant between CB[6] ring and the stalk decrease at high temperature, thus 
slipping off the cap and allowing the cargo to diffuse out. The authors not only demonstrated the 
release of RhB and DOX under OMFs, but they also showed that internal heat generated from the 
iron oxide core and not bulk heating actuated the CB[6]/stalk pseudorotaxane complex. 
The thermo-sensitive valve-controlled particles were taken up by MDA-MB-231 breast 
cancer cells and released DOX on-command in the cells. After being taken up by the cells, the 
mechanized nanoparticles showed minimal DOX release. Upon exposure to OMFs, the local 
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heating generated from the superparamagnetic core initiated the release of DOX from the silica 
pores and induced cell apoptosis. 
Croissant et al. demonstrated that this thermo-sensitive nanovalve was operable by 
plasmonic heating (Figure 2.5).26 The authors developed a novel one-pot method to synthesize the 
carrier, a core/shell structure with a 20 nm gold core and a 150 nm mesoporous silica shell 
(designated as Au@MSN). In this method, the authors used autoreduction of tetrachloroaurate ions 
in the presence of cetyltrimethylammonium bromide (CTAB), which is the template of mesopore 
formation. The Au@MSNs were mechanized with the stalks, loaded with RhB cargos, and finally 
capped with CB[6] rings. The nanovalves were activated through the localized heat generated from 
plasmonic heating of the Au core. Similar to the magnetic heating, the local temperature rise is 
useful for spatially controlled drug delivery. 
CB[7] Rings and Cinnamamide Stalks 
Another CB[n] analogue, CB[7], was found to possess a suitable cavity and form stable host-
guest complexes with trans-cinnamamide derivatives.20,27,28 This CB[7]-cinnamamide complex is 
responsive to UV light (300 nm).29 After UV irradiation, a trans- to cis- conformational change of 
cinnamamide is induced, leading to dissociation caused by a change in the steric hindrance. 
Utilizing this property, CB[7]-cinnamamide pseudorotaxane has been developed as a light-
switchable supramolecular nanovalve on MSNs [30]. The outer surface of the MSNs was first 
functionalized with 3-aminopropyl groups. Amino modified nanoparticles were reacted with 
cinnamoyl chloride, and then the pores of the functionalized MSNs were loaded with RhB. Finally, 
pores were capped with CB[7], which forms stable inclusion complexes with the grafted 
cinnamamide moieties. The authors showed that 300 nm UV light induced the release of the 
entrapped RhB due to the trans- to cis- conformational change of cinnamamide which dethreaded 
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the inclusion complex. The authors also showed that by using pulsed UV irradiation, a “ladder” 
controlled-release profile of RhB could be achieved, which could potentially control the dose of 
the released drugs for further applications.  
2.3.1.2 Cyclodextrins 
a-CD Rings and Anilinoalkane Stalks 
Alpha cyclodextrin (a-CD) molecules have been shown to have strong binding for benzene 
and benzene derivatives. The binding affinity between a-CD and the anilinoalkane group 
decreases after protonation of the aniline when the pH is lowered causing dissociation to occur.  
Du and coworkers31 designed a pH-responsive nanovalve based on a-CD and anilinoalkane stalks 
on hollow MSNs (Figure 2.6). Three different linkers were attached on the particles’ surfaces and 
the cargo, fluorescent Hoechst 33342, was loaded into pores. a-CD was added to MSN as the 
capping agent. To optimize the length of the linker control of the pore openings, N-
phenylaminomethyltriethoxysilane (PhAMTES) and N-phenylaminopropyltrimethoxysilane 
(PhAPTMS) were both tested. The amine group on PhAMTES was one carbon from silica, 
whereas that of PhAPTMS was three carbons away. To tune the trigger pH that opened the 
nanovalves, p-anisidine with higher pKa than that of aniline was linked to 3-
iodopropyltrimethoxysiliane (IPTMS) and used as the third linker. The release profiles of the three 
nanovalves were obtained by monitoring the emission intensity of cargos in aqueous solution after 
acidification. The trigger pH is governed by the pKa of aniline nitrogen: the release profiles of the 
three nanovalves were similar if triggered by pH 3.5 or 5, but only the nanovalve with IPTMS can 
be triggered at biorelevant pH 6. This nanovalve was an early example of a pH controlled 
pseudorotaxane nanovalve system in aqueous solution, and the study systematically explored the 
effects of stalk length and pH conditions on the cargo release profiles. 
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Dong and coworkers32 studied the effects of polymer coatings around MSNs on the aniline 
based pseudorotaxane nanovalves’ properties. Surface coatings of low molecular weight 
polyethylene imine (PEI)  carry and protect siRNA, and it was of interest to determine if the 
nanovalves would function properly for drug delivery underneath such a coating. For the initial 
study, 1.8 kDa PEI was coated by electrostatic interaction and hydrogen bonding on 120 nm MSNs 
with pH sensitive nanovalves that open at pH 3.5. The second model consists of polyethylene 
imine-polyethylene glycol (PEI-PEG)-coated 50 nm MSNs. The release profiles of fully 
assembled MSNs with both polymer coating and nanovalves were similar to those of MSNs with 
only nanovalves, which indicated that the polymer coating did not stop cargo release.  
Guardado-Alvarez and coworkers33 reported a light responsive nanovalve based on a-CD 
on a stalk containing an aniline derivative and a photoacid, 6,8-dihydroxy-1,3-pyrenedisulfonic 
acid (Figure 2.7). The latter was covalently bonded to an MSN’s surface next to a pH responsive 
nanovalve, and when it was photoexcited at 408 nm, it transferred protons to adjacent stalks. 
Protonation of the aniline nitrogen caused the a-CD to dissociate due to decreased binding 
affinity. Propidium iodide (PI) was used as the cargo and was monitored by fluorescence intensity 
excited at 448 nm. The release profile showed that there was little premature release at neutral pH, 
and an increase in florescence intensity in solution after irradiation. The pH of the bulk solution 
stayed neutral but the local pH on MSN surface became acidic. No release was observed when the 
solution surrounding the MSN was buffered at pH 8 because the buffer prevented acidification. In 
addition, no release was observed when the system was irradiated at 514 nm, a wavelength that 
was not absorbed by the photoacid. By turning on and off the pump laser, the amount of release 
was controllable.  
Hwang et al. further refined the pH-responsive aniline/a-CD inclusion complex toward in 
vitro and in vivo applications by attaching a targeting protein, transferrin (Tf), to the surface of the 
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particle (Figure 2.8).34 It was important to determine if the valve would still operate under a protein 
coating and if the system would actively target receptors on cancer cells. The authors put 
fluorescent imaging molecules in the pores and targeting proteins and pH-sensitive aniline/a-CD 
nanovalves on the same MSN. At neutral pH, the pseudorotaxane was stable and able to seal cargo 
inside the pores of MSNs. However, the binding constant between the stalk and a-CD decreased 
when the phenyl amine was protonated (pKa ≈ 6) in acidic environment, and thus dethreaded the 
a-CD and released the cargo. Because transferrin was also bonded onto the nanoparticles, the 
authors first optimized the relative surface coverages of the nanovalves and transferrin in order be 
able to deliver the maximum amount of cargo controlled by the valves and also obtain the 
maximum amount of cell targeting with the transferrin. Dox was used as the anticancer drug for 
both in vitro and in vivo studies. 
 In vitro testing with human pancreatic cancer cells (MiaPaCa-2) showed an enhanced 
delivery of Dox and cell killing effect. The in vivo study was done using SCID mice with 
xenografts of MiaPaCa-2. Animals were treated by IV injection with saline solution, free Dox, 
unloaded nanovalve-modified MSNs, nanovalve-modified MSNs loaded with Dox, and Tf-
nanovalve-modified MSNs loaded with Dox. The average body weights of those treated mice 
without DOX were unchanged. The results of the hematology and serology examinations also 
showed the safety of these nanoparticles to the mice. The tumors in the control group and unloaded 
nanovalve-modified MSN group kept growing. However, significant tumor growth inhibition was 
found in the mice treated with Dox-loaded nanovalve-modified MSNs, showing the effective 
delivery of Dox by the nanoparticles inside the tumor. There was almost no difference in growth 
inhibition between targeted and untargeted particles, which may be explained by a protein corona 
that blocks the transferrin protein from being sensed by the Tf receptors of cancer cells.35  
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β-CD Rings and Benzimidazole Stalks 
 Xue, et al.36 reported a different pH responsive pseudorotaxane nanovalve based on a 
benzimidazole stalk and a β-cyclodextrin (β-CD) ring, and studied its autonomous drug release in 
vitro (Figure 2.9). A series of benzimidazole derivates were tested, and methyl-1H-benzimidazole 
(MBI) was chosen as the stalk because of the pH range for protonation. It forms noncovalent 
bonding interactions with β-CD at pH 7.4, and protonates at lower pH (pH 6 or less) leading to 
weaker binding and release β-CD. THP-1 and KB-31 cell lines were chosen for in vitro study. 
After MBI was attached on the MSN surface, cargo was loaded followed by β-CD capping. 
Hoechst dye was first used to verify the delivery performance, and it showed little premature 
release at pH 7 and rapid release at pH 6 and lower. Then DOX was loaded for in vitro study. The 
release of  DOX was slower compared to that of the dye and incomplete due to electrostatic 
interactions between the positively charged DOX and the negatively charged pore walls of the 
MSNs. To mitigate these charge effects, positively charged ammonium groups were co-condensed 
on the MSN, and rapid triggered release was observed. This system was tested in cell culture media 
to study the biological influence on the delivery system and it was fully functional under culture 
media conditions.  
 Finally, the action of the MSNs were studied in vitro. FITC-labeled MSN was first used to 
demonstrate that MSN was taken up by cells in acidic lysosomes. Using confocal microscopy, it 
was shown that more than 80% FITC-labeled MSN was colocalized with TRITC-labeled anti-
LAMP-1 antibody labeled lysosomes in both cell lines. Then the release of Hoechst dye was 
studied in both cell lines. At 1 and 3 hours there was no release, but after 6 h, acidification caused 
the dye to be released to the nuclei of both THP-1 and KB-31. In the NH4Cl treated cells, where 
the pH of lysosomes was increased to pH 6, the Hoechst staining was not found in nuclei. The 
release of DOX was studied in KB-31. After taken up by cell, the MSNs released DOX and led to 
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apoptotic cell death. However, in the NH4Cl treated cells where acidification was suppressed, little 
cell death was observed.  
Pseudorotoxane Nanovalves for Treatment of Infectious Diseases 
 Two of the pH -activated cyclodextrin capped nanovalves described above, the one with 
the anilinoalkane stalk and the other with the benzimidazole stalk, were used to treat intracellular 
bacterial infectious disease. Mononuclear phagocytes, primarily monocytes and tissue 
macrophages, are known as professional phagocytes because of their reputation for avidly 
ingesting and killing bacteria.  However, one class of pathogens, known as intracellular parasites, 
intentionally induce their uptake by macrophages with the aim of hijacking host cell machinery 
towards their own end – survival and intracellular replication. The two pseudorotaxane nanovalves 
were used to kill Francisella tularensis (Ft), the agent of tularemia. This bacterium is referred to 
by the US government as a Tier 1 Select Agent because of especially high concern that they may 
be intentionally employed in a bioterrorist attack.  
 Li et al.37 optimized pH-responsive nanovalves functionalized MSN to deliver moxifloxacin 
(MXF) for Ft infection treatment both in vitro and in vivo (Figure 2.10). Two pH-responsive 
nanovalves were chosen: one consisted of anilinoalkane (ANA) stalks and a-CD caps, and the 
other was composed of 1-methyl-1H-benzimidazole (MBI) and β-CD caps. Both stalks become 
protonated at pH 6 and lower, thus the caps dissociated and cargo released in lysosomes. The 
MSNs were optimized in the following aspects: charge of pore wall, efficiency of stalk attachment, 
concentration and pH of loading solution, loading duration and MSN washing after loading.  
 MSN uptake by macrophages was first tested in vitro. A large amount of uptaken rhodamine-
labeled MSN was observed in both the monocyte-derived macrophages and the differentiated 
THP-1 cells. To investigate the efficacy in killing Ft, MXF loaded MSN with ANA/a-CD (MXF-
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MSN-ANA) or MBI/ β-CD (MXF-MSN-MBI) and control MSN without MXF loading were used 
to treat infected THP-1 for one day. Ft was killed by both MXF-MSN-ANA and MXF-MSN-MBI 
while the bacteria grew with control MSN or no treatment. Compared at the same concentration, 
MXF-MSN-MBI killed more Ft than MXF-MSN-ANA.  
 MXF-MSN-MBI was tested in vivo. Mice were infected with Ft and suffered severe weight 
loss without treatment. However, mice treated with MXF-MSN maintained their weight. Also, 
without treatment, Ft grew rapidly, but intravenously administered MXF-MSN-MBI decreased the 
number of bacteria in lung by 4.0 logs. MXF-MSN-MBI was more effective than 2 to 4 times 
higher dose of free MXF killing Ft in lung.  
β-CD Rings and Azobenzene Derivatives  
Most of the pseudorotaxane nanovalves discussed up to this point were stimulated by pH 
changes that switched stalks from hydrophobic to hydrophilic and thus decreased the binding 
constants to the hydrophobic interiors of cyclodextrins. The pH changes from that of blood to that 
of lysosomes caused autonomous cargo release and the use of transducers such as photoacids 
enable light activation. A different way of releasing cyclodextrin and drugs involves molecular 
geometry changes and accompanying polarity changes. 
Azobenzene derivatives undergo photo-induced reversible trans-cis isomerization when the 
molecules are irradiated with UV or blue light.38-40 Azobenzene derivatives can be grafted on the 
interior pore walls of MSNs and the back-and-forth wagging motion in the pores can trap and 
release cargo molecules. This type of nanomachine has been called an impeller.41-44 Azobenzene 
derivatives can also be grafted on the outside surface of MSNs and bind cyclodextrin when in the 
trans- conformation and dethread in the cis- conformation, serving as photosensitive gatekeepers, 
to control and regulate cargo release from MSNs. For example, Ferris et al. attached two types of  
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azobenzene derivatives prepared from 4-(3-triethoxysilylpropylureido)azobenzene and (E)-4-((4-
(benzylcarbamoyl)phenyl)diazenyl) benzoic acid to the outer surface of MSNs (Figure 2.11).45 
Those azobenzene derivatives bind β-CD in their trans- form and then the β-CD caps were released 
when the azobenzene derivatives photoisomerize to the cis- conformation after irradiation with 
UV light. The authors showed that RhB was released after the UV light actuation. 
Compared with UV light, red and near-infrared (NIR) light in the therapeutic window (600-
1000 nm) are preferable for biomedical applications due to better tissue penetrability and decreased 
photodamage to biological systems. Tetra-ortho-methoxy-substituted azobenzene (mAzo) can 
undergo trans-to-cis isomerization when irradiated with red light. Wang et al. attached mAzo and 
β-CD on the surface of MSNs as the capping systems to control release of DOX by using red light 
(625 nm) (Figure 2.12).46 To show the photo-responsiveness of this capping systems in deep tissue, 
drug release was investigated by placing a piece of pork tissue (2 mm thick) between the light 
source and the sample. Although a lower release rate and amount were observed compared with 
that without tissue, red light irradiation at low power (60 mW/cm2, 360 min) still induced DOX 
release (23%) after passing through the tissue. 
Electrochemical and Redox Activation of Pseudorotaxane Valves  
Khashab and coworkers47 reported a ferrocene and β-CD/ cucurbit[7]uril (CB7) based 
nanovalve that was responsive to redox and pH changes (Figure 2.13). Ferrocenedicarboxylic acid 
was coupled to amine-functionalized surface of MSN, and RhB dye was loaded as the cargo. 
Then β-CD or CB7 was capped by host-guest interaction. At pH 2, CB7 was bound to protonated 
ferrocenedicarboxylic acid, and when pH increased to 10, ferrocene dianion was formed and the 
binding affinity to CB7 was decreased. This mechanism was supported by NMR spectroscopy and 
cyclic voltammetry. The release profile of CB7 was tested: limited leakage was observed before 
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trigger, and the emission intensity of the released RhB increased immediately after trigger. The β-
CD cap was more sensitive to the electrochemical oxidation trigger and had minimal activation 
from pH modulation.  
2.3.1.3 Calix[n]arenes  
A third type of macrocyclic rings in supramolecular chemistry, in addition to cyclodextrins 
and cucurbit[n]urils, are the calix[n]arenes. They are made up of phenol units linked by methylene 
bridges. Although calix[n]arenes have been incorporated with mesoporous silica materials, only a 
few studies have used calix[n]arenes as stimulus-responsive nanovalves for controlled cargo 
release compared with cyclodextrins and cucurbit[n]urils. Among different analogues of 
calix[n]arenes, sulfonato-calix[n]arenes (designated as SC[n]A) are water-soluble and have been 
reported to be biocompatible.  
Calix[n]arenes Rings and Acetylcholine Stalks 
Yang et al. reported a supramolecular valve based on sulfonatocalix[4]arene (SC[4]A) that 
demonstrated NIR light-triggered cargo release (Figure 2.14).48 Mesoporous silica-coated gold 
nanorods (AuNR@MSNs) were synthesized followed by grafting acetylcholine stalks onto the 
nanoparticles. RhB as a model drug was loaded in the mesopores. SC[4]A was then added to 
encircle the stalks on the surface of AuNR@MSNs via host-guest complexation to form the 
supramolecular switches. Plasmonic heating generated from AuNR cores upon NIR light 
stimulation decreased the SC[4]A ring-stalk binding affinity, and thus dissociated the SC[4]A rings 
from the stalks and released the cargos. The release of RhB was monitored by UV-vis absorption 
spectroscopy. “Ladder” release profile generated by using periodic ON/OFF NIR laser irradiation 
showed the ability to control the dose. 
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2.3.1.4 Crown Ethers 
Crown ethers have been used to construct stable complexes with alkali and transition-metal 
cations via electrostatic interactions.49 The complexes can be perturbed by pH and ultrasonic 
waves,50,51 where the changes in pH may weaken the electrostatic interactions and hydrogen 
bonding, and the gain of energy form ultrasound may lead to the dissociation of metal cations from 
crown ethers. These properties make the crown ether/metal cation complexes candidates for 
supramolecular nanovalves. By conjugating crown ethers onto the pores entry of MSNs, the loaded 
cargos can be entrapped in the presence of capping agents (i.e., metal cations) and be released upon 
triggered by pH and ultrasonic waves. 
Leung et al. developed Fe3O4@SiO2 core−shell nanoparticles capped with crown ethers for 
ultrasound and pH-responsive drug release.52 The core-shell structure was prepared by coating 
Fe3O4 nanoparticles with a mesoporous silica shell using modified hydrothermal sol−gel reactions. 
The mesoporous silica shell was functionalized with APTES and then coupled to dibenzo-crown 
ethers through amide linkages. Then DOX was loaded and the pores of the core−shell nanoparticles 
were capped with Na+ and Cs+ ions through the formation of complexes with the crown ethers on 
the outer surface. DOX controlled release was tested in PBS at pH 4 or pH 7.4. The results showed 
that DOX release was triggered at pH 4 in combination with ultrasound. This is because the pores 
were uncapped by lowering pH in the presence of ultrasound which broke up the interaction 
between the metal cations and crown ether’s ethylene glycol chains. MTT assays confirmed that 
the crown ether/metal cation complexes capped nanoparticles were biocompatible to L929 cells (a 
murine aneuploidy fibrosarcoma cell line). Reasonable cellular uptake of the nanoparticles in L929 
cells was observed from MRI analysis. 
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2.3.1.5 Pillararenes 
Pillarenes are synthetic macrocycles that were first synthesized in 2008 and subsequently 
attracted attention in drug delivery research.53 A supramolecular construct incorporated in an MSN 
based drug delivery system was reported by Sun, et al. in 2013.54 A pyridinium compound that is 
positively charged at neutral pH was attached to MSN surface as a stalk (Figure 2.15). Negatively 
charged carboxylatopillar[5]arene (CP[5]A) was used as a cap and held in place by the electrostatic 
attraction to the stalk. When the pH was decreased below 5, CP[5]A was protonated which 
weakened its interaction with stalk and led to uncapping. Methyl viologen salts can also trigger 
uncapping because of its higher binding affinity with CP[5]A. 
Huang et al. utilized phosphonated pillar[5]arenes (PPA[5]) as capping agents in an MSN 
based drug delivery system.55 Specific ion paring between hydrated phosphonates on PPA[5] and 
quaternary ammoniums on stalks capped the pores tightly. When PPA[5] was protonated, the host-
guest interaction between cap and stalk weakened, leading to cargo release. Competitive binding 
by Zn2+ ions also caused decapping and cargo release. Additionally, when gold nanorods (GNRs) 
were embedded inside MSNs and irradiated with near-infrared (NIR) radiation, the photothermal 
increase in temperature weakened host-guest interaction.  
The PPA[5] gated GNR@MSNs were studied in vitro using human A549 lung carcinoma cell 
line. The empty particles showed no cytotoxicity. When the particles were loaded with DOX, cell 
apoptosis was observed and was increased with the NIR trigger due to the synergistic effect of 
photothermo-chemotherapy. 
2.3.2 Reversible Rotaxane Based Nanovalves 
Rotaxane supramolecular systems that can uncap and recap the pores of MSNs reversibly 
(without loss of the cap from the stalk) are discussed in this section. After assembling the complex 
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formed by nanocap and stalk on the surface of the nanoparticle, the “closed” state of the stalk with 
the region of highest affinity brings the nanocap close enough to the particle surface to prevent 
cargo leakage. The “open” state starts when binding between the nanocap and the stalk is no longer 
favorable, where the nanocap slides along the stalk away from the surface of the nanoparticle until 
reaching an end-terminating stopper group. The objective of putting the end-terminating stopper 
group is to prevent the nanocap from unthreading completely so that the above “closed” and “open” 
states can be switched reversibly. A variation on this theme is to position two binding sites on the 
stalk with the strongest binder nearest the pore opening. When the binding of the cap to the strong 
site is turned off, the ring slides to the weaker binding site and stops. When the strong binding is 
turned on again, the cap slides back. This motif resembles the action of a rotaxane but the blocking 
of cap release is caused by the second binding site and not a physical steric blocking group. 
CB[6] Rings and Trisammonium Stalks 
Angelos et al. have designed a completely reversible valve based on CB[6] and 
trisammonium stalks (Figure 2.16).56 Propidium iodide (PI) cargo was loaded by soaking the stalk-
attached nanoparticles in the PI solution overnight so that the dye molecules can diffuse into the 
empty nanopores. To complete the valve, CB[6] was added to the mixture to form an inclusion 
complex composed of the CB[6] rings and the trisammonium stalks. The beauty of this system is 
that it operates like a “dialed-in” clock system to selectively release the cargo at both low and high 
pH. At neutral pH, the two nitrogen atoms separated by four carbon atoms are protonated, therefore, 
through ion−dipole binding interactions between both portals of the macrocycle, the CB[6] ring is 
pulled down to sit close to and thus block the nanopores. When pH is low (~ 5), the anilinium 
nitrogen atom separated by six carbon atoms from the ammonium nitrogen is protonated thus 
moving the CB[6] ring to the distal hexamethylenediammonium station and releasing PI. The 
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binding constant of  CB[6] is strongest with nitrogens separated by the six carbons. At high pH 
(~10), all three nitrogen atoms on the stalk are deprotonated thus dethreading the CB[6] ring and 
releasing PI. These mechanized nanoparticles are highly dispersible in water, making this system 
a good candidate for the biological applications whose goal is to kill cells at both low and high pH. 
α-CD Rings and Azobenzene Derivatives 
Tarn et al. developed two azobenzene-based rotaxane nanovalves with reversibility in response to 
blue light (403 nm) irradiation (Figure 2.17).57 These nanovalves were synthesized as follows. 
First, p-nitrobenzoic acid was reacted with glucose to give 4,4’-azobenzenecarboxylic acid. Then, 
4,4’-azobenzenecarboxylic acid was reacted with N-hydroxysucciminide to conjugate at one end 
with two adamantane-based molecules of different lengths, respectively. Next, the resulting 
azobenzene-containing molecules were complexed with α-CD to form the α-CD/azobenzene 
pseudorotaxanes. Finally, those pseudorotaxanes of different lengths were attached to 
aminopropyltriethoxysilane (APTES) modified-MSNs, yielding the ready-to-use nanocarriers. It 
is notable that the authors completed all the nanovalve attachment including stalks and nanocaps 
before loading cargos instead of vice versa. The method of loading cargos was by suspending the 
nanovalves in organic solvents under UV light irradiation to destabilize hydrophobic interactions 
between α-CD and the azobenzene moiety. To cap the pores after cargo loading, the particles were 
suspended in water in the dark to allow rebinding of the α-CD to azobenzene. Three fluorescent 
dyes with size between 1 and 2 nm, alizarin red S, PI, and Hoechst 33342, were chosen as the 
cargo molecules. The authors demonstrated that the two stalks of different lengths allowed the 
selective loading and release of those dyes based on the size. The adamantane functional group 
was selected as the stopper for two reasons: it is bulky enough (diameter of 0.5 nm) to prevent α-
CD from unthreading; its binding affinity (binding constants of 100 M−1 [58]) with α-CD is lower 
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than trans-azobenzene with α-CD so that competitive binding is limited. In this way, α-CD will 
either bind trans-azobenzene (“closed” state) or forms a metastable adamantane/α-CD state that 
holds the nanocap away from the pore openings (“open” state) when cis-azobenzene is formed by 
photoexcitation. The reversibility of the designed nanomachines was demonstrated by sequential 
fluorescence spectra. When the near-UV light was turned off, the fluorescence intensity leveled 
off until the stimulus was reapplied.  
2.3.3 Inactive Supramolecular Systems 
In addition to the supramolecular systems discussed above, there are other types of 
mechanisms involving bulky host-guest supramolecules that are not themselves serving as the 
active parts. These types of systems are called “inactive supramolecular systems”.  They typically 
use a bulky inclusion complex with a labile bond linked to the particle. The whole supermolecular 
complex is removed intact by bond cleavage through heat,59 photo-redox,60 or pH61 at a location 
between the inclusion complex and nanoparticles.  
Activation Using Thermal-Sensitive Bonds 
Very recently, Chen et al. developed a β-CD-adamanatane cap held on to the 
superparamagnetic core@silica shell nanoparticles by a thermo labile bond on 4,4′-azobis(4-
cyanovaleric acid) (ACVA).62 This bond was cleaved by the localized heat generated from the 
superparamagnetic core by oscillating magnetic field (OMF) actuation (Figure 2.18). The authors 
first demonstrated that the release amount of fluorescein cargos was adjustable by controlling the 
OMF exposure time. In vitro drug release study was conducted to deliver DOX to PANC-1 cells. 
A positive correlation between the viability of the cells treated with DOX-loaded Mag@MSNs-
AMA-CD and the OMF trigger time showed that dose control was achieved. Cells treated with 
nanoparticles without DOX under 10 min of OMF exposure didn’t show any adverse effect, 
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confirming that the heat generated from OMF interacting with the superparamagnetic core was not 
harmful to the cells. 
Megagates and Supramolecular Amplifiers 
 A unique use of the admantane/β-CD interaction is formation of megagates over the large 
(6.5 nm) pores of SBA-15 silica. Xue, et al. designed and synthesized pH-responsive “weblike” 
megagates to cover the bigger pores with the goal trapping cargo molecules (Figure 2.19).61 Two 
types of megagates, MG-1 and MG-2, were designed to cap and block larger and relatively smaller 
molecules, respectively. The extended structure of MG-1, which has a diameter of about 5.5 nm, 
was synthesized by linking a 1,3,5-triphenylbenzene core to three adamantane arms through 
triethylene glycol chains. MG-1 sufficiently prevents leakage of 4 nm dextran from the 
nanoparticle. To be able to reduce the gap between adamantane moieties for storing a smaller 
fluorescein disodium salt (FDS) cargo, hexaalkyne was chosen to be the core of MG-2 to generate 
a megagate with twice as many adamantane moieties as MG-1. To attach the megagate to the silica, 
ammine-modified β-CD stalks were grafted on the surface of SBA-15 through imine formation. 
Then, the adamantane arms form inclusion complexes with the β-CD and block the pores. FDS 
can diffuse freely out of the pore when a megagate is capped by MG-1, while dextran can only 
escape from the pore when the gate is opened due to the cleavage of imine bonds in the stalks at 
low pH. 
Xue, et al. employed this megagate system to construct an enzyme-encapsulated MSN based 
chemical amplifier (Figure 2.20).63 In this study, the pH-responsive MG-2 enables substrate size-
selectivity and thus controls the substrate access toward the encapsulated porcine liver esterase 
(PLE) in the MSN pores. PLE substrates 4-acetozycinnamic acid (ACA) and 5-carboxy-
fluorescein diacetate (CFDA) were chosen due to their different sizes. The CFDA molecules are 
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too big to pass through the megagate; only the small ACA analytes are able to diffuse in and out 
of the gaps between the adamantane moieties. ACA analytes undergo hydrolysis reactions after 
they interact with the hydrolase enzymes in the pores, generating acetic acid to actuate the 
megagate and allowing CFDA molecules to diffuse into the pore. Hydrolysis of CFDA produces a 
fluorescent product. The catalytic amplification process then occurs due to the subsequent gate 
opening of the neighboring pores resulted from the additional hydrolysis of CFDA, and the process 
is monitored by increase in the fluorescence signal. 
 
2.4 Supramolecular Snap-Tops for Stimuli Responsive Cargo Delivery 
A “snap-top” rotaxane is a supramolecule composed of a cyclic molecule on a stalk and a 
large “stopper” molecule attached to the end of the stalk to keep the cyclic molecule in place. The 
closed system is snapped open when the bulky stopper is removed thus allowing the cyclic 
molecule to move away from the pore. Patel et al. reported an enzyme-responsive snap-top 
nanovalve based on [2]rotaxane and α-CD (Figure 2.21).64 MSNs were first modified with APTES 
to introduce amine groups which were then alkylated with tri(ethylene glycol)monoazide 
monotosylate units. Next, the cargo loading step was performed followed by the incubation with 
α-CD at 5°C for 24 h. At low temperature, α-CD threaded onto the tri(ethylene glycol) chains and 
effectively blocked the nanopores. The azide terminals of the cargo-loaded particles were then 
attached to adamantyl ester stopper molecules through Cu(I)-catalyzed azide-alkyne 
“click”cycloaddition. In this design, porcine liver esterase (PLE) catalyzed hydrolysis of the 
adamantyl ester stopper, allowing α-CD to dethread and release the cargo molecules from the pores. 
RhB was used as a model drug and the result from luminescence spectroscopy showed that 
rhodamine B was released only after adding PLE. 
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Ambrogio et al. reported another snap-top system in which stalks with disulfide bonds were 
encircled by CB[6] or α-CD rings and bulky adamantly groups at the terminal acted as the stoppers 
(Figure 2.22).65 The stalks were grafted onto MSNs through the reaction between azide-terminated 
diethylene glycol monotosylates and amino groups of APTES on the surface of MSNs. Then, 
nanoparticles were loaded with RhB followed by adding either CB[6] or α-CD to thread the stalks. 
The entire snap-top system was completed by click chemistry between the azide group at the end 
of the stalks with propargyl ethers that contained disulfide linkages and bulky adamantly groups 
at the end. The two snap-top systems showed no leakage but released rhodamine B upon the 
addition of dithiothreitol (DTT) and 2-mercaptoethanol (ME) which reduced the disulfide bonds, 
removed the adamantly stoppers, and thus uncapped the pores of the CB[6] or α-CD-capped 
nanoparticles, respectively. 
Another example of supramolecular snap-tops was designed by He et al. (Figure 2.23).66 In 
this design, an alkoxysilane and α-CD was also used as a stalk and a nanocap, then serial peptide 
sequences were attached as the stopper molecule. The stopper, Gly-Phe-Leu-Gly (GFLG), can be 
hydrolyzed by cathepsin B, which is an overexpressed protease in various tumors. Almost 60% 
and 80% of the loaded DOX was released from the nanoparticles in the presence of cathepsin B at 
pH 7.4 and 5.0, respectively. Cervical cancer cells (HeLa) and a normal cell line of African green 
monkey SV40-transformed kidney fibroblast cells (COS7) were used to evaluate the targeting and 
drug release ability of DOX-loaded MSN-GFLGR7RGDS/α-CD nanoparticles. These 
nanoparticles were shown not only to be efficiently taken up by tumor cells via integrins receptor-
mediated targeting, but also can specifically release DOX into tumor cells via enzymatic digestion 
of GFLG peptide.  
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2.5 Nanopistons and Their Use as Size-Selective Caps  
A supramolecular nanopiston can serve as a gate to control cargo release. The piston consists 
of a molecule that moves in or out of a cavity provided by a ring (such as β-CD) that is immobilized 
around the opening of the pores. In this section, combination of a nanopiston with an inactive 
supramolecular system that allows sequential release of small molecules by the first stimulus and 
larger molecules by a second different stimulus is discussed.  
Zhao et al. designed and fabricated a MSN-based nanopiston (Figure 2.24).64 This pH-
mediated dual cargo delivery system consisted of β-CD which is covalently linked around the 
portal of the nanopores of MSNs and a RhB/benzidine compound that is inserted into the cavity 
of β-CD and moves in and out like a piston. It can control the trapping and release of the cargo 
molecules in response to pH changes. At neutral conditions, small cargos are trapped in the pore 
of MSNs and the RhB/benzidine plug blocks the β-CD gate tightly. As the pH value of the system 
decreased from 7 to 4, the protonated RhB/benzidine plug left the cavities of β-CDs and the small 
cargo was released by diffusing through the cavities of β-CD.  
A similar design can be used for dual-cargo delivery that can sequentially deliver two 
different sizes of cargos on-command. It has the potential to achieve combination drug therapy. 
Wang et al. functionalized MSN surfaces with β-CD, which served as a gate to store large Hoechst 
33342 molecules (Figure 2.25).68 The second smaller cargo, p-coumaric acid (CA), was loaded by 
diffusing it through the cavities of the β-CD into the pores of MSNs. Methyl orange (MO) was 
then added into the system to form a complex with the β-CD and plug the β-CD rings. Upon 
lowering the pH to 3.5, the formation constant between β-CD and MO decreased. The removal of 
the protonated MO molecules from the β-CD cavities was followed by the release of the small CA 
cargo while the larger Hoechst 33342 were still blocked by the β-CD rings. Release of Hoechst 
33342 was then triggered by introducing a reducing agent 2-mercaptoethanol that cleaved the 
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disulfide bonds that linked the β-CD rings covalently onto the MSN surfaces. Removal of the β-
CD rings released Hoechst 33342. 
 
2.6 Summary 
In keeping with the theme of this special issue of Theranostics, this review focused on 
supramolecular systems that carry out on-command, stimulated drug delivery. The review 
emphasized the mesoporous silica nanoparticles that have demonstrated efficacy in vitro and in 
vivo. There are of course very many other capping methods in addition to pseudorotaxanes and 
rotaxanes, and also many different types of nanoparticles have been studied.53,69-74 Mesoporous 
silica forms a type of “hard” inorganic particle that is structurally stable for drug delivery.75,76 For 
biomedical applications other important types of hard nanoparticles include those made from 
amorphous silica, gold, iron oxide, quantum dots and nanodiamonds.77-81 Important types of “soft” 
nanomaterials include liposomes (the most successful in biomedical applications to date), 
polymers and dendrimers. Hybrid organic/inorganic particles have also been examined; particles 
made from organosilanes and lipid bilayer-coated silica are examples closely related to those 
discussed in this review. Many innovative capping systems on nanoparticles have also been used 
including thermal- and pH-sensitive polymers, and DNA to name a few. Supramolecular capping 
systems are fascinating, versatile, highly controllable, reversible, and biologically compatible. As 
is the case with other drug delivery systems, it is a long and costly road to clinical trials and 
eventual use in the clinic,82 but all of the above properties make supramolecular capping systems 
together on mesoporous silica nanoparticles worthy of the attention that they are being given. 
Because of the importance of the biomedical applications, imaginative chemists, biologists, 
medical doctors, physicists and engineers will develop innovative new functional and controllable 
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nanomaterials that will eventually advance to the clinic and help mankind. 
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2.8 Figures and Tables 
 
Figure 2.1. (A) A pseudorotaxane on a solid silica support. Reprinted with permission from Ref. 13, 
copyright (2001) Angew. Chemie - Int. Ed. (B) Graphical representations of operation of nanovalves gating 
the pore openings on silica particles. (i) The orifices of the nanopores (diameter 2 nm) are covered with 
pseudorotaxanes (formed between DNPD and CBPQT4+) which trap the luminescent Ir(ppy)3 molecules 
inside the nanopores. (ii) Upon their reduction, the CBPQT2+ bisradical dications are released and allow 
the Ir(ppy)3 to escape. Reprinted with permission from Ref. 14, copyright (2004) J. Am. Chem. Soc. (C) 
Graphical representations of the surface attachment of bistable rotaxanes to silica particles along with a 
cycle for loading and release of guest molecules. Left: The structural formula of the bistable [2]rotaxane 
R4+ and the procedure used for tethering R4+ to the surface of mesoporous silica particles. Right: The 
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proposed mechanism for the operation of the nanovalve. The moving part of the molecular valve is a 
CBPQT4+ ring (blue), which shuttles between a TTF station (green) and a DNP station (red) under redox 
control. The openings of the cylindrical pores on the silica are blocked by the CBPQT4+ ring when the valve 
is closed. Guest molecules (turquoise spheres) are loaded in Step 1 by diffusion into the open pores when 
the CBPQT4+ ring is located on the TTF station. The valve is closed in Step 2 by oxidation of the TTF unit 
to its dication, causing the CBPQT4+ ring to move to the DNP station, which is much closer to the openings 
of the pores. The valve can be opened (Step 3) by adding ascorbic acid to reduce the TTF dication back to 
its neutral state, whereupon the CBPQT4+ ring moves back from the DNP station to be relocated around the 
much more π electron-rich TTF station, releasing the guest molecules in Step 4. The valve is ready for 
recharging (i.e., returning to Step 1). Thus, the valve can be closed and opened reversibly. The silica 
particles are not drawn to scale, and only a few of the ordered pores are shown. Reprinted from Ref. 15, 
copyright (2005) Proc. Natl. Acad. Sci. 
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Figure 2.2. The alkyne-functionalized mesoporous silica nanoparticles MCM-41 are loaded (A→B) with 
rhodamine B (RhB) molecules, and capped (A→B) with CB[6] during the CB[6]-catalyzed alkyne-azide 
1,3-dipolar cycloadditions. RhB molecules are released (B→C) by switching off the ion–dipole interactions 
between the CB[6] rings and the bisammonium stalks by raising the pH and deprotonating the amines. 
Reprinted with permission from Ref. 23, copyright (2008) Angew. Chemie - Int. Ed. 
 
 
 
Figure 2.3. Design and preparation of viologen threads (stalk component) and CB[6] (cap) on MSNs that 
operate under pH-control. Reprinted with permission from Ref. 24, copyright (2009) Chem. Commun. 
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Figure 2.4. Scheme of the synthesis of the mechanized nanoparticles and their operation under oscillating 
magnetic fields (OMFs). (1) Supraparamagnetic nanoparticles are synthetically positioned at the core of 
MSNs; (2) the molecular machine is then attached to the nanoparticle’s surface; (3) the drug is loaded into 
the particle and (4) the pores are capped to complete the system. (5) Drug release is realized using remote 
heating via an OMF. Reprinted with permission from Ref. 25, copyright (2010) J. Am. Chem. Soc. 
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Figure 2.5. External heating of a suspension of Au@MSN@Valve to 60 °C causes dissociation of the CB[6] 
caps from the stalks and release of the cargo molecules from the pores. Reprinted with permission from 
Ref. 26, copyright (2012) J. Am. Chem. Soc. 
 
 
Figure 2.6. Depiction of a cross section of a hollow nanoparticle illustrating the wormlike pores connecting 
the interior to the surrounding solution. The stalks and the α-CD rings that control the pore openings are 
also shown. Reprinted with permission from Ref. 31, copyright (2009) J. Am. Chem. Soc. 
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Figure 2.7. Light activation of a pH nanovalve. A photoacid is attached adjacent to an acid-stimulated 
aniline/a-CD valve. Photoexcitation of the photoacid causes protonation of the stalk and releases the cap 
and cargo. Reprinted with permission from Ref. 33, copyright (2014) Chem. Commun. 
 
 
 
Figure 2.8. Depiction of the fully assembled Tf-nanovalve-modified MSN system. The operation of the 
aniline/a-CD valve was not inhibited by the Tf coating. Reprinted with permission from Ref. 34, copyright 
(2015) Small. 
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Figure 2.9. (A) Steps of stalk synthesis, cargo loading, capping, and release. (B) Cap dissociation from 
protonated stalk after pH decreases below 6. (C) TEM image of the capped MSN. Reprinted with permission 
from Ref. 36, copyright (2010) J. Am. Chem. Soc. 
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Figure 2.10. Moxifloxacin-loaded MSNs functionalized with pH-responsive capping system were uptaken 
into lysosomal compartments in a macrophage. The pH-responsive cap was opened and moxifloxacin was 
released to kill the intracellular Francisella tularensis. Reprinted with permission from Ref. 37, copyright 
(2015) ACS Nano. 
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Figure 2.11. Synthesis of 4-(3-triethoxysilylpropylureido)azobenzene (TSUA)- and (E)-4-((4-
(benzylcarbamoyl)phenyl)diazenyl) benzoic acid (BPDB)-modified MCM-41. Two approaches to the 
operation and function of the azobenzene-modified MCM-41 NPs carrying nanovalves. Py-β-CD or β-CD 
threads onto the trans- azobenzene stalks to seal the nanopores. Upon irradiation (351 nm), the 
isomerization of trans-to-cis azobenzene units leads to the dissociation of Py-β-CD or β-CD rings from the 
stalks, thus opening the gates to the nanopores and releasing the cargo. Reprinted with permission from Ref. 
45, copyright (2009) J. Am. Chem. Soc. 
  
 47 
 
Figure 2.12. Cartoon of the red-light-responsive drug delivery system constructed by MSNs modified with 
mAzo/β-CD supramolecular valves. Reprinted with permission from Ref. 46, copyright (2016) Langmuir. 
 
 
Figure 2.13. Design and preparation of ferrocene-based mechanized nanoparticles, which operate under 
redox or pH control according to the nature of the ring (β-CD in the top route and CB7 in the bottom route) 
capping the pores. Reprinted with permission from Ref. 47, copyright (2009) European J. Org. Chem. 
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Figure 2.14. Schematic representation of SC[4]A-QAS nanovalves based on AuNR@MSN. The 
nanovalves can be operated by either NIR light irradiation or external heating to regulate the release of RhB. 
Reprinted with permission from Ref. 48, copyright (2014) Chem. Sci. 
 
 
Figure 2.15. Diagram of pillar[5]arenes derivative based MSN drug delivery system. It can be 
triggered by both pH and competitive binding. Rhodamine B (RhB), calcein, and doxorubicin 
hydrochloride (DOX) were used as cargos. Reprinted with permission from Ref. 54, copyright 
(2013) Small. 
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Figure 2.16. Design and pH-dependent operation of mechanized nanoparticles. (A) When pH is lowered 
such that the anilinium nitrogen atom is protonated, the CB[6] ring shuttles to the distal 
hexamethylenediammonium station, and PI is released. (B) At neutral pH, the CB[6] ring sits on the 
tetramethylenediammonium recognition unit, blocking the nanopores. (C) When the pH is raised, all of the 
nitrogen atoms on the stalk are deprotonated resulting in dethreading of the CB[6] ring. The system is 
designed such that the pH-response can be fine-tuned by changing the functional group R to modulate the 
pKa of the anilinium nitrogen atom. Reprinted with permission from Ref. 56, copyright (2009) J. Am. Chem. 
Soc. 
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Figure 2.17. (A) Size illustration of various cargo molecules and (B) azobenzene stalks FRS1-
MSN and EXT2-MSN. Because of the shorter stalk length, FRS1-MSN is limited to loading cargo 
molecules <2 nm. Hoechst 33342 and propidium iodide dyes remain excluded from FRS1-MSN 
as a result of their size. However, EXT2-MSN is observed to load all three of the listed 
fluorophores. (C) Schematic illustration of the fully assembled rotaxane nanovalve and operation. 
(1) After synthesis, the nanovalves are suspended in an organic solvent, which destabilizes 
hydrophobic interactions between the α-cyclodextrin and azobenzene moiety and allows for cargo 
loading. (2) Upon solvent exchange to water, rebinding of the cyclodextrin to azobenzene seals in 
the loaded cargo. (3) Irradiation with light induces isomerization to cis-azobenzene, forcing 
cyclodextrin to move to the end of the stalk, and allowing cargo to release. (4) Upon removal of 
the light stimulus, thermal relaxation of cis-azobenzene to its more stable trans isomer allows 
rebinding of the cyclodextrin and seals in the remaining cargo. Reprinted with permission from 
Ref. 57, copyright (2014) Nanoscale. 
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Figure 2.18. Synthesis and operation of the thermal-sensitive supramolecular platform activable by an 
oscillating magnetic field. Adapted with permission from Ref. 62, copyright (2019) ACS Nano. 
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Figure 2.19. (A) The structure of a weblike megagate using MG-2 as the capping molecule. The relative 
sizes of the pore (dashed circle), the dextran cargo (the light green ball), and the smaller FDS cargo (the 
dark green pyramid) are shown. (B) Schematic representation of the cyclodextrin attachment onto the silica 
modified with aldehyde through imine formation. (C) The capping of megagate by MG-1 prevents the 
dextran from escaping, while FDS can freely diffuse out from the pore. Addition of acid allows the release 
of dextran. Reprinted with permission from Ref. 61, copyright (2012) Nanoscale. 
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Figure 2.20. Schematic representation of the self-amplifying chemical sensing process. The megagate 
selectively allows only the small analyte molecule (blue ball) to diffuse into the pore to actuate megagate. 
Upon the opening of the gate, the substrate (blue cubes) is able to access the enzyme to initiate a catalytic 
production of fluorescent molecules. Reprinted with permission from Ref. 63, copyright (2013) J. Am. 
Chem. Soc. 
 
 
 
Figure 2.21. Synthesis and activation of an enzyme-responsive snap-top system. Reprinted with 
permission from Ref. 64, copyright (2008) J. Am. Chem. Soc. 
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Figure 2.22. Synthesis of the alkyne-terminated stopper and assembly of disulfide-based snap-top 
nanocarriers. The nanocarriers studied utilize CB[6] or α-CD as the capping agent and Rhodamine B as the 
cargo. Reprinted with permission from Ref. 65, copyright (2010) Org. Lett. 
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Figure 2.23. Preparation and structure of MSN-GFLGR7RGDS/α-CD snap-top. Reprinted with 
permission from Ref. 66, copyright (2015) ACS Appl. Mater. Interfaces. 
 
 
 
 
Figure 2.24. Schematic illustration of rhodamine B/benzidine inserted in the cavity of β-CD and acting like 
a piston due to the pH change, which makes cargo release. An ideal mode is to have one nanopore 
functionalized with one β-CD ring, as shown in the figure. Reprinted with permission from Ref. 67, 
copyright (2010) J. Am. Chem. Soc.  
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Figure 2.25. Schematic illustration of the dual-cargo release process. The first cargo release is achieved by 
lowering of pH and is followed by the second cargo release triggered by the presence of the reducing agent 
mercaptoethanol. Reprinted with permission from Ref. 68, copyright (2012) Angew. Chemie - Int. Ed. 
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Table 2.1. Cell lines used in studies with supramolecular nanomachines 
 
 
Table 2.2. Animal models used in studies with supramolecular nanomachines 
Animal model Description Drug delivered References 
mice MiaPaCa-2 xenografts doxorubicin 34 
mice Francisella tularensis infection moxifloxacin 37 
 
  
Cell line Description 
Drug 
delivered 
Reference 
MDA-MB-
231 
human breast cancer cells doxorubicin 25 
MiaPaCa-2 human pancreatic cancer cells doxorubicin 34 
THP-1 and 
KB-31 
THP-1: human differentiated leukemia monocytes 
KB-31:  human squamous carcinoma cells 
doxorubicin 36 
MDM and 
THP-1 
MDM: human monocyte-derived macrophages 
THP-1: human differentiated leukemia monocytes 
(macrophage-like cells) 
moxifloxacin 37 
L929 murine aneuploidy fibrosarcoma cells - 52 
A549 adenocarcinomic human alveolar basal epithelial cells doxorubicin 53 
PANC-1 human pancreatic cancer cells doxorubicin 62 
HeLa and 
COS7 
HeLa: human cervical cancer cells 
COS7: African green monkey SV40-transformed 
kidney fibroblast cells 
doxorubicin 66 
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CHAPTER 3 
Spatial, Temporal, and Dose Control of Drug Delivery using 
Noninvasive Magnetic Stimulation 
This chapter of the dissertation was adapted and reprinted with permission from Wei Chen#, Chi-
An Cheng#, Jeffrey I. Zink ACS Nano 2019, 13, 1292-1308. Copyright 2019 American Chemical 
Society. Co-author contributions: Chen W.# and Cheng C. A.# (co-first authors) designed and 
performed all the experiments. Jeffrey I. Zink was the P.I. 
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3.1 Abstract 
Noninvasive stimuli-responsive drug delivery using magnetic fields in conjunction with 
superparamagnetic nanoparticles offers the potential for the spatial and temporal control of drug 
release. When hyperthermia is not desired and control of the dosage is required, it is necessary to 
design a platform in which local heating on the nanoscale releases the therapeutic cargo without 
the bulk heating of the surrounding medium. In this study, we report a design using a stimuli-
 65 
responsive nanoparticle platform to control the dosage of the cargo released by an alternating 
magnetic field (AMF) actuation. A core@shell structure with a superparamagnetic doped iron 
oxide (MnFe2O4@CoFe2O4) nanoparticle core in a mesoporous silica shell was synthesized. The 
core used here has a high saturation magnetization value and a high specific loss power for heat 
generation under an AMF. The mesoporous shell has a high cargo-carrying capacity. A 
thermoresponsive molecular-based gatekeeper containing an aliphatic azo group was modified on 
the core@shell nanoparticles to regulate the cargo release. The mesoporous structure of the silica 
shell remained intact after exposure to an AMF, showing that the release of cargo is due to the 
removal of the gatekeepers instead of the destruction of the structure. Most importantly, we 
demonstrated that the amount of cargo released could be adjusted by the AMF exposure time. By 
applying multiple sequential exposures of AMF, we were able to release the cargo step-wise and 
increase the total amount of released cargo. In vitro studies showed that the death of pancreatic 
cancer cells treated by drug-loaded nanoparticles was controlled by different lengths of AMF 
exposure time due to different amount of drugs released from the carriers. The strategy developed 
here holds great promise for achieving the dosage, temporal, and spatial control of therapeutics 
delivery without the risk of overheating the particles’ surroundings. 
 
3.2 Introduction 
Precision medicine, defined as “right drug, right dosage at right timing to right patient”, is a 
rapidly developing and popular global trend for cancer treatment.1 This emerging approach takes 
the individual variability into account for personalized disease treatment regimen design.1 
However, the necessity to deliver the desired therapeutic, at the desired time, to the specific site of 
the disease, and with accurate dosage of therapeutics remains a challenge.2 Over the past decade, 
many examples of stimuli-responsive drug delivery platforms responsive to internal cellular 
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stimuli (such as pH change,3–6 redox potential,7,8 enzymes9 or biomolecules10,11) and external 
stimuli (such as light,12–15 heat,16–23 or ultrasound24,25) have been developed for cancer treatment 
because they offer the ability to both enhance the therapeutic efficacy at the target sites and reduce 
the premature release of drug molecules thus reducing off-target side effects. Delivery of the 
accurate dosage is a key feature in chemotherapy.26–28 The dosage of the therapeutics should be in 
the optimal range called therapeutic window, where the dosages exceed the threshold concentration 
and can treat disease effectively, while below the concentration which is significantly toxic to 
normal cells.29 In view of this, after getting information from genetic databases to find out the right 
drug to the right patients, the next challenge is to deliver the right dosage of therapeutics in a 
spatio-temporal controlled manner to the desired lesion location.2,30 However, important 
limitations of the above stimuli-responsive drug delivery exist: the platforms responsive to pH 
change, redox potential, and enzyme cannot precisely control the delivery time, the delivery 
location, and the delivery dosage; the light responsive platforms have the most focused spatial 
control (on the order of mm3) but suffer from the limited penetration depth in tissue; the heat 
responsive platforms create a risk of inducing tumor metastasis when hyperthermia occurs;31–35 
and ultrasound suffers from blockage by bone and air even though under ideal condition can attain 
the spatial focus on the order of 10 mm3.36  
Non-invasive magnetic fields in conjunction with superparamagnetic nanoparticles offer a 
possible solution to overcome these limitations. Magnetic fields are harmless, are localized with 
dimensions governed by the size of the magnetic coil (on the order of cm3), and can be turned on 
and off under precise control. Superparamagnetic nanoparticles have been investigated extensively 
for a wide variety of biomedical applications including magnetic resonance imaging (MRI) 
contrast enhancement,37,38 hyperthermia therapy,39 and drug delivery.22,40–42 Among them, drug 
delivery triggered by heat generated when magnetic nanoparticles are exposed to an alternating 
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magnetic field (AMF) actuation is an emerging approach to externally and non-invasively 
triggered drug release.43–49 AMF actuation of drug delivery has the following benefits: (1) the 
release of drugs can be spatially and temporally controlled, offering the advantages for delivering 
a high local concentration of therapeutics to the lesion site and reducing off-site drug delivery from 
the carriers, (2) no penetration depth limitation of the magnetic field, enabling the actuation be 
initiated in the deep animal body without the concern of light scattering or absorption by 
tissues,22,50–52 and (3) less restriction on the type of tissues being treated compared with ultrasound 
stimulation that is strongly attenuated by air and bone structures.36 In hyperthermia therapy, when 
the blood is congested locally during heating, more energy will be provided for the tumor 
growth.31–35,53 In this case, the original tumor cells suffering from necrosis, starvation or 
suffocation due to insufficient internal blood supply may be rescued, thus accelerating tumor cell 
metastasis.31–35 Therefore, it is critical to monitor the temperature while doing AMF actuation, in 
order to prevent the bulk solution from being overheated.  
Only a limited amount of drugs can be carried on and released from the surface of a magnetic 
nanoparticle. To increase the amount of drugs that can be delivered, polymers,54 dendrimers,55,56 
and lipid bilayers,57 have been attached to magnetic nanoparticles to enhance the payload of drugs. 
Mesoporous silica has aroused much attention during the past decade due to its high surface area 
and large pore volume for cargo loading and delivery.58–66 Additionally, the stability, high 
biocompatibility, high cellular internalization efficiency, and easy surface functionalization of 
mesoporous silica makes it a strong candidate for use as a coating of superparamagnetic 
nanoparticles in a drug delivery platform.17,18,67–70  
To achieve the controllable drug delivery under the magnetic field actuation, various thermal 
responsive gatekeepers have been developed during the past several years. Thomas et al. designed 
the first nanovalve for magnetic triggered release study based on MSNs, in which cucurbit[6]uril 
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was used as a cap that released the cargo when the supramolecular interaction between the cap and 
the stalk on the surface of MSNs was decreased.41 Thermo-sensitive polymers such as azo-
functionalized polyethylene glycol,17 poly(N-isopropylacrylamide),21 and poly[(ethylene glycol)-
co-(L-lactide)]23 polymer have also been used as the capping agents to prevent premature release. 
In this work, we reported small molecular-based gatekeeper that is responsive to the heat generated 
by a superparamagnetic core in an AMF. 
     The nanoplatform consists of 4,4′-azobis(4-cyanovaleric acid) (ACVA), an aliphatic azo-
containing compound which can be irreversibly cleaved by heat and ultrasound,43,71 that was 
attached on the surface of core@shell nanoparticles consisting of a manganese and cobalt doped 
iron oxide magnetic nanoparticle cores and a mesoporous silica shell (Scheme 3.1). Adamantane 
molecules were conjugated to ACVA through an amide bond coupling reaction. After loading the 
cargo in the pores of core@shell nanoparticles, bulky β-cyclodextrin (β-CD) was used to bind with 
the adamantane forming a well-known supramolecular host-guest complex with a high association 
equilibrium constant (5.2 x 104 M-1).7,14,72–79 The pores of core@shell nanoparticles were blocked 
by this bulky complex and the cargo inside was prevented from being released prematurely. We 
demonstrate that this small molecular-based gatekeeper can be triggered by magnetic heating with 
minimal bulk heating. In addition, we demonstrate that the exposure time to the AMF controlled 
the dosage of the released cargo. We quantify the cargo release efficiency while simultaneously 
monitoring the temperature of the bulk solution, and obtain both dosage and temporal controlled 
release with no dangerous bulk heating. This proof-of-concept of precision on command drug 
delivery establishes the opportunities to enhance the treatment efficacy, reduce the side effect of 
chemotherapy and at the same time avoid the risk of inducing tumor metastasis generated by 
hyperthermia. 
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3.3. Synthesis and Characterization of MnFe2O4@CoFe2O4 Nanoparticles 
To achieve superior magnetic heating efficacy, we synthesized MnFe2O4@CoFe2O4 
nanoparticles with a magnetically soft MnFe2O4 core, and a magnetically hard CoFe2O4 shell using 
a seed-mediated method (Figure 3.1a).39 First, 6.3 nm MnFe2O4 nanoparticles were synthesized 
by a thermal decomposition method.37,38,80 The larger MnFe2O4 nanoparticles (8.2 nm) were then 
obtained by using the synthesized 6.3 nm MnFe2O4 nanoparticles as the seeds. Next, the CoFe2O4 
shell layer was grown on the surface of the synthesized 8.2 nm MnFe2O4 nanoparticles to form 
10.1 or 11.4 nm MnFe2O4@CoFe2O4 nanoparticles (Figure 3.1bc). Both the MnFe2O4 (6.3 and 8.2 
nm) and the MnFe2O4@CoFe2O4 (10.1 and 11.4 nm) nanoparticles have uniform size distributions 
as measured by transmission electron microscopy (TEM) (Figure 3.1bc and Figure 3.2ab). From 
the corresponding diffraction peaks in high angle X-ray diffraction patterns (Figure 3.3), the 11.4 
nm core@shell MnFe2O4@CoFe2O4 nanoparticles possess the typical spinel structure.81  
To quantify field dependent magnetization of MnFe2O4@CoFe2O4 at 300 K, a superconducting 
quantum interference device (SQUID) was used. The saturated magnetization of 11.4 nm 
MnFe2O4@CoFe2O4 is 105 emu/g (Figure 3.2c), higher than that of Fe3O4 nanoparticles (80 
emu/g).82 The higher magnetization of the MnFe2O4@CoFe2O4 produces a greater magnetic 
heating efficiency compared with Fe3O4 under an AMF (vide infra). The tiny hysteresis loop 
(Figure 3.2c) shows almost no coercive force which validates the superparamagnetic property of 
MnFe2O4@CoFe2O4 nanoparticles. 
To further confirm the nanoparticle identity, both Fourier transform-infrared (FT-IR) 
spectroscopy and thermogravimetric analysis (TGA) were conducted. In the FT-IR spectrum 
(Figure 3.4a), the three peaks at 2851, 2921, and 2955 cm-1 arise from the CH2 symmetric and 
antisymmetric stretches in oleic acid and oleylamine and confirm that the surface of 
MnFe2O4@CoFe2O4 nanoparticles is covered with oleic acid and oleylamine. The TGA results 
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show that the amount of oleic acid and oleylamine on the surface of MnFe2O4@CoFe2O4 
nanoparticles is 13 wt% (Figure 3.4b). Due to the abundant capping agents with long hydrocarbon 
chains, the MnFe2O4@CoFe2O4 nanoparticles can be well suspended in hexane (Figure 3.2c). 
To investigate the heat generation efficiency of 11.4 nm MnFe2O4@CoFe2O4 nanoparticles, 
the specific loss power (SLP) was quantified. The SLP of MnFe2O4@CoFe2O4 was calculated 
using equation (1), where C is the volumetric heat capacity of solvent, Vs is the sample volume, m 
is the mass of MnFe2O4@CoFe2O4, and dT/dt is the initial slope of the time-dependent temperature 
increase curve. 
Specific loss power = CVs
m
dT
dt
     (1) 
MnFe2O4@CoFe2O4 nanoparticles were dispersed in toluene and an AMF (375 kHz, 5kW) was 
applied for heat generation. Time- and concentration-dependent temperature increase profiles 
(Figure 3.2d) show that the solution temperature abruptly increased upon the application of AMF 
trigger. The temperature of the toluene solution containing nanoparticles finally achieved 44, 55, 
and 67 °C after 6 min magnetic actuation at the concentrations of MnFe2O4@CoFe2O4 are 0.5, 1, 
and 2.5 mg/mL, respectively. The SLP of the MnFe2O4@CoFe2O4 nanoparticles was calculated to 
be 1510.8 W/g (equation 2), 5 times higher than that of 20 nm Fe3O4 nanoparticles (302.2 W/g) 
(equation 3).83 This superior heating performance of MnFe2O4@CoFe2O4 nanoparticles under the 
AMF shows its potential of serving as an efficacious heat source for thermal-triggered drug release. 
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For MnFe2O4@CoFe2O4: 
Specific loss power = CVs
m
dT
dt
  (1) 
= 
1.5108 "J mL-1K-1# × 1 (mL)
1 × 10-3 (g)  × 1 (K)1 (s)  
=1510.8 Wg     (Fe+Mn+Co)
-1      (2) 
        
For Fe3O4: 
Specific loss power = CVs
m
dT
dt
  (1) 
= 
1.5108 "J mL-1K-1# × 1 (mL)
1 × 10-3 (g)  × 1 (K)5 (s)  
=302.2 Wg     (Fe)
-1      (3) 
 
3.4 Synthesis and Characterization of Mag@MSNs-APTS Core@Shell Nanoparticles 
To construct nanoparticles with cargo-carrying capability, we synthesized nanoparticles with a 
mesoporous silica shell around the superparamagnetic core. The coating was achieved by 
hydrolysis and condensation of tetraethyl orthosilicate (TEOS) in the presence of 
hexadecyltrimethylammonium bromide (CTAB) surfactant templates in basic solution.84 The 
resulting nanoparticles are designated as Mag@MSNs (Mag denotes magnetic 
MnFe2O4@CoFe2O4 and MSNs denotes mesoporous silica nanoparticles). 
In order to attach thermal sensitive caps, the surface of the mesoporous silica shell was 
functionalized with amine groups by hydrolysis and condensation reactions of 3-
(aminopropyl)triethoxysilane (APTS). The modified nanoparticles are designated as 
Mag@MSNs-APTS. By using TEM, the average diameter of Mag@MSNs-APTS core@shell 
nanoparticles is 55 nm and their shell thickness is 22 nm with obvious mesoporous structure 
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(Figure 3.5a and Figure 3.6). From the dynamic light scattering (DLS) diameter distribution 
(Figure 3.7), the average diameter of Mag@MSNs-APTS is 105.6 nm at room temperature, 
showing that the nanoparticles are well dispersed in water. 
N2 adsorption-desorption isotherms and pore diameter distribution were used to further 
characterize the pores of Mag@MSNs-APTS core@shell nanoparticles. The Brunauer-Emmett-
Teller (BET) surface area, Barrett-Joyner-Halenda (BJH) average pore diameter, and total pore 
volume of Mag@MSNs-APTS are 653.4 m2/g, 2.8 nm, and 1.06 cm3/g, respectively (Figure 3.5b). 
In addition, the high surface area and pore volume of Mag@MSNs-APTS – the desired properties 
of MSNs – suggest that cargos such as small molecules can be loaded inside the pores of 
Mag@MSNs-APTS (vide infra), allowing those cargos to be efficiently carried and delivered by 
the nanoparticles. 
 
3.5 Synthesis and Characterization of Mag@MSNs-APTS, Mag@MSNs-ACVA and 
Mag@MSNs-AMA Core@Shell Nanoparticles 
Particles for magnetically stimulated release need not only cargo-carrying capability but also 
a stimulus-responsive capping mechanism. To introduce the latter functionality to the 
nanoparticles, the surface of the core@shell nanoparticles were conjugated with a thermolabile 
gatekeeper 4,4’-azobis(4-cyanovaleric acid) (ACVA).43,71 ACVA was chemically bonded to 
Mag@MSNs-APTS using 1-ethyl-3-(3-diethylaminopropyl) carbodiimide (EDC) and N-
hydroxysuccinimide (NHS) coupling agents.85 The carboxylic acid on ACVA formed an amide 
bond with the primary amine of APTS, and the resulting particles were designated as 
Mag@MSNs-ACVA (Scheme 3.1b). Subsequently, 1-adamantylamine (AMA) was conjugated on 
the surface of the nanoparticles through the same standard crosslinking method, with the terminal 
carboxylic acid of ACVA forming another amide bond with the primary amine of AMA. The 
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nanoparticles modified with AMA were designated as Mag@MSNs-AMA (Scheme 3.1b).  
The successful attachment of APTS, ACVA, and AMA on the surface of Mag@MSNs was 
confirmed by zeta potential measurements, FT-IR, and TGA after each step. The zeta potential of 
Mag@MSNs, Mag@MSNs-APTS, Mag@MSNs-ACVA, and Mag@MSNs-AMA were measured 
in deionized water at room temperature (Figure 3.8a). The zeta potential value of Mag@MSNs-
APTS was +46.2 mV, much more positive than that of Mag@MSNs (-26.1 mV), showing abundant 
primary amines on the surface of Mag@MSNs-APTS. Mag@MSNs-ACVA has a negative zeta 
potential value of -21.0 mV. This significant decrease in the zeta potential value indicates that 
ACVA molecules with carboxylates on both ends were successfully attached to the surface of 
Mag@MSNs-APTS, with one end stretching out from the surface of Mag@MSNs-ACVA 
available for further AMA conjugation. Mag@MSNs-AMA with the nearly neutral zeta potential 
value of -0.45 mV confirms the conjugation of the amine on AMA to the free carboxylate on the 
surface of Mag@MSNs-ACVA, leaving the uncharged functional group on AMA stretching out 
from the surface of the particles (Scheme 3.1b). 
FT-IR spectroscopy was used to characterize surface functional groups after each conjugation 
step (Figure 3.8b). The appearance of two bands in the IR spectrum of Mag@MSNs-APTS due 
to N-H stretching vibrations at ν = 3628 cm-1 and ν	=	3648 cm-1 shows the presence of primary 
amines attached to the surface of Mag@MSNs-APTS. The successful conjugation of ACVA to the 
surface of Mag@MSNs-APTS through secondary amide bond formation was confirmed by a new 
characteristic amide absorption (amide II) at ν	=	1550 cm-1. Additionally, a nitrile absorption 
appears at ν	= 2253 cm-1 (nitrile stretching) from ACVA also supports the successful conjugation 
of ACVA on the Mag@MSNs-APTS. This is also supported by newly emerging absorptions at 
ν = 1719 cm-1 (C=O stretching), ν	= 1451 cm-1 (C-H bending), and three absorption peaks at 
ν	= 2904 cm-1, 	ν	=	2934 cm-1, and 	ν	= 2981 cm-1 (C-H stretching) from ACVA. Finally, the 
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conjugation of AMA on the surface of Mag@MSNs-ACVA is confirmed by the appearance of the 
absorption at ν	= 1474 cm-1 (C-H bending) from AMA.  
TGA was used to determine the weight of organic moieties on the particles (Figure 3.8c). The 
weight loss of Mag@MSNs, Mag@MSNs-APTS, Mag@MSNs-ACVA, and Mag@MSNs-AMA 
after heating to 550 °C in air were 6 %, 8 %, 11 %, and 13 %, respectively. The increase in weight 
loss after each conjugation indicates that the weight of APTS, ACVA, and AMA modified on the 
surface of core@shell nanoparticles were 2 %, 3 %, and 2 %, respectively. The results from zeta 
potential measurements, FT-IR, and TGA show that APTS, ACVA, and AMA were successfully 
and sequentially attached on the surface of Mag@MSNs. 
To confirm that the morphology and mesoporous structure of core@shell nanoparticles 
remains intact after surface modification, we conducted TEM and N2 adsorption-desorption 
isotherms analysis of the core@shell nanoparticles after ACVA and AMA conjugation. By TEM, 
Mag@MSNs-AMA (Figure 3.8d) is 55 nm in size with obvious mesoporous structure, very 
similar to that of Mag@MSNs-APTS (Figure 3.5a), indicating that the particles were not damaged 
after the surface functionalization. The BET surface area, total pore volume, and BJH average pore 
diameter of Mag@MSNs-AMA are 593.5 m2/g, 0.96 cm3/g, and 2.8 nm, respectively (Figure 3.8e). 
Similar to Mag@MSNs-APTS (Figure 3.5b), Mag@MSNs-AMA preserves the characteristics of 
mesoporous structure – high surface area and large pore volume – enabling efficient loading and 
delivery of cargos. AMA and thermolabile ACVA are mainly attached to the outer surface rather 
than to the inner pore wall of the core@shell nanoparticles, as evidenced by the unchanged average 
pore diameter of Mag@MSNs-AMA and Mag@MSNs-APTS. Those thermal sensitive 
gatekeepers selectively bonded on the outer surface of the core@shell nanoparticles can effectively 
bind to β-cyclodextrin (β-CD) that blocks the pore openings to prevent cargos from leakage, and 
act as a thermal-sensitive switch to release the cargos on-demand. 
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3.6 Thermal Responsiveness of the Gatekeeper and Bulk Heating-Triggered Cargo 
Release  
To investigate the thermal responsiveness of the gatekeeper, we first demonstrated the cleavage 
of the gatekeeper triggered by increasing the temperature of the surrounding water. Sample tubes 
containing Mag@MSNs-ACVA dispersed in deionized water (0.5 mg/mL) were placed for 10 min 
in the hot water baths heated by a hot plate set at 37 °C, 60 °C, and 80 °C (called bulk heating) 
(Figure 3.9c). The cleavage of C-N bonds of ACVA was confirmed by the zeta potential 
measurement. After Mag@MSNs-ACVA was heated at 37 °C, 60 °C, and 80 °C for 10 min, the 
zeta potential values were -20.0 mV, -6.7 mV, and 0.3 mV, respectively (Figure 3.9ab). The sample 
heated at 37 °C shows very similar zeta potential value compared to that of the control without 
heating (-21.0 mV), showing that the gatekeepers were stable at physiological temperature and the 
C-N bonds were intact. However, when the temperature increased, the C-N bonds were cleaved, 
producing fragments of 4-cyanopentanoic acid and nitrogen (Figure 3.9a). The removal of the 
carboxylate group after cleavage explains why the zeta potential becomes increasing after heating. 
The bulk heating-triggered cargo release was studied using fluorescein as a model molecule 
due to its stability and size similar to that of many anticancer drugs (1.5 nm), e.g., doxorubicin or 
paclitaxel. Fluorescein molecules were loaded in Mag@MSNs-AMA by soaking the particles in 3 
mM of the fluorescein solution for 24 h. To trap fluorescein in the pores of core@shell 
nanoparticles, the pores were capped by bulky β-CD, which strongly binds to AMA on the surface 
of the nanoparticles and forms a non-covalent supramolecular bond with adamantane.72,73,86 The 
particles capped by β-CD were designated as Mag@MSNs-AMA-CD. Fluorescein loaded 
Mag@MSNs-AMA-CD were washed thoroughly with deionized water to remove the untrapped 
fluorescein molecules.  
To trigger the release of fluorescein, the bulk heating was performed in hot water baths at 
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various temperatures according to the following procedure (Figure 3.9c). Sample tubes containing 
fluorescein loaded Mag@MSNs-AMA-CD dispersed in deionized water (0.5 mg/mL) were placed 
in water baths set at 37 °C, 60 °C, and 80 °C for 10 min. To monitor the fluorescein released from 
Mag@MSNs-AMA-CD, the samples after heating were spun down and aliquots of the 
supernatants were collected for fluorescence measurements. An unheated sample at room 
temperature (23 °C) served as the control. The release efficiency is defined as (mass of released 
fluorescein/mass of loaded fluorescein) x 100 %. Only slight release (less than 3%) of fluorescein 
from Mag@MSNs-AMA-CD at 23 °C and 37 °C after 10 min heating was observed (Figure 3.9d), 
indicating that the CD cap blocked the pore opening of the particles tightly and minimized 
premature leakage. The release efficiency of fluorescein strongly increased to 39 % upon heating 
at 60 °C for 10 min. When the samples were heated in a hot water bath at a higher temperature (80 
°C), more than half (55 % release efficiency) of the fluorescein was released after 10 min heating. 
In addition, after 3 cycles of 10 min heating at 80 °C, almost all fluorescein (near 100 % release 
efficiency) was released after 3 cycles of 10 min heating (Figure 3.10). To determine the long-
term release profile of fluorescein, the samples heated at 37 °C, 60 °C, and 80 °C were performed 
with 9, 9, and 4 such heating/monitoring cycles. The time period between each heating cycle is 
also 10 min. The cumulative release of fluorescein gradually increased with heating time and 
finally reached 78 % after 9 cycles of 10 min heating at 60 °C (Figure 3.10). On the contrary, the 
release efficiency of fluorescein after 9 cycles of 10 min heating at 37 °C is only 24 %, which is 
much lower than that from 60 °C heating, and is close to the control group at 23 °C (19 %). This 
implies that the CD cap was constructed successfully on the surface of the Mag@MSNs so that 
little premature leakage was observed either at room temperature or physiological temperature. 
Most importantly, the cargo release amount and cargo releasing rate can be controlled simply by 
tuning the temperature of the water bath. 
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3.7 Alternating Magnetic Field-Triggered Cargo Release 
 Two types of release studies were conducted by using another heat source – an alternating 
magnetic field (AMF) – which can induce localized heating (here called magnetic heating): (a) a 
single exposure to AMF for different lengths of time, and (b) multiple sequential exposures each 
for the same length of time. Fluorescein loaded Mag@MSNs-AMA-CD particles were dispersed 
in deionized water (0.5 mg/mL) at room temperature. To confirm the tightness of the gatekeeper, 
release of fluorescein before triggering with magnetic heating was monitored by spinning down 
the nanoparticles and collecting aliquots of the supernatants for fluorescence measurements. After 
monitoring the release every 20 min over a period of 40 min at room temperature, the sample was 
placed in a water-cooled five-turn copper coil generating an AMF at a power of 5 kW and a 
frequency of 375 kHz (Figure 3.11a). Exposure times were 1, 2, 3, 5, or 10 min, followed again 
by monitoring the release. To have enough time for dye to diffuse out from the pores, monitoring 
cycles were performed every 10 min at room temperature until the maximum release of fluorescein 
was achieved. Only slight leakage (less than 5 %) of fluorescein was observed in the first 40 min 
at room temperature before exposure to an AMF, showing the effectiveness of the gatekeeper to 
prevent premature leakage of the dye (Figure 3.11b-f). The release efficiency of fluorescein was 
10 % immediately after 1 min of the AMF trigger, showing that some caps were successfully 
removed by the magnetic heating. The amount of released fluorescein gradually increased over 
time at room temperature until it leveled off (total release efficiency of 23.6 %) at 70 min post-
AMF trigger (Figure 3.11b). After the caps are removed, it takes time for fluorescein molecules 
to diffuse out from the pores of nanoparticles and reach equilibrium at the end. To correlate the 
release efficiency of fluorescein with the AMF trigger exposure time, the samples were exposed 
to the AMF for longer actuation times of 2, 3, 5, and 10 min. Similar time-dependent release 
profiles were observed in all cases: (i) the burst of release during magnetic heating, (ii) the gradual 
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increase in the release at room temperature, and (iii) the plateau reached 80 min post-AMF trigger 
(Figure 3.11b-f). Even though the initial rise in release during the burst stage (i) was not obviously 
increased as a function of the longer magnetic heating time, the cumulative release efficiencies of 
fluorescein at plateau were significantly enhanced, reaching 41.9 %, 56.5 %, 65.3 %, and 75.9 % 
with 2, 3, 5, and 10 min of heating time, respectively. This suggested that the number of caps 
removed from the surface of nanoparticles is directly correlated with the AMF trigger time.  
To know whether the removal of the cap is a result of localized internal heating from the 
magnetic core under the AMF or an increase in the ambient temperature, we simultaneously 
monitored the temperature of the solution containing Mag@MSNs-AMA-CD immediately after 1, 
2, 3, 5, and 10 min of AMF actuation. Less than 6 degrees of temperature increase was observed, 
where the temperatures were found to be 24, 24, 26, 27, and 29 °C after 1, 2, 3, 5, and 10 min of 
AMF actuation (Figure 3.11g), respectively. Even the highest temperature of the solution after 
exposing to AMF was below 30 °C, indicating that the release of fluorescein was not triggered by 
bulk heating from the surrounding solution. Instead, the fairly high local temperature (that can be 
above 65 °C)83 achieved internally from the magnetic core was the main heat source to cleave the 
thermolabile ACVA, which will undergo thermolysis over 60 °C.17,71 
To confirm that the mesoporous structure of silica particles can withstand the temperature of 
localized magnetic heating, the structure of Mag@MSNs-AMA-CD after 10 min of the AMF 
actuation was analyzed by TEM. The TEM image (Figure 3.12) shows that the mesoporous silica 
structure was intact without any damage and the diameters of the particles didn’t change after 
exposing to the internal heating from the inner magnetic core. The cleavage of the C-N bonds was 
supported by the change in the zeta potential of the Mag@MSN-ACVA particle from -21.0 mV 
before exposure to -1.8 mV after 10 min of exposure (Figure 3.13). The results confirm that the 
release of fluorescein molecules from Mag@MSNs-AMA-CD is through the removal of the 
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thermal-sensitive gatekeepers on the surface rather than the destruction of the mesoporous 
structure of silica particles. 
The second type of release study was performed with multiple sequential exposures of AMF to 
achieve the maximal release of fluorescein. To confirm the tightness of the gatekeeper, the release 
of fluorescein before each trigger was monitored by fluorescence spectroscopy every 10 min. Only 
slight leakage (less than 10 %) of fluorescein was observed in the first 30 min at room temperature 
before exposure to the first cycle of AMF actuation. Three cycles of AMF actuation for 3 min 
followed by 70 min of the monitoring at room temperature were carried out. The temperature of 
the solution right after each AMF exposure was measured to be 26 °C, 26 °C, and 26 °C, 
respectively, only 3 degrees higher than that before each AMF exposure. The minimal temperature 
increase indicates that the observed release was not triggered by the bulk heating from the 
surrounding solution but by the higher local temperature achieved internally from the magnetic 
core. The release efficiency at plateau where fluorescein molecules achieved equilibrium after the 
first cycle was 60 % (Figure 3.14), which is similar to the release efficiency of fluorescein after 3 
min of AMF actuation shown in Figure 3.11d (56.5 %). Subsequently, the second cycle of AMF 
actuation was applied and the release efficiency increased to approximate 80 % compared to the 
background. The second heating cycle caused an additional 20 % more fluorescein can be released. 
However, when the third cycle of AMF actuation was applied, no increase in the release of 
fluorescein was observed. This implies two possibilities: (1) part of the caps still block the pore 
openings after the trigger, and/or (2) even after the caps are fully removed, some fluorescein 
molecules adhere to the pores of Mag@MSNs-AMA-CD. Stepwise time-dependent release profile 
triggered by multiple cycles of AMF actuation was observed in three stages which is similar to 
Figure 3.11b-f. Based on this stepwise release profile, we can control the release of desired amount 
of fluorescein in the specific time period. 
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3.8 Alternating Magnetic Field-Triggered Release of Doxorubicin 
In preparation for in vitro cancer cell studies, we investigated the loading and AMF release of 
doxorubicin (DOX), a widely used anticancer drug. DOX was loaded in Mag@MSNs-AMA by 
soaking the particles in a 2.6 mM DOX solution for 24 h followed by the capping by β-CD. The 
loading capacity of DOX in Mag@MSNs-AMA-CD was calculated to be 4 % after the DOX-
loaded Mag@MSNs-AMA-CD was thoroughly washed with deionized water and PBS to remove 
the untrapped DOX molecules. The absorption peak at 503 nm of UV-vis spectrum (Figure 3.15a) 
provides spectroscopic evidence that DOX was loaded in Mag@MSNs-AMA-CD. 
To prove that the dosage of released DOX from Mag@MSNs-AMA-CD could be controlled 
after being triggered by different durations of AMF exposure, sample tubes containing DOX-
loaded Mag@MSNs-AMA-CD in PBS were placed in the center of the coil with 2, 5, or 10 min 
of exposure time. Before the AMF exposure, the release of DOX was monitored every 30 min over 
a period of 60 min at room temperature. Only slight leakage (less than 5 %) of DOX was observed 
in the first 60 min at room temperature before the AMF exposure. After the AMF exposure, the 
release of DOX was monitored every 30 min over a period of 3 h followed by every 2 h over a 
period of 6 h. The released DOX gradually increased over time at room temperature until it leveled 
off at 540 min post AMF exposure. The cumulative release efficiencies of DOX reach 35.6 %, 
45.6 %, and 53.1 % with 2, 5, and 10 min of AMF exposure, respectively (Figure 3.15b-d). The 
temperature of the solution after the AMF exposure was measured to be 24, 26, and 28 °C, 
respectively. The minimal temperature increase shows that the release of DOX was not triggered 
by bulk heating from the surrounding solution but by the localized high temperature from the 
magnetic core. The results demonstrated that the release of DOX can be triggered by an AMF and 
that the dosage of the DOX released from the nanocarriers can be controlled by different lengths 
of the AMF exposure. 
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3.9 In vitro Studies of Cytotoxicity and Stability of Drug Delivery System 
In vitro cytotoxicity studies were carried out to evaluate the potential biological 
applications of the drug delivery system. A pancreatic cancer cell line (PANC-1) was used to 
evaluate the cytotoxicity of Mag@MSNs-AMA-CD by a colorimetric cell counting kit-8 (CCK-8) 
assay. The cell viabilities of PANC-1 after 20 h and 70 h incubation at various nanoparticle 
concentrations are shown in Figure 3.16a. No significant decrease in cell viability was detected 
even at a very high particle concentration (200 µg/mL) at both 20 h and 70 h. The Mag@MSNs-
AMA-CD particles we developed are not toxic and are suitable to be used as drug delivery carriers. 
To test the stability of the gatekeepers of Mag@MSNs-AMA-CD in vitro, PANC-1 cells were 
treated with DOX-loaded Mag@MSNs-AMA-CD at various concentrations. The results show that 
no significant cell viability decrease was observed after 4 h incubation (Figure 3.16b). The 
minimal cytotoxicity proves the tightness of the gatekeepers which prevent the leakage of DOX 
from the nanocarriers in a biological environment at 37 °C. In addition, the proliferation of PANC-
1 (Figure 3.16c) was not hindered in a 12 h growth in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10 % fetal bovine serum (FBS) after 4 h treatment by DOX-loaded 
Mag@MSNs-AMA-CD. These results demonstrate that the drug delivery system prevents the 
leakage of DOX and thus minimizes the cytotoxicity before activation, and that the proliferation 
of the PANC-1 was not hindered. 
 
3.10 In vitro Cellular Killing Studies 
In vitro cellular killing by DOX-loaded Mag@MSNs-AMA-CD after AMF exposure was 
studied. PANC-1 cells were treated with DOX-loaded Mag@MSNs-AMA-CD for 4 h followed by 
the AMF exposure for 2, 5, and 10 min (Figure 3.17a). The cell viabilities of the control groups 
including without the treatment by nanoparticles, and treatment by Mag@MSNs-AMA-CD 
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without DOX were also investigated. Figure 3.17b shows that without the treatment by 
Mag@MSNs-AMA-CD, the exposure of the cells to AMF (2, 5, and 10 min) did not kill the PANC-
1 cells. The results corroborated that the magnetic field was harmless to cells and is a safe stimulus 
for the drug delivery. No decrease of PANC-1 cell viability was observed after the 4 h incubation 
with 50 µg/mL Mag@MSNs-AMA-CD followed by exposure to various lengths of AMF (2, 5, 
and 10 min). The results indicate that the localized heating generated from Mag@MSNs-AMA-
CD during the AMF exposure was not harmful to the cells, and was desirable because killing by 
hyperthermia did not occur. 
The effects of the release of DOX from Mag@MSNs-AMA-CD in PANC-1 cells triggered 
by the AMF were studied. The PANC-1 cells were incubated with 50 µg/mL DOX-loaded 
Mag@MSNs-AMA-CD followed by various lengths of exposure to AMF (2, 5, and 10 min). The 
results show that the viabilities of PANC-1 were 72 %, 63 %, and 47 % after 2, 5, and 10 min of 
AMF exposure, respectively (Figure 3.17b), which demonstrates that the loss of cell viabilities 
was correlated with the lengths of AMF exposure time. As AMF exposure time was increased, the 
dosage of released DOX from the nanocarriers increased and thus killed more PANC-1 cells. The 
results demonstrate that not only the release of DOX from Mag@MSNs-AMA-CD in cellular 
environment can be remotely triggered by an AMF, but also that the dosage of the released DOX 
is controlled by the lengths of AMF exposure and thus different levels of cell killing can be 
achieved. 
Uptake of DOX-loaded Mag@MSNs-AMA-CD by PANC-1 cells and the release of DOX from 
the nanocarriers in PANC-1 cells after the exposure of the AMF were verified by fluorescence 
microscope images. PANC-1 cells were treated with 50 µg/mL DOX-loaded Mag@MSNs-AMA-
CD for 4 h. Before the AMF trigger, the red fluorescence derived from DOX was located around 
the nuclei but not overlapped with blue fluorescence derived from the nucleus stained by Hoechst 
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33342 dye ((ii) in Figure 3.17c), compared with that of control group (without the treatment of 
nanoparticles, (i) in Figure 3.17c). The results indicate that before the exposure to AMF, DOX 
was not released from the Mag@MSNs-AMA-CD nanoparticles taken up by the PANC-1 cells. 
However, after the AMF exposure, some of the red fluorescence derived from DOX overlapped 
with the blue fluorescence of the Hoechst-stained nuclei ((iii) in Figure 3.17c). This result 
demonstrates that DOX was released from Mag@MSNs-AMA-CD in PANC-1 cells after the 
exposure of the AMF, and thus stained the nuclei and caused cell death. 
 
3.11 Significance for Potential Biomedical Applications 
 To reduce the side-effects of drugs, release of therapeutics within a specific time, to a targeted 
location, and with a controlled dosage has always been a goal for drug delivery applications. 
Although many proof-of-concept stimulated release of drugs have been studied, a majority of them 
are responsive to internal stimuli such as pH,3,87 redox,7,8 or enzymes,9 and it is almost impossible 
to precisely control the amount of therapeutics released from the carriers. Even though several 
studies have reported the externally triggered release of drugs via magnetic fields, none of them 
quantified the release efficiency of the cargos, making is hard to estimate the amount of cargo 
released upon trigger, nor did they test the tunable dosage released by changing the trigger duration 
under the magnetic field. In this work, we successfully demonstrated that the release efficiency 
(hence, the release amount) of fluorescein and DOX can be well controlled by manipulating the 
AMF trigger time (Figure 3.11g). Additionally, with the AMF as an external stimulus, the particles 
with therapeutics can be delivered and released to the target site on-demand. For those treatments 
to some disease requiring multiple dosing such as multiple dose insulin injection therapy, the 
common way is to inject therapeutics several times daily. With the drug delivery strategy 
developed in this study, by simply applying multiple sequential exposure of AMF, the therapeutics 
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could be released stepwise in situ with the desired amount in the specific time period, and finally 
reach the required amount in its therapeutic window. The designed controllable drug delivery 
provides alternative method to those therapies required multiple injection, and at the same time 
reduces the off-target side effects in chemotherapy. 
 In addition to chemotherapy, high temperatures (hyperthermia) can also damage and kill 
cancer cells, usually with minimal injury to normal tissues. Although hyperthermia is a promising 
way to kill cancer cells, a number of challenges must be overcome including: (1) increasing 
probability of tumor metastasis,31-35 (2) difficulty in accurate temperature measurement inside a 
tumor, (3) problems of keeping an area at a constant temperature without affecting nearby tissues, 
and (4) body tissue’s heterogeneity in response to heat.31 Even using local hyperthermia for which 
energy (such as microwave, radiofrequency, or ultrasound) must be delivered to a small volume 
(e.g. a tumor) does not solve all the problems stated above. On the other hand, the internal heat 
source generated by applying AMF to magnetic cores only heats up a small local area (within a 
range of magnetic core) as compared to area affected by microwave, radiofrequency, and 
ultrasound. Thus, this magnetic heating method in combination with drug delivery provides an 
alternative approach of cancer treatment that has the potential to overcome the challenges faced 
with traditional chemotherapy and hyperthermia, and is especially beneficial to the case where 
thermal ablation or necrosis is undesired. 
 
3.12 Summary 
In summary, monodisperse manganese and cobalt doped iron oxide (MnFe2O4@CoFe2O4) 
nanoparticles with a high magnetization (105 emu/g) and high specific loss power (1510.8 W/g) 
were synthesized. The high magnetization of these superparamagnetic nanoparticles provides 
efficient magnetic heating under an alternating magnetic field (AMF), thus holding great promise 
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for magnetic heating triggered drug delivery. To increase the amount of drug over that available 
using the nanoparticles themselves, mesoporous silica shell “containers” are synthesized around 
the magnetic core, forming a core@shell structure with 55 nm in diameter. The spatial, temporal, 
and dose control of drug release was achieved using a thermal-responsive gatekeeper containing a 
thermal-labile molecule 4,4′-azobis(4-cyanovaleric acid), and a host guest complexation formed 
by adamantylamine and β-cyclodextrin. This gatekeeper was stable at physiological temperature, 
while at the higher temperature (60 or 80 °C) the gatekeeper was cleaved. When the fluorescein 
loaded gatekeeper modified nanoparticles were heated for 10 min in 60 or 80 °C water baths, 39 
% or 55 % respectively of fluorescein was released. However, when the AMF was applied, the 
magnetic core served as a heat source, and the localized heating generated from the core led to 
more efficient fluorescein release (75.9 % of the highest) with the temperature rise of the bulk 
solution no more than 5 degrees. Most importantly, in this study we demonstrated externally-
controlled dosage of fluorescein or doxorubicin (DOX) by controlling the AMF exposure time. 
Multiple sequential exposure of AMF allows cargo release in a stepwise manner. In vitro studies 
show that the drug delivery system is biocompatible. DOX-loaded nanoparticles did not cause a 
decrease in cell viability in the absence of AMF stimulation, but the viabilities of the pancreatic 
cancer cells decreased by 28 %, 37 %, and 53 % as the AMF exposure time increased from 2, 5 to 
10 min. Taken together, the thermal-responsive drug delivery actuated by AMF offers the potential 
of becoming an emerging chemotherapy that non-invasively and precisely control the dosage of 
drugs, and avoiding the risk generated when overheating the bulk solution. 
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3.13 Methods 
3.13.1 Materials and Chemicals 
Iron(III) acetylacetonate (Fe(acac)3, 97%), Manganese(II) acetylacetonate (Mn(acac)2, 21%-
23% Mn), cobalt(II) acetylacetonate (Co(acac)2, 97%), 1,2-dodecanediol (90%), oleic acid (90%), 
oleylamine (70%), benzyl ether (98%), hexane (98.5+%), chloroform (99.5+%), 
hexadecyltrimethylammonium bromide (CTAB, 99+%), tetraethyl orthosilicate (TEOS, 98%), (3-
aminopropyl)triethoxysilane (APTS, 99%), 4,4′-azobis(4-cyanovaleric acid) (ACVA, 98+%) 1-
adamantylamine (AMA, 97%), β-cyclodextrin (β-CD, 97+%), ammonium nitrate (NH4NO3, 
98+%), 1-Ethyl-3-(-3-dimethylaminopropyl) carbodiimide (EDC, 98+%), N-hydroxysuccinimide 
(NHS, 98%), phosphate-buffered saline (PBS, 10X), bisBenzimide H 33342 trihydrochloride 
(Hoechst 33342, 98+%), and fluorescein sodium salt were purchased from Sigma-Aldrich. 
Doxorubicin hydrochloride (DOX-HCl) was purchased from Cayman Chemical. Dimethyl 
sulfoxide (DMSO, 99.9+%), sodium hydroxide (NaOH, 97+%), hydrochloric acid (HCl, 36.5%-
38%, tracemetal grade), and nitric acid (HNO3, 67%-70%, tracemetal grade) were purchased from 
Fisher Scientific. Dulbecco’s modified Eagle’s medium (DMEM) with high glucose, fetal bovine 
serum (FBS), antibiotics (10,000 U/mL penicillin, 10,000 µg/mL streptomycin, and 29.2 mg/mL 
L-glutamine), Dulbecco’s phosphate-buffered saline (DPBS), and trypsin-
ethylenediaminetetraacetic acid (trypsin-EDTA) (0.05 %) were purchased from Gibco. Cell 
counting kit-8 (CCK-8) was purchased from Dojindo Molecular Technologies, Inc. 
Paraformaldehyde solution (4 % in PBS) was purchased from USB Corporation. Ethanol (200 
proof) was purchased from Decon Laboratories, Inc. All chemicals were used without further 
purification. 
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3.13.2 Characterization 
  The size and morphology of nanoparticles were investigated by transmission electron 
microscopy (TEM, Tecnai T12) with an operating voltage of 120 kV. MnFe2O4@CoFe2O4 or 
Mag@MSN core@shell nanoparticles were dispersed in hexane or ethanol at a low concentration 
(0.2 mg/mL). The suspension (10 µL) of the nanoparticles was dropped onto the carbon-coated 
copper grid and dried at room temperature. The X-ray diffraction pattern of the powder was 
obtained by a PANalytical, X’Per PRO diffractometer with Cu Kα radiation (λ= 1.5418 Å); the 
operating voltage and current were 45 kV and 40 mA, respectively. The field-dependent 
magnetization of MnFe2O4@CoFe2O4 was measured using a superconducting quantum 
interference device (SQUID) Quantum Design MPMS7 magnetometer at 300 K. The 
iron/manganese/cobalt ratio of the MnFe2O4@CoFe2O4 nanoparticles was quantitatively 
determined by ICP-OES using a Shimadzu ICPE-9000 instrument. Typically, 2 mg of 
MnFe2O4@CoFe2O4 powder was dissolved in 0.5 mL of hydrochloric acid solution. The solution 
was diluted with 2 % HNO3 for quantitative measurement. The calibration curves for iron, 
manganese, and cobalt were created from 0 ppm to 10 ppm. The surface area, pore volume, and 
pore size of Mag@MSN core@shell nanoparticles were determined by N2 adsorption-desorption 
isotherm measurements at 77 K (Autosorb-iQ, Quantachrome Instruments). Mag@MSN 
core@shell was degassed at 110 °C for 12 h before the measurement. The surface area and pore 
size distribution of Mag@MSN core@shell were determined by Brunauer-Emmett-Teller (BET) 
and Barrett-Joyner-Halenda (BJH) methods. The dynamic light scattering (DLS) size and zeta 
potential values were determined by a laser particle analyzer LPA-3100 at room temperature. The 
functional groups on the surface of Mag@MSN core@shell were characterized by Fourier 
transform infrared spectroscopy (FTIR, JASCO FT/IR-420) spectrometer in the range of 4000–
400 cm-1. Thermogravimetric analysis (TGA) was performed on a Perkin-Elmer Pyris Diamond 
 88 
TG/DTA machine under air flow. About 10 mg of Mag@MSN core@shell were loaded in 
aluminum pans and the data were recorded from 50 °C to 550 °C at a scan rate of 10 °C/min. An 
empty aluminum pan was used as the reference. The loading capacities of fluorescein or DOX 
were determined by UV-Vis Spectroscopy (Cary 5000). The absorbance of the peaks at 477 nm 
(fluorescein) or 503 nm (DOX) was used for quantification, respectively. The release of fluorescein 
or DOX was measured by an Acton Spectra Pro 2300i CCD cooled with liquid nitrogen. 
Fluorescein or DOX were excited by a CUBE 445-40C laser (Coherent Inc.) at a wavelength of 
448 nm and a power of 4 mW (fluorescein) or 2 mW (DOX). 
3.13.3 Synthesis of Magnetic MnFe2O4@CoFe2O4 Nanoparticles 
Synthesis of 6.3 nm MnFe2O4 nanoparticles: MnFe2O4 nanoparticles were synthesized 
following a previously reported method with a slight modification.37,38 Two mmol of Fe(acac)3, 1 
mmol of Mn(acac)2, 10 mmol of 1,2-dodecanediol, 6 mmol of oleic acid, and 6 mmol of oleylamine 
were dissolved in 20 mL of benzyl ether in a three-neck flask. The reaction was heated to 200 °C 
under the flow of nitrogen with vigorously stirring and kept at that temperature for 1 h. The reaction 
mixture was then heated up and refluxed for 1 h (298 °C). Afterwards, the resulting solution 
containing MnFe2O4 nanoparticles was cooled to room temperature. The nanoparticles were 
precipitated by adding 40 mL of ethanol and further separated by centrifugation (7830 rpm, 10 
min). Finally, MnFe2O4 nanoparticles were dispersed in 10 mL of hexane with 50 µL of oleic acid 
and 50 µL of oleylamine. 
 Synthesis of 8.2 nm MnFe2O4 nanoparticles: The larger MnFe2O4 nanoparticles were 
synthesized by growing MnFe2O4 on the MnFe2O4 nanoparticles prepared previously. Generally, 
two mmol of Fe(acac)3, 1 mmol of Mn(acac)2, 10 mmol of 1,2-dodecanediol, 2 mmol of oleic acid, 
and 2 mmol of oleylamine were dissolved in 20 mL of benzyl ether in a 100 mL three-neck flask. 
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The MnFe2O4 nanoparticles (90 mg) obtained previously in 10 mL of hexane were added to the 
reaction mixture. The reaction mixture was heated to 90 °C and kept at that temperature for 30 min 
to remove hexane. Then the reaction mixture was heated to 200 °C under the flow of nitrogen with 
vigorously stirring. After 1 h, the reaction mixture was heated to 298 °C and refluxed for 1 h. The 
nanoparticles were precipitated by adding 40 mL of ethanol and further separated by centrifugation. 
Finally, the MnFe2O4 nanoparticles were re-dispersed in 10 mL of hexane with 50 µL of oleic acid 
and 50 µL of oleylamine. 
 Synthesis of 10.1 nm MnFe2O4@CoFe2O4 nanoparticles: To coat CoFe2O4 on the surface of 
MnFe2O4 nanoparticles, two mmol of Fe(acac)3, 1 mmol of Co(acac)2, 10 mmol of 1,2-
dodecanediol, 2 mmol of oleic acid, and 2 mmol of oleylamine were dissolved in 20 mL of benzyl 
ether in a 100 mL three-neck flask. MnFe2O4 (8.2 nm) nanoparticles (180 mg) obtained previously 
in 10 mL of hexane were added to the reaction mixture. The synthetic procedure and reaction 
temperature were the same as that of the 8.2 nm MnFe2O4 nanoparticles synthesis. Finally, 
MnFe2O4@CoFe2O4 nanoparticles (10.1 nm) were re-dispersed in 10 mL of hexane with 50 µL of 
oleic acid and 50 µL of oleylamine. 
Synthesis of 11.4 nm MnFe2O4@CoFe2O4 nanoparticles: To coat CoFe2O4 on the surface of 
MnFe2O4@CoFe2O4 (10.1 nm) nanoparticles to obtain the larger nanoparticles, two mmol of 
Fe(acac)3, 1 mmol of Co(acac)2, 10 mmol of 1,2-dodecanediol, 2 mmol of oleic acid, and 2 mmol 
of oleylamine were dissolved in 20 mL of benzyl ether in a 100 mL three-neck flask. 
MnFe2O4@CoFe2O4 (10.1 nm) nanoparticles (270 mg) obtained previously in 10 mL of hexane 
were added to the reaction mixture. The synthetic procedure and reaction temperature were the 
same as that of 10.1 nm MnFe2O4@CoFe2O4 nanoparticle synthesis. Finally, MnFe2O4@CoFe2O4 
nanoparticles (11.4 nm) were re-dispersed in 10 mL of hexane with 50 µL of oleic acid and 50 µL 
of oleylamine for further use. 
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3.13.4 Measurement of Specific Loss Power 
 Measurement of the heat generation from 11.4 nm MnFe2O4@CoFe2O4 nanoparticles was 
performed using a magnetic hyperthermia system (MSI Automation, Inc.) The diameter of the 
five-turn copper coil was 50 mm. The alternating frequency, induction power, and magnetic field 
strength were 375 kHz, 5 kW, and 20 kAm-1, respectively. The MnFe2O4@CoFe2O4 nanoparticles 
were dispersed in toluene in a 2 mL of glass sample vial and the concentrations were 2.5, 1, or 0.5 
mg/mL. The temperature of the solution was recorded after the exposure to the AMF as a function 
of time. The specific loss power of MnFe2O4@CoFe2O4 was calculated using equation (1), where 
C is the volumetric heat capacity of solvent, Vs is the sample volume, m is the mass of 
MnFe2O4@CoFe2O4, and dT/dt is the initial slope of the time-dependent temperature increase 
curve. 
                       Specific loss power	= CVs
m
dT
dt
    (1) 
3.13.5 Synthesis of APTS-Functionalized MnFe2O4@CoFe2O4@Mesoporous Silica 
(Mag@MSNs-APTS) Core@Shell nanoparticles 
MnFe2O4@CoFe2O4 nanoparticles (11.4 nm, 2.5 mg) were dispersed in 0.2 mL of chloroform. 
2 mL of CTAB aqueous solution (40 mg of CTAB, 54 mM) was added to the MnFe2O4@CoFe2O4 
colloidal solution, and the mixture was sonicated for 10 min with a fully sealed cover to generate 
oil-in-water emulsion. The emulsion was then sonicated for 1 h to evaporate chloroform. The clear 
well-dispersed MnFe2O4@CoFe2O4 colloidal aqueous solution (2 mL) was obtained and 
designated as MnFe2O4@CoFe2O4@CTAB. Meanwhile, 40 mg of CTAB was dissolved in 18 mL 
of water with 120 µL of NaOH solution (2 M) in a 100 mL flask. Then, the previous 2 mL of 
MnFe2O4@CoFe2O4@CTAB colloidal solution was added to the reaction solution with vigorously 
stirring, and the temperature of the solution was brought up to 70 °C. To coat mesoporous silica 
shell on the surface of MnFe2O4@CoFe2O4@CTAB, 200 µL of TEOS and 1.2 mL of ethyl acetate 
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were added dropwise into the solution. After stirring for 2 h, 40 µL of APTS was added dropwise 
into the solution and stirred for another 2 h to generate amine functionalized 
MnFe2O4@CoFe2O4@MSNs (Mag@MSNs-APTS, Mag denotes magnetic). Afterwards, the 
solution was cooled to room temperature and Mag@MSNs-APTS was centrifuged and washed 3 
times with ethanol. Subsequently, Mag@MSNs-APTS was dispersed in 20 mL of ethanol 
containing 120 mg of NH4NO3 and the reaction was stirred at 60 °C for 1 h to remove the 
surfactants. The surfactant removal procedures were repeated twice and Mag@MSNs-APTS was 
washed several times with D.I. water and ethanol to obtain the surfactant-free Mag@MSNs-APTS. 
3.13.6 Synthesis of ACVA Functionalized Mag@MSNs-APTS (Mag@MSNs-ACVA) 
The conjugation of 4,4′-azobis(4-cyanovaleric acid) (ACVA) on the surface of Mag@MSNs-
APTS was carried out by using an amide bond coupling reaction. At first, the carboxylic acid of 
ACVA (20 mg) was activated by 40 mg of EDC and 20 mg of NHS in 4 mL of DMSO. To crosslink 
the activated ACVA to the primary amine of APTS, after 30 min activation at room temperature, 
20 mg of Mag@MSNs-APTS dispersed in 4 mL of DMSO were added dropwise to the activated 
ACVA in DMSO and stirred for 24 h. The ACVA functionalized Mag@MSNs-APTS 
(Mag@MSNs-ACVA) was washed, centrifuged, and re-suspended in DMSO 3 times to remove 
the excess ACVA, EDC, and NHS. 
3.13.7 Synthesis of AMA Functionalized Mag@MSNs-ACVA (Mag@MSNs-AMA) 
The conjugation of 1-adamantylamine (AMA) on the surface of Mag@MSNs-ACVA was 
carried out through amide bond formation between the carboxylic acid group of ACVA and the 
primary amine of AMA. Typically, the carboxylic acid groups of Mag@MSNs-ACVA (20 mg) 
were activated by 40 mg of EDC and 20 mg of NHS in 4 mL of DMSO. To crosslink ACVA to 
AMA, after 30 min activation at room temperature, 20 mg of AMA dissolved in 4 mL of DMSO 
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was added to the activated Mag@MSNs-ACVA in DMSO and stirred for 24 h. Finally, AMA 
functionalized Mag@MSNs-ACVA (Mag@MSNs-AMA) was washed, centrifuged, and re-
suspended in DMSO 3 times to remove the excess AMA, EDC, and NHS. 
3.13.8 Loading of Fluorescein or DOX in Mag@MSNs-AMA and Snap-Top Attachment 
(Mag@MSNs-AMA-CD) 
The loading of fluorescein or DOX was carried out by using water as the solvent. In general, 
1 mg of Mag@MSNs-AMA was dispersed in 1 mL of D.I. water with 3 mM fluorescein or 2.6 
mM DOX. After stirring for 24 h, 16 mg of the β-CD capping agent was added to the solution to 
prevent fluorescein or DOX from being released. The sample was designated as Mag@MSNs-
AMA-CD. After mixing for 48 h, the fluorescein or DOX-loaded Mag@MSNs-AMA-CD was 
centrifuged and washed with water 5 times (fluorescein) or with water 7 times followed by PBS 2 
times (DOX) to remove the free fluorescein or DOX molecules. The final product was suspended 
in 2 mL of D.I. water for the water bath heating or magnetic heating triggered release experiments. 
3.13.9 Triggered Release of Fluorescein from Mag@MSNs-AMA-CD by Water Bath Heating 
0.5 mg of fluorescein loaded Mag@MSNs-AMA-CD was dispersed in 1 mL of water in an 
Eppendorf tube. Water baths at 37, 60, or 80 °C were prepared. The samples were heated in the 37, 
60, or 80 °C water baths for 10 min per heating cycle (heating on = 10 min). After each heating 
cycle, the solution was centrifuged and 20 µL of supernatant was collected and diluted. The 
released fluorescein molecules were then monitored by fluorescence spectroscopy, followed by 
another heating cycle. The time period between each heating cycle was 10 min (heating off = 10 
min). In total, 9 such heating/monitoring cycles were performed for the samples in both the 37 °C 
and the 60 °C water baths; 4 such heating/monitoring cycles were performed for the sample in the 
80 °C water bath. For comparison, the supernatant of the sample in the air at room temperature (23 
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°C) was collected and the released fluorescein was monitored at the same time with the samples 
heated in water baths. The intensity of the fluorescein released from Mag@MSNs-AMA-CD was 
integrated from 510 nm to 520 nm. 
3.13.10 Triggered Release of Fluorescein or DOX from Mag@MSNs-AMA-CD by Single 
Cycle of Magnetic Heating  
0.5 mg of fluorescein or DOX-loaded Mag@MSNs-AMA-CD was dispersed in 1 mL of water 
in an Eppendorf tube. Before being triggered by magnetic heating, the fluorescein or DOX loaded 
nanoparticle solution at room temperature was centrifuged and 20 µL of supernatant was collected 
every 20 min (fluorescein) or 30 min (DOX) and measured by fluorescence spectroscopy. After 
monitoring the release every 20 min over a period of 40 min (fluorescein) or every 30 min over a 
period of 60 min (DOX) at room temperature, the sample was exposed to an alternating magnetic 
field (AMF) in the center of a water-cooled five-turn copper coil (5 cm height and diameter) at a 
power of 5 kW and a frequency of 375 kHz for 1, 2, 3, 5, and 10 min, respectively, followed by 
monitoring the release of fluorescein or DOX. After that, several monitoring cycles were 
performed every 10 min (fluorescein), or every 30 min over a period of 180 min followed by every 
2 h over a period of 6 h (DOX) until the release of fluorescein or DOX leveled off. The intensities 
of the fluorescein or DOX released from Mag@MSNs-AMA-CD was integrated from 510 nm to 
520 nm or 580 nm to 605 nm, respectively. 
3.13.11 Triggered Release of Fluorescein from Mag@MSNs-AMA-CD by Sequential Cycles 
of Magnetic Heating  
0.5 mg of fluorescein loaded Mag@MSNs-AMA-CD was dispersed in 1 mL of water in an 
Eppendorf tube. Before being triggered by magnetic heating, the fluorescein loaded nanoparticle 
solution at room temperature was centrifuged and 20 µL of supernatant was collected every 10 
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min and measured by fluorescence spectroscopy. After monitoring the release every 10 min over 
a period of 30 min at room temperature, the sample was exposed to an AMF in the center of a 
water-cooled five-turn copper coil (5 cm height and diameter) at a power of 5 kW and a frequency 
of 375 kHz for 3 min, followed by monitoring the release of fluorescein. Several monitoring cycles 
were performed every 10 min until the release of fluorescein leveled off, followed by another AMF 
heating for 3 min. In total, 3 such heating/monitoring series were performed to achieve the 
maximum release of fluorescein. The intensity of the fluorescein released from Mag@MSNs-
AMA-CD was integrated from 510 nm to 520 nm. 
3.13.12 Zeta Potential Value Measurement of Mag@MSNs-ACVA after Bulk or Magnetic 
Heating 
 0.5 mg of Mag@MSNs-ACVA was dispersed in 1 mL of water in an Eppendorf tube. For 
bulk heating treatment, the Eppendorf tubes containing the samples were put in a hot water bath 
at 37, 60, or 80 °C for 10 min. Afterwards, the solution was centrifuged and the nanoparticles were 
washed and redispersed in D.I. water. For magnetic heating treatment, the Eppendorf tube 
containing the sample was exposed to an AMF at a power of 5 kW and a frequency of 375 kHz for 
10 min. Similarly, after the treatment, the solution was centrifuged and the nanoparticles were 
washed and redispersed in D.I. water. The zeta potential values of the samples after bulk heating 
or magnetic heating treatment were measured. 
3.13.13 Loading Capacity Analysis of Fluorescein or DOX 
 After loaded with 3 mM fluorescein or 2.6 mM DOX and capped with β-CD, Mag@MSNs-
AMA-CD were washed with water 5 times (fluorescein) or washed with water 7 times followed 
by PBS 2 times (DOX). The supernatants collected during each washing step were collected and 
their absorption spectra were measured by UV-Vis spectroscopy. To calculate the amount of 
fluorescein or DOX loaded in Mag@MSNs-AMA-CD, the amount of fluorescein or DOX 
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removed during all the washing steps was subtracted from the total amount of fluorescein or DOX 
in the initial loading solution. The loading capacities of fluorescein or DOX were calculated using 
the maximum absorbance at 491 nm (fluorescein) or 503 nm (DOX) and the following definition 
of loading capacity: (mass of loaded fluorescein or DOX / mass of particles) x 100%.  
3.13.14 Release Efficiency Analysis of Fluorescein or DOX 
To determine the release efficiency of fluorescein, 0.5 mg of fluorescein or DOX-loaded 
Mag@MSNs-AMA-CD in 1 mL of water was put in a hot water bath at 90 °C. The fluorescein or 
DOX released from the nanoparticles was separated from the nanoparticles by centrifugation and 
recorded by spectrophotometry. The intensities of the fluorescein or DOX released from 
Mag@MSNs-AMA-CD were integrated from 510 nm to 520 nm or 580 nm to 605 nm, respectively. 
The fluorescence intensities corresponding to the fluorescein or DOX released after being heated 
at 90 °C for 50 min was set as the 100% release. The release efficiencies of fluorescein or DOX is 
defined as (mass of released cargo/mass of loaded cargo) x 100%. 
3.13.15 Cell Culture 
 Human pancreatic cancer cells (PANC-1) were cultured in T-75 flasks (Corning) with vented 
caps in a high glucose Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10 % 
fetal bovine serum (FBS), and 1 % antibiotics (100 U/mL penicillin and 100 µg/mL streptomycin) 
in a humidity-controlled incubator at 37 °C with 5 % CO2. In all culture conditions, the PANC-1 
culture media were daily changed and the cells were harvested by trypsinization with 0.05 % 
trypsin-ethylenediaminetetraacetic acid (EDTA) for passaging every 2-3 days. 
3.13.16 In Vitro Cytotoxicity 
 The viabilities of PANC-1 after the treatment of Mag@MSNs-AMA-CD and DOX-loaded 
Mag@MSNs-AMA-CD were examined by using a cell counting kit-8 (CCK-8) assay. The cells 
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were seeded in 96-well plates at a density of 5 x 103 cells per well in 200 µL of Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% FBS and 1% antibiotics in a humidity-
controlled incubator at 37 °C for 24 h attachment. After the attachment, the medium was removed 
and the cells were incubated in 200 µL of fresh DMEM containing 0, 2, 5, 10, 15, 20, and 40 µg 
of Mag@MSNs-AMA-CD (i.e. 0, 10, 25, 50, 75, 100, and 200 µg/mL) for 20 or 70 h in an 
incubator at 37 °C. After incubation, the medium was removed and the treated cells were washed 
twice with DPBS. To measure the cell viability, 100 µL of DMEM and 10 µL of CCK-8 cellular 
cytotoxicity reagent were added to each well. Then, the plates were put in the incubator for 2 h at 
37 °C. To measure the number of the viable cells in each condition, a plate reader (Tecan M1000) 
was used to measure the absorbance at 450 nm and 650 nm (as the reference). The DMEM medium 
(100 µL) mixed with CCK-8 reagent (10 µL) served as a background control. 
3.13.17 In Vitro Drug Delivery Triggered by an AMF and Cellular Cytotoxicity 
 PANC-1 cells were seeded in 8-well chamber slides at a density of 2.5 x 104 cells per well in 
500 µL of DMEM supplemented with 10% FBS and 1% antibiotics in a humidity-controlled 
incubator at 37 °C for 24 h attachment. After the attachment, the medium was removed and the 
cells were incubated in 300 µL of fresh DMEM containing 15 µg of DOX-loaded Mag@MSNs-
AMA-CD (50 µg/mL) for 4 h in an incubator at 37 °C. The control groups including cells not 
treated by nanoparticles and those treated with Mag@MSNs-AMA-CD (50 µg/mL) without DOX 
were also investigated. After 4 h incubation, the medium was removed and the treated cells were 
washed twice with DPBS (500 µL x 2).  
The chamber slides containing the treated or untreated PANC-1 cells in 500 µL of medium 
were exposed to an AMF in the center of a water-cooled five-turn copper coil at a power of 5 kW 
and a frequency of 375 kHz for 2, 5, and 10 min, respectively. After the AMF treatment, the cells 
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were further incubated in an incubator at 37 °C for 12 h. To measure the cell viability after the 
treatment, the medium was removed and 200 µL of DMEM and 20 µL of CCK-8 reagent were 
added to each well. Afterwards, the chamber slides were put in the incubator for 2 h at 37 °C. 
Finally, 100 µL of the reaction solution was transferred to a 96-well plate and the viability was 
measured by a plate reader described above. 
3.13.18 Fluorescence Microscope Images of PANC-1 Cells after Treatment 
PANC-1 cells were seeded in 8-well chamber slides at a density of 2.5 x 104 cells per well in 500 
µL of DMEM supplemented with 10% FBS and 1% antibiotics in a humidity-controlled incubator 
at 37 °C for 24 h attachment. After the attachment, the medium was removed and the cells were 
incubated in 300 µL of fresh DMEM containing 15 µg of DOX-loaded Mag@MSNs-AMA-CD 
(50 µg/mL) for 4 h in an incubator at 37 °C followed by washing with DPBS 2 times (500 µL x 2). 
The control group including cells not treated by nanoparticles was also investigated. After the 
washing, the chamber slides containing the treated or untreated PANC-1 cells in 500 µL of medium 
were exposed to an AMF in the center of a water-cooled five-turn copper coil at a power of 5 kW 
and a frequency of 375 kHz for 10 min. After the AMF treatment, the cells were further incubated 
in an incubator at 37 °C for 12 h followed by washing with DPBS 3 times (500 µL x 3) and fixed 
with 4 % paraformaldehyde in PBS for 20 min. Then, the fixed cells were washed with DPBS 3 
times (500 µL x 3) with slightly shake. Afterwards, the nuclei of the cells were stained with 
Hoechst 33342 (500 µL, 5 µg/mL) for 20 min followed by washing with DPBS 5 times (500 µL x 
5). Finally, the stained cells covered by mounting medium cover glass before being visualized 
under a Zeiss fluorescence microscope. 
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3.15 Scheme and Figures 
 
Scheme 3.1. (a) Schematic illustration of the synthesis of azo snap-top core@shell mesoporous silica 
nanoparticles and triggered release under an alternating magnetic field. (b) Scheme of the conjugation and 
capping of APTS, ACVA, AMA, and β-CD on the surface of core@shell nanoparticles (EDC = 1-ethyl-3-
(-3-dimethylaminopropyl) carbodiimide; NHS = N-hydroxysuccinimide; DMSO = dimethyl sulfoxide). 
After the trigger with heat, the cleavage of C-N bonds of ACVA makes the bulky β-CD and AMA 
complexation leave from the surface, and the cargo could thus be released from Mag@MSN-. 
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Figure 3.1. (a) Schematic illustration of the synthesis of MnFe2O4@CoFe2O4 nanoparticles by a seed-
mediated thermal decomposition method. (b) Corresponding TEM images and (c) diameter distributions of 
MnFe2O4 and MnFe2O4@CoFe2O4 nanoparticles after each step. 
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Figure 3.2. (a) TEM image and (b) size distribution of 11.4 nm MnFe2O4@CoFe2O4 nanoparticles. Inset 
shows the schematic illustration of magnetic core@shell MnFe2O4@CoFe2O4 structure. (c) Field dependent 
magnetization curve of MnFe2O4@CoFe2O4 nanoparticles at 300 K. Inset shows small scale of field 
dependent magnetization curves and MnFe2O4@CoFe2O4 nanoparticles in hexane were attracted by a 
magnet. (d) Time- and concentration-dependent temperature increase profiles of toluene solution containing 
MnFe2O4@CoFe2O4 nanoparticles triggered by an AMF. 
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Figure 3.3. High angle X-ray diffraction pattern of MnFe2O4@CoFe2O4 nanoparticles. 
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Figure 3.4. (a) Fourier-transform Infrared (FTIR) spectrum and (b) thermogravimetric analysis (TGA) of 
MnFe2O4@CoFe2O4 nanoparticles. 
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Figure 3.5. (a) TEM image of APTS functionalized core@shell nanoparticles (Mag@MSNs-APTS). (b) 
Nitrogen adsorption/desorption isotherms of Mag@MSNs-APTS at 77 K. The BET surface area and pore 
volume are 653.4 m2/g, and 1.06 cm3/g, respectively. Inset shows the pore diameter distribution of 
Mag@MSNs-APTS. The average pore diameter is 2.8 nm. 
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Figure 3.6. Size distribution of 55.0 nm Mag@MSNs-APTS core@shell nanoparticles. 
 
 
 
Figure 3.7. Dynamic light scattering diameter distribution of Mag@MSNs-APTS in deionized H2O at room 
temperature. 
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Figure 3.8. (a) Zeta potential values, (b) Fourier transform infrared spectroscopy (FT-IR), and (c) 
thermogravimetric analysis (TGA) of Mag@MSNs, Mag@MSNs-APTS, Mag@MSNs-ACVA, and 
Mag@MSNs-AMA, respectively. (d) TEM image of Mag@MSNs-AMA. Inset shows the enlarged 
Mag@MSNs-AMA. (e) N2 adsorption/desorption isotherms of Mag@MSNs-AMA at 77 K. Inset shows 
the pore diameter distribution of Mag@MSNs-AMA. The BET surface area, pore volume, and average pore 
diameter are 593.5 m2/g, 0.96 cm3/g, and 2.8 nm, respectively. 
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Figure 3.9. (a) The cleavage of C-N bonds caused by bulk heating for 10 min. (b) Zeta potential values of 
Mag@MSNs-ACVA after 10 min of bulk heating in D.I. water. The concentration of Mag@MSNs-ACVA 
in D.I. water is 0.5 mg/mL. (c) The release of fluorescein from Mag@MSN- caused by bulk heating trigger 
in water bath at 37 °C, 60 °C, or 80 °C. The sample stayed at room temperature (23 °C) was also recorded 
as a control. (d) Release efficiency of fluorescein from Mag@MSNs- after the bulk heating at 23 °C, 37 °C, 
60 °C, or 80 °C trigger for 10 min (N = 3). 
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Figure 3.10. Time dependent release efficiency of fluorescein from Mag@MSN- caused by bulk heating 
trigger in water bath at 37 °C, 60 °C, and 80 °C. The sample stayed at room temperature (23 °C) was also 
recorded as a control. 
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Figure 3.11. (a) Dose control of cargo release from Mag@MSNs- by adjusting the AMF “ON” time. Time-
dependent release profile of fluorescein from Mag@MSNs- through magnetic actuation under AMF for (b) 
1, (c) 2, (d) 3, (e) 5, and (f) 10 min, respectively. (g) The release efficiency of fluorescein at plateau and the 
solution temperature after the various time periods of trigger under AMF (N = 3). 
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Figure 3.12. TEM images of fluorescein-loaded Mag@MSN-AMA-CD after 10 min exposure of the AMF 
trigger. 
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Figure 3.13. (a) The cleavage of C-N bonds caused by 10 min of AMF trigger. (b) Zeta potential values of 
Mag@MSNs-ACVA before and after 10 min of AMF trigger in D.I. water. The concentration of 
Mag@MSNs-ACVA in D.I. water is 0.5 mg/mL. 
  
 112 
 
Figure 3.14. Time dependent release profile of fluorescein from Mag@MSNs- through magnetic actuation 
under AMF for 3 min for 3 cycles (N = 3). The temperature of the solution right after each exposure was 
measured to be 26 °C, 3 degrees higher than that before each AMF exposure. 
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Figure 3.15. (a) UV-Vis spectra of Mag@MSNs-AMA-CD and DOX-loaded Mag@MSNs-AMA-CD in 
PBS. Inset shows the photograph of tubes containing (1) Mag@MSNs-AMA-CD and (2) DOX-loaded 
Mag@MSNs-AMA-CD in PBS. Time-dependent release profile of DOX from Mag@MSNs- in PBS 
through magnetic actuation under AMF for (b) 2, (c) 5, and (d) 10 min, respectively (N=3). The 
concentration of DOX-loaded Mag@MSNs-AMA-CD in PBS for each release study was 0.5 mg/mL. 
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Figure 3.16. (a) Cytotoxicity of Mag@MSNs-AMA-CD. PANC-1 was incubated with Mag@MSNs-AMA-
CD at various nanoparticle concentrations for 20 and 70 h, and the viability was determined by a CCK-8 
assay and normalized to the control without Mag@MSNs-AMA-CD treatment. Data are means ± SD of 
three independent experiments. (b) Cytotoxicity of DOX-loaded Mag@MSNs-AMA-CD. PANC-1 was 
incubated with DOX-loaded Mag@MSNs-AMA-CD at various concentrations for 4 h. The viability was 
determined by a CCK-8 assay and normalized to the control without DOX-loaded Mag@MSNs-AMA-CD 
nanoparticle treatment. Data are means ± SD of three independent experiments. (c) After the 4 h treatment 
of DOX-loaded Mag@MSNs-AMA-CD, cells were allowed to grow in the regular culture medium for 12 
h, and the viability was determined by a CCK-8 assay and normalized to the control without DOX-loaded 
Mag@MSNs-AMA-CD treatment. Data are means ± SD of three independent experiments.  
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Figure 3.17. (a) In vitro cellular killing effect of DOX-loaded Mag@MSNs-AMA-CD after AMF exposure. 
PANC-1 cells were treated with DOX-loaded Mag@MSNs-AMA-CD followed by various lengths of AMF 
exposure. (b) The viability of PANC-1 after treatment by Mag@MSNs-AMA-CD, or DOX-loaded 
Mag@MSNs-AMA-CD. The control is cells without treatment by nanoparticles. The cells were treated for 
4 h at a concentration of 50 µg/mL followed by 2, 5, or 10 min of AMF exposure. The cells were allowed 
to grow in the regular culture medium for 12 h, and the viability was determined by a CCK-8 assay. Data 
are means ± SD of four independent experiments. The viable cells in each sample were determined by the 
absorbance at 450 nm and 650 nm (as a reference). (c) Fluorescence microscope images of PANC-1 cells 
(ii) after 4 h treatment by DOX-loaded Mag@MSNs-AMA-CD, and (iii) after 4 h incubation with DOX-
loaded Mag@MSNs-AMA-CD followed by 10 min of AMF exposure. The control group (i) is cells without 
the treatment by nanoparticles. Panels from left to right: cells of PANC-1 with the blue-emitting nucleus 
stained by Hoechst 33342; red emission from DOX; and the merged images. Scale bar is 20 µm. 
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CHAPTER 4 
A Responsive Mesoporous Silica Nanoparticle Platform for 
Magnetic Resonance Imaging-Guided High-Intensity 
Focused Ultrasound-Stimulated Cargo Delivery with 
Controllable Location, Time, and Dose 
This chapter of the dissertation was adapted and reprinted with permission from Chi-An Cheng#, 
Wei Chen#, Le Zhang, Holden H. Wu, Jeffrey I. Zink J. Am. Chem. Soc. 2019, 141, 17670–17684. 
Copyright 2019 American Chemical Society. Co-author contributions: Cheng C. A.# and Chen 
W.# (co-first authors) designed and performed the synthesis and characterization of material, and 
all the chemistry related studies. Zhang L. performed the magnetic resonance imaging-guided high 
intensity focused ultrasound experiments. Holden H. Wu and Jeffrey I. Zink were the P.Is. 
 
Table of Content Figure 
 
4.1 Abstract 
Magnetic resonance imaging (MRI) is an essential modality for clinical diagnosis, and MRI-
guided high-intensity focused ultrasound (MRgHIFU) is a powerful technology for targeted 
therapy. Clinical applications of MRgHIFU primarily utilize hyperthermia and ablation to treat 
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cancerous tissue, but for drug delivery applications thermal damage is undesirable. A biofriendly 
MRgHIFU-responsive mesoporous silica nanoparticle (MSN) platform that is stimulated within a 
physiological safe temperature range has been developed, reducing the possibility of thermal 
damage to the surrounding healthy tissues. Biocompatible polyethylene glycol (PEG) was 
employed to cap the pores of MSNs, and the release of cargo molecules by HIFU occurs without 
substantial temperature increase (∼4 °C). To visualize by MRI and measure the stimulated delivery 
in situ, a U.S. Food and Drug Administration (FDA)-approved gadolinium-based contrast agent, 
gadopentetate dimeglumine (Gd(DTPA)2− ), was used as the imageable cargo. Taking advantage 
of the three-dimensional (3-D) imaging and targeting capabilities of MRgHIFU, the release of 
Gd(DTPA)2− stimulated by HIFU was pinpointed at the HIFU focal point in 3-D space in a tissue-
mimicking gel phantom. The amount of Gd(DTPA)2− released was controlled by HIFU stimulation 
times and power levels. A positive correlation between the amount of Gd(DTPA)2− released and 
T1 was found. The MRgHIFU-stimulated cargo release was further imaged in a sample of ex vivo 
animal tissue. With this technology, the biodistribution of the nanocarriers can be tracked and the 
MRgHIFU-stimulated cargo release can be pinpointed, opening up an opportunity for future 
image-guided theranostic applications. 
 
4.2 Introduction 
Noninvasive imaging is an essential technology for theranostics (i.e., integrated diagnosis and 
therapy). Compared with modalities such as X-ray, computed tomography, ultrasound, positron 
emission tomography, or optical imaging, magnetic resonance imaging (MRI) provides an 
especially powerful suite of information that identifies and characterizes diseased tissues.1 In 
addition, MRI does not involve ionizing radiation and achieves three-dimensional (3-D) 
anatomical coverage with flexible imaging orientations even for tissues deep in the body. 
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Accordingly, MRI is increasingly being used in clinical practice to guide therapies, such as 
hyperthermia and ablation using high-intensity focused ultrasound (HIFU)2,3 or near-infrared laser 
light,4−6 in conjunction with real-time MRI temperature measurement during the procedures.7 
To date, MRI-guided HIFU (MRgHIFU) therapies for uterine fibroids, prostate tissue, 
essential tremor, tremor-dominated Parkinson’ s disease, and bone metastases have been approved 
by the U.S. Food and Drug Administration (FDA).8,9 HIFU is a noninvasive technique with 
millimeter-sized energy-focusing ability and deep tissue penetration capability.8 When ultrasound 
waves propagate in the body, both thermal and mechanical effects (e.g., cavitation) occur.10 A 
variety of HIFU-responsive nanoparticles that take advantage of these effects have been developed 
in order to enhance image contrast or to enable controlled release of encapsulated theranostic 
cargos at specific sites of interest.11−13 Most of the well-developed HIFU-responsive drug carriers 
include heat-responsive thermosensitive liposomes.14−18 Just recently, ThermoDox (lyso-
thermosensitive liposomal doxorubicin) in combination with MRgHIFU-generated hyperthermia 
has received Institutional Review Board (IRB) approval to begin a Phase I study for the local 
treatment of the primary tumor in metastatic breast cancer.19 As a source of localized hyperthermia, 
HIFU enhanced the delivery of doxorubicin carried by thermosensitive liposomes.14 
Although chemotherapy combined with mild hyperthermia (39−42 °C) have synergistic 
effects that may increase anticancer efficacy,20,21 the temperature window for effective 
hyperthermia is narrow,15,22,23 and exceeding the window may induce tumor cell metastasis or 
vascular shutdown.24−26 Even though the HIFU energy can be spatially focused, it may not always 
be possible to effectively increase the temperature in the targeted tissue because of heat dissipation 
by the blood flow in the body (i.e., heat sink effect). 
Another category of HIFU-responsive nanoparticles relies on ultrasound-associated 
mechanical forces.27 Polymers were found to degrade faster and release incorporated cargos upon 
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ultrasound exposure.28 A wide range of mechanically responsive cargo carriers29,30 such as 
microbubbles,31,32 micelles,33−35 emulsions,36 and polymeric nanoparticles37−40 have been 
developed for drug delivery. However, most of the organic carriers formed via self-assembly are 
stable only above the critical micelle concentration (CMC) and are prone to disassembly when 
diluted in the biological environment.41 Other factors such as shear stress, serum protein 
interactions, ionic strength, or pH may also lead to premature rupture of those drug carriers during 
circulation in the bloodstream and result in leakage of drugs before arriving at the target site.42−44 
In contrast, sturdy structures of particulate drugs may be too stable to release drugs at the target 
tissue.45 
We have developed a new MRgHIFU-responsive platform based on mesoporous silica 
nanoparticles (MSNs). MSNs are rigid nanomaterials with precise size control of the particle 
diameter, high surface area and large pore volume for cargo loading and delivery,46−50 high 
biocompatibility,51−53 high cellular internalization efficiency, and easy surface 
functionalization.54−60 Several ultrasound-responsive caps have thus been designed as the 
gatekeepers of cargo-loaded MSNs.61 Most of the caps are thermally responsive polymers that 
require a temperature rise to undergo physical change (e.g., phase transition or conformation 
change) in order to release cargos. Only a few examples of mechanically operable caps activated 
within a physiological temperature range or even at a lower temperature have been reported.62−66 
A copolymer cap including an ultrasound-labile tetrahydropyranyl moiety that is cleavable by 
laboratory ultrasound was shown to control the cargo release from MSNs, but the temperature 
during ultrasound stimulation was not closely examined.63,64 In an effort to set the stage for clinical 
translation, biocompatible polyethylene glycol (PEG), one of the most widely used polymers in 
biomedical research, was chosen in this work to cap the pores of MSNs. PEG was shown to cleave 
because of mechanical forces generated by ultrasound,67 so that cargos can be released primarily 
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in response to the mechanical effects of MRgHIFU without substantial temperature increase. 
In this work, an FDA-approved gadolinium-based MRI contrast agent gadopentetate 
dimeglumine (Gd(DTPA)2− ) (Magnevist, Bayer) was used as the imageable cargo to demonstrate 
the performance of our proposed nanoparticle delivery system; Gd(DTPA)2− release causes an 
easily measurable MRI contrast change. Taking advantage of the 3-D capabilities of MRI and 
HIFU, the release of Gd(DTPA)2− from the nanoparticles was pinpointed at the HIFU focal point 
in 3-D space. The spatial- and temporal-control of Gd-(DTPA)2− release was further demonstrated 
in ex vivo tissue, paving the way for in vivo studies in the future. Combining the advantages of 
mechanically responsive PEG and the focusing ability of MRgHIFU, HIFU-stimulated cargo 
delivery was achieved within a physiological temperature range, avoiding the need to substantially 
increase local temperature in areas with potential heat sink effects and reducing the possibility of 
thermal damage to the surrounding healthy tissues. With this technology, the biodistribution of the 
nanocarriers can be tracked by MRI and stimulated cargo release pinpointed by HIFU so as to have 
improved information for diagnosis or treatment of certain diseases (e.g., cancer). In future studies, 
a drug (e.g., anticancer chemotherapeutic agent) can be encapsulated together with an imaging 
agent (e.g., Gd-(DTPA)2− ), providing a new tool to achieve precision medicine—to deliver the 
precise dosage of drugs at a specific and controlled time and location. 
 
4.3 Design of Ultrasound-Responsive MSNs 
The nanoparticles that were designed to release cargo molecules by HIFU stimulation under 
MRI guidance have three main components: an MSN as the cargo carrier, MRI contrast agents as 
the cargo, and ultrasound-responsive PEG as the cap (Scheme 4.1). The FDA-approved contrast 
agent gadolinium-diethylenetriamine pentaacetic acid (Gd(DTPA)2−) and its counterions 
meglumines (i.e., gadopentetate dimeglumine: Magnevist) were chosen as the cargo. The PEG cap 
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is an FDA-approved polymer that has been clinically used for pharmaceutical formulations. 
PEGylated nanoparticles exhibit the stealth effect because their interactions with the 
reticularendothelial system are reduced, thus prolonging their circulation time and enhancing their 
uptake in tumor tissues via the enhanced permeability and retention (EPR) effect.68−71 PEG also 
improves the colloidal stability of the nanoparticles. In this design, conjugated PEG seals the pores 
of the MSNs and exposes them only when stimulated by HIFU, where vigorous vibration and/or 
cleavage of PEG67 are induced. The entrapped Gd(DTPA)2− that is released by externally 
controlled HIFU stimulation causes T1-weighted MRI contrast changes. Therefore, MRI can be 
used to characterize the amount of HIFU-stimulated cargo release from the MSNs. Most 
importantly, this HIFU-stimulated cargo release does not require substantial heating, opening up 
an opportunity for drug delivery when temperature increase is not practical or not desired. 
The MSN nanocarriers were synthesized by a sol−gel reaction in the presence of cationic 
surfactant templates by following published procedures.46,72 The obtained nanoparticles were 91.6 
± 15.1 nm in diameter (Figure 4.1) and possessed an MCM-41 type structure (Figure 4.2a). To 
enable both the loading of Gd(DTPA)2− in the pores of MSNs and the conjugation of dicarboxylic 
acid-terminated PEG (HOOC-PEG-COOH) (average Mn = 2000 Da) on the surface of MSNs, the 
inner and outer surfaces of MSNs were functionalized with amine groups by postgrafting the silica 
surface with (3-aminopropyl)triethoxysilane (APTS) (designated as MSNs-APTS) (Scheme 4.1). 
Negatively charged Gd(DTPA)2− can interact electrostatically with those positively charged amine 
groups on the inner surfaces and thus increase its loading amount. On the outer surface, HOOC-
PEG-COOH was conjugated to those amine groups by a standard 1-ethyl-3-(3-diethylaminopropyl) 
carbodiimide hydrochloride (EDC-HCl) and N-hydroxysulfosuccinimide sodium salt (sulfo-NHS) 
coupling reaction through amide bond formation (designated as MSNs-PEG). From transmission 
electron microscopy (TEM) images, the amine functionalization and PEGylation did not change 
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the morphology or mesoporous structures of the nanoparticles (Figure 4.2a). The amine 
functionalization and PEGylation to MSNs was confirmed by zeta potential (Figure 4.2b), Fourier 
transform-infrared spectroscopy (FT-IR) (Figure 4.2c), thermogravimetric analysis (TGA) 
(Figure 4.2d), N2 adsorption−desorption isotherms (Figures 4.2e, 4.3 and Table 4.1), and 
dynamic light scattering (DLS) measurements (Figure 4.2f) after each functionalization step. 
Characterization details are described in Section 4.13 Methods. The grafting amounts of APTS 
and PEG on the surface of MSNs were 3% and 18% of the total mass, respectively (Figure 4.2d). 
Compared with as-synthesized MSNs having 1045 m2/g in Brunauer−Emmett−Teller (BET) 
surface area, 1.04 cc/g in pore volume, and 2.9 nm average pore diameter, MSNs-APTS and 
MSNs-PEG showed smaller BET surface areas (595 and 108 m2/g, respectively), smaller total pore 
volumes (0.52 and 0.19 cc/g, respectively), and smaller average pore diameters (2.4 nm for MSNs-
APTS and not available for MSNs-PEG) (Table 4.1 and Figure 4.3). These decreases can be 
explained by the surface coverage of the nanoparticles and the blockage of the pore openings after 
the sequential grafting of APTS and PEG.73 The increased DLS size of MSNs (282.1 ± 8.6 nm), 
MSNs-APTS (337.5 ± 5.7 nm), and MSNs-PEG (384.2 ± 4.1 nm) in deionized H2O provided 
additional evidence of successful amine functionalization and PEGylation (Figure 4.2f). The 
colloidal stability of the PEGylated nanoparticles was examined in phosphate-buffered saline (PBS) 
(pH 7.4). Before PEGylation, the DLS size of MSNs-APTS in PBS was markedly greater (959.2 
± 27.9 nm) than that in H2O, indicating serious aggregation in PBS due to its high ionic strength 
(Figure 4.2f).63  However, after PEGylation, the DLS size of MSNs-PEG in PBS (356.6 ± 1.4 
nm) was very similar to that in H2O (Figure 4.2f), showing good colloidal stability of MSNs-PEG 
in both solvents. The difference in their colloidal stabilities is clearly illustrated in Figure 4.4, 
where MSNs-PEG and MSNs-APTS in PBS were kept undisturbed for 30 min, 1 day, and 3 days 
at room temperature. Substantial aggregation of MSNs-APTS was observed within 30 min, 
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whereas MSNs-PEG remained well-suspended even after 3 days. The improved colloidal stability 
of PEGylated nanoparticles can be explained by the blocking of surface contact between 
nanoparticles by surface PEG and preventing aggregation of the nanoparticles by such steric 
repulsion.74 
 
4.4 Gd(DTPA)2− Loading, PEG Capping, and PEG Cap Stability at Body 
Temperature 
The loading of Gd-(DTPA)2− was carried out by soaking MSNs-APTS in a Gd(DTPA)2− 
solution (500 mM) and stirring overnight. The Gd-(DTPA)2−-loaded MSNs-APTS were then 
conjugated with HOOC-PEG-COOH (Mw= 2000 Da) to seal the pores. The mixture reacted 
overnight and was washed thoroughly with deionized H2O to remove the unloaded or surface Gd-
(DTPA)2−. To evaluate the loading capacity of Gd-(DTPA)2− in MSNs-PEG, Gd-(DTPA)2−-loaded 
MSNs-PEG was digested by aqua regia at 95 °C. The amount of Gd ions in the resulting powder 
was then dissolved by 2% HNO3 and measured by inductively coupled plasma optical emission 
spectrometry (ICP-OES). The loading capacity of Gd-(DTPA)2−, defined as (mass of Gd-
(DTPA)2− loaded in pores/mass of MSNs) × 100%, was calculated to be 24.1 ± 1.2%. This high 
loading of Gd-(DTPA)2− in the pores resulted in the decreased BET surface area and the decreased 
total pore volume (Table 4.1). Because of both the small size of Gd-(DTPA)2− molecules (ca. 0.8 
nm) and the electrostatic interaction between the negatively charged Gd-(DTPA)2− and the 
positively charged pore walls, the Gd-(DTPA)2− may easily diffuse into the pores and stick to the 
pore wall. Another type of positively charged amine, N-trimethoxysilylpropyl-N,N,N-
trimethylammonium (TA), was attached to the pore walls of MSNs (designated as MSNs-TA) to 
compare the loading of Gd-(DTPA)2− with that of MSNs-APTS. MSNs-TA showed lower loading 
capacity of Gd-(DTPA)2− (11.0 ± 0.5%), implying that the steric hindrance of the bulky trimethyl 
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groups in TA weakened the electrostatic interaction between the quaternary amine and Gd-
(DTPA)2− 
How to prevent the leakage of small Gd-(DTPA)2− molecules from the MSNs was the next 
challenge to overcome. To cover multiple pores, in our design, we conjugated both carboxylic 
acids of HOOC-PEG-COOH to amines on the surface of MSNs-APTS through stepwise 
conjugation method and formed U-shaped PEG caps. To confirm the formation of U-shaped PEG, 
its Gd-(DTPA)2− loading capacity after thorough washing was compared to that of the control 
group capped with monocarboxylic acid-terminated PEG, where the PEG can be attached to 
MSNs-APTS only at one end, leaving the other end extended into the solvent. As expected, the 
stretched form PEG cap showed lower Gd-(DTPA)2− loading capacity (18.4%), confirming that 
the stepwise conjugation method that attaches both ends of HOOC-PEG-COOH to MSNs-APTS 
improves the pore-capping capability. In addition to the geometry of PEG caps, the distance 
between PEG caps and the surface of MSNs-APTS was also another factor to optimize. Here, the 
capping capabilities of HOOC-PEGCOOH with higher molecular weight (Mn = 6500 Da and 
25000 Da) were explored, with which the Gd-(DTPA)2− loading capacities were 19.0% and 19.1%, 
respectively. The lower Gd-(DTPA)2− loading capacities using these longer PEG caps compared 
to that of the shorter PEG (Mn = 2000 Da) may be attributed to the larger gap space between the 
U-shaped cap chain and the pore opening, allowing more Gd-(DTPA)2− molecules to diffuse out 
during the washing steps.  
The stability of the PEG cap in aqueous solution at both room temperature (23 °C) and body 
temperature (37 °C) was examined. Gd-(DTPA)2−-loaded MSNs-PEG (3 mg/mL) was suspended 
in deionized H2O in Eppendorf tubes. Each tube was immersed in a water bath at room temperature 
(23 °C) or 37 °C for 2, 5, 8, 10, or 30 min. Negligible leakage of Gd-(DTPA)2− molecules was 
observed at room temperature (Figure 4.5). At 37 °C, only 3.8% of Gd-(DTPA)2− was released 
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over a period of 30 min, showing that PEG was tight enough to cap the pores and remained stable 
on the MSN’s surface even at a physiological temperature. 
4.5 Proof-of-Concept: Ultrasound-Stimulated Release of Gd(DTPA)2− 
To examine the ultrasound responsiveness of the PEG cap, a probe sonicator (VCX 130, 
Sonics & Materials, Inc., Newtown, CT) was used as an ultrasound source for a proof-of-concept 
experiment. Gd(DTPA)2−-loaded MSNs-PEG suspended in deionized H2O was stimulated with 
the probe sonicator (20 kHz, power density: 75 W/cm2) for 2, 5, 8, 10, or 30 min. The Gd(DTPA)2− 
release efficiency was defined as (mass of released Gd(DTPA)2−/mass of Gd(DTPA)2− loaded in 
pores) × 100%, where the mass of released Gd(DTPA)2− was quantified by ICP-OES. The amount 
of released Gd(DTPA)2− increased with the sonication time, where 30 min of sonication led to a 
release efficiency of 62% (Figure 4.5). This result confirms that ultrasonication uncapped the 
PEG-covered pores of MSNs and that the amount of released cargo was controllable by the 
sonication time. The temperatures of the samples measured with a thermometer immediately after 
sonication were 31, 42, 47, 49, and 51 °C after the 2, 5, 8, 10, and 30 min stimulation, respectively, 
by the probe sonicator. To measure the effect of only heat on the release, a control experiment was 
carried out using a water bath at 50 °C. Over a period of 30 min 24% of the Gd(DTPA)2− was 
released, which is less than half of that (62%) triggered with sonication and heating to a similar 
temperature (Figure 4.5). This result shows that although heat can cause partial release of 
Gd(DTPA)2− molecules, the released amount was relatively small because PEG is not degradable 
at 50 °C.75 Mechanical effects of ultrasound, such as shock waves created during cavitation, induce 
PEG rupture67,76 and thus efficiently release the entrapped cargo. Cavitation causes a rapid 
compression and rarefaction of the liquid. On a molecular level it causes a rapid motion of small 
molecules (e.g., solvent molecules and Gd(DTPA)2−) that the polymer in the solvent cannot follow, 
thereby generating friction, increasing strain, and eventually leading to bond rupture.67,76 The TEM 
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image of the nanoparticles after being exposed to ultrasound and high temperature (50 °C) for 30 
min (Figure 4.6) shows that the mesoporous structure was intact. The release of Gd(DTPA)2− was 
primarily through opening of the pores stimulated by the rupture of the mechanically sensitive 
PEG gatekeeper rather than by the destruction of the mesoporous silica structure. 
 
4.6 MRI-Guided HIFU-Stimulated Release of Gd(DTPA)2− and MRI Contrast 
Change 
The stimulated release experiments were carried out using a research HIFU system (Image 
Guided Therapy, Bordeaux, France) integrated with a whole-body 3 T MRI scanner (Prisma, 
Siemens Healthineers, Erlangen, Germany) (Figure 4.7). MRI was used to guide the HIFU 
stimulation, monitor the temperature during the stimulation, and pinpoint the release of 
Gd(DTPA)2− in real time. The HIFU transducer has a 128-element array with a frequency of 1 
MHz and a peak electrical power output of 1200 W. The mechanical and electronic steering 
capabilities of the HIFU system can precisely steer the 1 × 1 × 7 mm3 cigarshaped HIFU focal 
point in three dimensions.  
In the fields of MRI and ultrasound (including HIFU), it is customary to first use tissue-
mimicking “phantoms” to evaluate feasibility, train operators, optimize protocols, and characterize 
technical performance of MRgHIFU technology before studying animal or human subjects.77−79 
Tissue-mimicking phantoms use materials designed to mimic pertinent properties of biological 
tissues and thus are used in preclinical research as an alternative to ex vivo tissues and organs. The 
advantages of using tissue-mimicking phantoms include superior availability and shelf life, high 
structural uniformity, and customizability. Several HIFU tissue-mimicking phantom formulations 
such as agar, gelatin, and polyacrylamide with additives to adjust their thermal and acoustic 
properties to be comparable to human soft tissues have been reported.77−84 For example, the 
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acoustic attenuation and speed of sound of tissue-mimicking phantoms may be adjusted via the 
addition of silicon dioxide particles, concentrated milk, bovine serum albumin, corn syrup, glass 
beads, intralipid, graphite, or n-propanol.84−86 Because of the similar convection and diffusion 
properties to that of extracellular space around tumor tissues,87 agarose phantoms are commonly 
used for ultrasound-stimulated drug delivery studies.80,88,89 For example, other researchers have 
used an agarose-based phantom with a thermosensitive indicator to study the spatial drug delivery 
profile using ultrasound-induced mild hyperthermia.80 In addition to the above-mentioned 
phantoms, researchers in the community of MRI or ultrasound also commonly study nanoparticle 
samples in water or gel for initial demonstration of their new techniques.58,90,91 
In this work, we followed the methodology in the community of MRI or ultrasound by using 
an agarose phantom as the sample holder to mimic aqueous tissues92,93 and by placing nanoparticle 
samples in water for sample recycling and further quantification or in methylcellulose gel to mimic 
a tissue scaffold.90,94 Concentrated milk was selected as the primary attenuation component in this 
work for its widespread availability, a high attenuation coefficient (∼0.8 dB/cm/MHz) with a speed 
of sound that is typical of biological fluids (1547 m/s), and its previous uses in water-based 
phantoms.80,95 The agarose phantom used in this work was 10 cm in diameter and contained sample 
wells that were 1.3 cm in diameter and 5 cm in height (Figure 4.8a). Agarose is sturdy and does 
not liquefy below 65 °C. The ultrasound waves penetrate through agarose without being absorbed 
because of its low acoustic attenuation coefficient.96 The agarose phantom was placed on the HIFU 
transducer on the patient bed in the MRI scanner (Figures 4.8a and 4.7a,b). Two samples of 
water-suspended Gd(DTPA)2−-loaded MSNs-PEG, three samples of Gd(DTPA)2−-loaded MSNs-
PEG mixed in methylcellulose (2.5 wt %) and concentrated milk (v/v = 1/1) (designated as 
gel/milk), and gel/milk itself were placed in the six sample wells in the agarose phantom. The 
phantom on the transducer was moved into the MRI scanner for further MRgHIFU experiments.  
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The aqueous suspension of Gd(DTPA)2−-loaded MSNs-PEG (sample 1) was stimulated with 
HIFU (3 cycles of 1 min, 74 W). T1-weighted turbo-spin−echo images of the entire agarose 
phantom were acquired before and after the HIFU stimulation, termed pre- and post-T1-weighted 
images, respectively. The post-T1-weighted image of sample 1 was darker than the pre-T1-
weighted image (Figure 4.8b). To clearly depict the change in MR image intensity, T1-weighted 
images were processed by subtracting the post-T1-weighted image from the pre-T1-weighted image 
to generate the ΔT1-weighted image (Figure 4.8b). The HIFU-stimulated sample 1 exhibited a 
bright signal in the ΔT1-weighted image. The homogeneous brightness in the well was the result 
of diffusion of the released Gd(DTPA)2− in the well. The unstimulated control groups, including 
Gd(DTPA)2−-loaded MSNs-PEG in water (control 2), Gd(DTPA)2−-loaded MSNs-PEG in 
gel/milk (controls 3−5), and gel/milk itself (control 6), showed negligible changes between pre- 
and post-T1-weighted images as expected. The agarose phantom background (control 7) also 
showed no image change. In the entire 3-D ΔT1-weighted image of the agarose phantom containing 
the sample wells, only the HIFU-stimulated sample 1 strikingly showed an intense signal.  
The amount of Gd(DTPA)2− released by HIFU stimulation was quantified by ICP-OES. 
HIFU-stimulated sample 1 had the released amount of Gd(DTPA)2− of 0.47 µmole of 
Gd(DTPA)2−/mg of MSNs-PEG. The change in T1-weighted image intensity, evaluated as [(pre-
T1-weighted image intensity − post-T1-weighted image intensity)/pre-T1-weighted image intensity] 
× 100%, was calculated to be 39% for the HIFU-stimulated sample 1 (Figure 4.9). This result 
confirmed that HIFU-stimulated Gd(DTPA)2− release occurred primarily in the well into which 
the HIFU was focused, with negligible effect on the other wells. 
The above discussion emphasized the magnitude of the change in the T1-weighted image 
intensity. Initially it seemed surprising that Gd(DTPA)2− release caused a decrease in the intensity. 
However, the decrease in T1-weighted image intensity when the encapsulated Gd(DTPA)2− was 
 136 
released from the pores of the nanoparticles can be explained by the 
Solomon−Bloembergen−Morgan theory that describes the parameters affecting T1 caused by a 
given Gd(III)-based contrast agent.97,98 
According to the theory, T1 decreases when the rotational correlation time (τr) increases (i.e., 
decreased rotation or tumbling rate of the Gd(III) contrast agent). Numerous studies have shown 
that Gd(III)-based contrast agents bonded to bulky proteins, nanoparticles, or peptides tumble 
more slowly and thus increase the contrast.99−101 In the case of Gd(DTPA)2− loaded in the MSN’s 
pores, electrostatic interactions with the positively charged pore wall of the bulky MSNs-PEG 
(Figure 4.10a) decreased the tumbling rate and thus enhanced r1 to 8.6 s−1mM−1 (Figure 4.10b). 
After the HIFU stimulation (3 cycles of 1 min, 74 W), where 26% of the loaded Gd(DTPA)2− was 
released, r1 of Gd(DTPA)2−-loaded MSNs-PEG was reduced (6.9 s−1mM−1) compared to that 
before HIFU stimulation (Figure 4.10b), similar to what was found by ultrasound stimulation with 
a probe sonicator (Figure 4.11a; T1-weighted images of each sample are shown in Figure 4.11b). 
No changes in either r1 or r2 of Gd(DTPA)2− itself were observed after HIFU or the probe sonicator 
stimulation under the same conditions (Figures 4.12 and 4.13), confirming that the structure of 
the Gd(DTPA)2− molecule was not changed by HIFU stimulation. 
By using this nanoparticulated Gd(DTPA)2−, the total amount of Gd(DTPA)2− required to 
enhance T1-weighted MR image contrast to the same level as that of free Gd(DTPA)2− can be 
reduced. This may be beneficial for avoiding accumulation of gadolinium-based contrast agents in 
the body over repeated contrast-enhanced examinations, which was described in a warning by the 
FDA in 2018.102 
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4.7 Mechanisms of HIFU-Stimulated Gd(DTPA)2− Release 
To study if the activation of the PEG cap by HIFU and the ensuing release of Gd(DTPA)2− 
was caused by heat, mechanical forces, or both, the temperature change caused by HIFU 
stimulation was measured. The increase in temperature was monitored by dynamic MRI 
temperature mapping acquired using a 2D gradient-echo protocol (TE= 20 ms, TR= 30 ms, spatial 
resolution of 1 × 1 × 3 mm3, and temporal resolution of 2.8 s). The maximum temperature rise of 
water-suspended Gd(DTPA)2−-loaded MSNs-PEG was only 4 °C during the 1 min HIFU 
stimulation period, and the temperature returned to the starting temperature (20 °C room 
temperature) shortly after HIFU stopped (Figure 4.14a). The minimal temperature rise can be 
explained by the low sound attenuation coefficient of water; negligible sound energy was absorbed, 
and thus very little heat was generated during HIFU stimulation. Even at this low temperature (less 
than 24 °C), HIFU can stimulate 0.47 µmole of Gd(DTPA)2−/mg of MSNs-PEG release from the 
pores of MSNs-PEG. In contrast, the temperature rose by 11 °C after 1 min of HIFU stimulation 
of the sample mixed in the gel/milk mixture that has a higher sound attenuation coefficient (Figure 
4.14a). Water therefore served as an ideal medium to demonstrate the mechanical sensitivity of 
PEG in the absence of appreciable temperature changes. The mechanical effects of HIFU allowed 
cargos to be released with minimal temperature increase, unlike the case where probe sonication 
was used (Figure 4.5). 
To confirm the mechanical sensitivity of the polymer cap, PEG cleavage by HIFU at room 
temperature was examined by matrix-assisted laser desorption ionization-time-of-flight mass 
spectrometry (MALDI-TOF MS). The peaks from intact PEG were located around m/z = 2000 
(Figure 4.14b). After HIFU stimulation (3 cycles of 1 min, 1 MHz, 74 W), small peaks around 
m/z = 1000 appeared. The signal intensity of those peaks increased with longer HIFU stimulation 
duration (2 cycles of 5 min). The intensity ratios of the fragment peaks around m/z = 1000 to m/z 
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= 2000 (defined as [the highest intensity of the peaks around m/z = 1000/the highest intensity of 
the peaks around m/z = 2000]) were 0.11 (without HIFU), 0.20 (after 3 cycles of 1 min HIFU), 
and 0.71 (after 2 cycles of 5 min HIFU). The PEG cleavage was likely caused by HIFU-induced 
cavitation103,104 and is consistent with previous studies showing that ultrasonic chain scission 
occurred around the center of the polymer chain.67,76 PEG itself may also accelerate polymer 
degradation because hydrophilic PEG enhances the penetration of water and thus the rate of 
hydrolysis.67,76 Further evidence of PEG degradation by HIFU was the decrease in colloidal 
stability of MSNs-PEG (Figure 4.15). Aggregation of the HIFU-stimulated nanoparticles implies 
that the PEG on the surface was degraded. 
 
4.8 Dose and Temporal Control of Released Gd(DTPA)2− by MRgHIFU Stimulation 
Time and Power Level 
The effects of exposure time and HIFU power levels on the amount of Gd(DTPA)2− released 
were measured based on the change of the T1-weighted image intensity. Gd(DTPA)2−-loaded 
MSNs-PEG samples were dispersed in deionized H2O and stimulated with HIFU at a fixed power 
level (74 W) for 3, 5, or 10 min. The T1-weighted intensities decreased by 13%, 26%, and 35%, 
respectively (Figure 4.16a), and the corresponding ΔT1- weighted images increased in brightness 
with increasing HIFU stimulation time (Figure 4.16c). Similarly, the dependence of the 
Gd(DTPA)2− release on HIFU power levels was also measured. Three samples of water-suspended 
Gd(DTPA)2−-loaded MSNs-PEG were stimulated with HIFU for 3 min at power levels of 9, 74, 
and 290 W. The changes in T1-weighted image intensity were 5%, 13%, and 60%, respectively 
(Figure 4.16b). The ΔT1-weighted image of the sample stimulated at 290 W showed strong signal 
changes (Figure 4.16c), which can be explained by strong cavitation and PEG fragmentation 
caused by such high acoustic intensity. The temperature increases during these HIFU stimulations 
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were monitored by dynamic MRI temperature mapping. During 3 min of HIFU stimulation at 74 
W, the temperature increased by only 4 °C. The temperature increased by 7 °C during a 5 min 
exposure and by 10 °C during 10 min of exposure. For the 3 min stimulations at different power 
levels, the temperature increases were 1 °C at 9 W and 10 °C at 290 W.  
The correlation between the amount of Gd(DTPA)2− released and T1 was quantified. The T1 
relaxation times from the HIFU-stimulated samples in Figure 4.16a,b were measured by MRI T1 
mapping, and the amount of Gd(DTPA)2− released was measured by ICP-OES. Increased 
Gd(DTPA)2− release from the pores of MSNs-PEG resulted in longer T1 relaxation times (Figure 
4.16d,e). By adjusting the HIFU stimulation time or power level, the released amount of 
Gd(DTPA)2− could be controlled and monitored from the T1 relaxation time. Table 4.2 summarizes 
the Gd(DTPA)2− release efficiency and temperature increase under various HIFU parameters 
(power levels and stimulation time). Similar results were found using probe sonication: T1 
relaxation times increased with increasing duration of ultrasonication and thus higher release 
efficiency of Gd(DTPA)2− (Figure 4.17). 
To demonstrate that HIFU can control the released dose of Gd(DTPA)2− over time, 
Gd(DTPA)2−-loaded MSNs-PEG samples were mixed in gel/milk and stimulated with HIFU for 
various durations and at different power levels. Again, the greater the HIFU stimulation times and 
power levels, the greater the decrease in T1-weighted image intensity (Figure 4.18a,b). To control 
the release of Gd(DTPA)2− over time, multiple cycles of HIFU stimulations were performed 
(Figure 4.18c). After the first cycle of HIFU stimulation, the T1-weighted image intensity 
decreased over a period of 30 min and leveled off. The second and third cycles of HIFU stimulation 
resulted in similar profiles. This sequence shows that the desired dose of released Gd(DTPA)2− 
can be achieved within a specific time window by adjusting the ON and OFF times of HIFU 
stimulation. The structure of the MSNs-PEG was intact after HIFU stimulation for 3 min (Figure 
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4.19), suggesting that the release of Gd(DTPA)2− was due to the opening of the pores gated by the 
mechanically sensitive PEG rather than by the destruction of the nanoparticle. 
 
4.9 Three-Dimensional Spatial Control of Released Gd-(DTPA)2− at the Focal Point 
of MRgHIFU Stimulation 
To visualize the 3-D precision with which the Gd(DTPA)2− cargo is released from the 
nanoparticles, Gd(DTPA)2−-loaded MSNs-PEG particles were mixed in a viscous gel to minimize 
diffusion of the Gd(DTPA)2− molecules after release. The particles were homogeneously mixed in 
2.5 wt % methylcellulose, and the sample was transferred into sample wells (1.3 × 1.3 × 5 cm3) 
molded in the agarose phantom. The well dimensions were large enough to allow the cigar-shaped 
HIFU focal point (1 × 1 × 7 mm3) to be positioned well within the well’s interior. The axial, coronal, 
and sagittal cross sections of the sample well of interest in the agarose phantom are shown in 
Figure 4.20a.  
Considering the release studies in the previous sections, three cycles of 1 min HIFU 
stimulation (1 MHz, power level: 74 W) were chosen to activate the release of Gd(DTPA)2−. The 
MRI was acquired with a turbo-spin−echo inversion−recovery protocol shortly after the HIFU 
stimulation, and cross sections of the ΔT1-weighted images are shown in three orientations (Figure 
4.20b). A clearly defined region of image signal change appeared. The cigar-shaped red spot, the 
position with maximal image intensity change, pinpoints the HIFU focal point which was near the 
center of the sample well. The change of image intensity away from the focal point sharply 
decreased, showing that the majority of the Gd(DTPA)2− was released at the focal point. The 
temperature increased 4 °C after the HIFU stimulation, again confirming that the release was 
primarily due to the mechanical responsiveness of the PEG cap. 
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4.10 Ex Vivo MRgHIFU-Stimulated Gd(DTPA)2− Release and MRI Contrast Change 
To demonstrate the potential of transferring our technology to preclinical and clinical in vivo 
studies in the future, 3-D spatial and dose-controlled cargo release in ex vivo chicken breast tissue 
samples was investigated. A 3 × 6 cm2 piece of chicken breast was injected with methylcellulose 
gel containing Gd(DTPA)2−-loaded MSNs-PEG at two different locations and imaged before 
HIFU stimulation. The two injection sites were observable as bright regions in T1-weighted images 
(Figure 4.21a). A HIFU transducer with an 8-element annular array and similar size (25 mm in 
diameter) as the chicken breast was used for MRgHIFU. The HIFU focal point was 0.7 × 0.7 × 3 
mm3 in size, and the peak electrical power output of the HIFU transducer was 200 W. One of the 
injection sites was stimulated with HIFU for 3 cycles of 3 min (2.5 MHz, 8 W). The color-coded 
ΔT1-weighted images and T1-weighted image intensity changes (%) of the HIFU-stimulated 
sample, the control sample without HIFU stimulation, and the chicken tissue background after 
each HIFU cycle are shown in panels a and b of Figure 4.21, respectively. The intensity changes 
of the HIFU-stimulated sample close to the focal point greatly increased with the number of HIFU 
cycles. After 3 cycles of HIFU stimulation, a clearly confined region of intensity change close to 
the HIFU focal point was observed in 3-D space (axial, coronal, and sagittal) (Figure 4.22). 
Negligible changes in T1-weighted image intensity were observed at the sample injection site 
without HIFU stimulation or in the background. These results confirm that MRgHIFU can achieve 
spatially selective stimulation for cargo release close to the HIFU focal point in ex vivo tissue. By 
using this technique, we can first visualize the presence of Gd(DTPA)2−-nanoparticles with MRI, 
stimulate with MRgHIFU at the focal point, and characterize the cargo release from the MRI 
contrast change. 
A potentially challenging property of tissue is its acoustic energy-absorbing ability due to the 
abundance of proteins that may generate significant heat during HIFU stimulation and produce 
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overall image contrast changes caused by the temperature increase.105,106 To examine if such 
temperature interference occurred, a control experiment was done by injecting methylcellulose gel 
into a 3 × 5 cm2 sample of chicken breast. The gel injection site was stimulated by HIFU for 2 
cycles of 3 min (2.5 MHz, 8 W). The temperature increase at the focal point measured by a 2D 
gradient-echo protocol was 10 °C. A negligible change in T1-weighted image intensity was 
observed showing that the temperature interference was not a confounder (Figure 4.23a−c). 
 
4.11 Significance for Potential Biomedical Applications 
The phantom and ex vivo experiments open the door for further biomedical applications using 
the MRgHIFU-stimulated cargo release technology developed in this work. For future biomedical 
applications, drugs such as anticancer chemotherapeutics can be used as cargo. Combined with the 
use of MRgHIFU, a clinically available therapeutic modality, the MSNs-PEG drug delivery 
platform may lead to clinical applications such as cancer diagnosis and treatment. For example, 
we can identify the target tissues (e.g., cancer) for treatment, confirm the delivery of cargo to the 
target tissues and avoid healthy tissues, and quantify the amount of cargo that has been released at 
the target tissues. If both a therapeutic and an imageable cargo such as a gadolinium-based contrast 
agent (e.g., gadopentetate dimeglumine) are co-encapsulated in MSNs-PEG, the drug carriers can 
be monitored using MRI, and the drug release can be activated by MRgHIFU only when the drug 
carriers are observed at the tumor site. The drug release behavior can be observed in situ by MRI. 
The released dose of drugs may be calculated from the correlation between the released amount of 
gadolinium-based contrast agent with the change in T1-weighted image intensity and/or T1  
relaxation time as shown in this work. To achieve the required dosage in a desired therapeutic 
window, the released amount of therapeutics can be further controlled by adjusting HIFU 
parameters such as power level, stimulation duration, and number of stimulation cycles. The goal 
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of precision medicine, defined as giving a precise dosage of drugs in a specific location at a 
controlled time, could then be achieved. 
Another advantage of this work is that only minimal to mild bulk heating is required to release 
cargos such as contrast agents and drugs. This is different from the ablation therapy widely 
investigated using HIFU and other thermally triggered drug delivery platforms. The predominantly 
mechanically triggered drug delivery strategy presented in this work may be especially beneficial 
for treating tissues in regions where it is impractical or undesirable to heat (e.g., pancreatic or liver 
cancer near blood vessels and bile ducts). 
 
4.12 Summary 
In summary, this work showed that the combination of MRI-guided high-intensity focused 
ultrasound (MRgHIFU) and a polyethylene glycol (PEG)-capped mesoporous silica nanoparticle 
(MSN) platform can deliver cargos at a precisely predesignated localized spot monitored and 
visualized in real time by MRI. Both MRI and HIFU are clinically available and noninvasive, do 
not require ionizing radiation, and can access tissues deep in the body. The activation mechanism 
of the PEG cap does not require tissue-destructive heating. The MRgHIFU experiments carried 
out in a tissue-mimicking agarose phantom showed that when imageable cargo molecules 
(Gd(DTPA)2−, 24% of loading capacity) were released from the pores of MSNs-PEG, both the T1-
weighted image intensity and the T1 relaxivity (r1) decreased as predicted by the Solomon− 
Bloembergen− Morgan theory. The minimal to mild temperature increase during HIFU stimulation 
and verification of PEG bond cleavage after the stimulation confirmed that the mechanism of 
Gd(DTPA)2− release was mainly caused by mechanical forces of HIFU and not heat. The amount 
of Gd(DTPA)2− released was controllable by adjusting different durations and power levels of 
HIFU stimulation. A positive correlation between the release efficiency of Gd(DTPA)2− and T1  
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relaxation time was found: higher release efficiency of Gd(DTPA)2− led to longer T1. 3-D MR 
images of the contrast intensity changes after HIFU stimulation allowed us to precisely pinpoint 
(with millimeter resolution) the location of Gd(DTPA)2− release that is chosen and controlled by 
the position of the HIFU focal point. The MRgHIFU-stimulated release study in ex vivo chicken 
breast tissue samples showed a sharply defined region where the T1-weighted image intensity 
changed the most (14%) after HIFU stimulation (3 cycles of 1 min, 8 W). The technology in this 
work takes advantage of the powerful MRgHIFU platform as a clinical translation pathway and 
may enable new image-guided theranostic applications as a viable strategy for personalized 
therapy—delivering a precisely controlled dosage of drug to the specific diseased tissue location 
monitored by MRI in real time. 
 
4.13 Methods 
4.13.1 Materials and Chemicals 
Hexadecyltrimethylammonium bromide (CTAB, 99+ %), tetraethyl orthosilicate (TEOS, 
98%), (3- aminopropyl)triethoxysilane (APTS, 99%), ammonium nitrate (NH4NO3, 98+ %), 2-
(N-morpholino)ethanesulfonic acid hydrate (MES hydrate, 99.5+ %), and methylcellulose 
(viscosity: 4000 cP) were purchased from Sigma-Aldrich. Ethanol (200 proof) was purchased from 
Decon Laboratories, Inc. Toluene (99.5+ %) was purchased from Macron Fine Chemicals. 1-
Ethyl-3-(-3-dimethylaminopropyl) carbodiimide hydrochloride (EDC-HCl, 99+ %) and N-
hydroxysulfosuccinimide sodium salt (sulfo-NHS, 99+ %) were purchased from CovaChem. 
Magnevist was purchased from Bayer. α,ω-Bis-carboxy polyethylene glycol (HOOC-PEG-COOH, 
Mw= 2000 Da) was purchased from Iris Biotech GmbH. Hydrochloric acid (HCl, 36.5%−38%, 
tracemetal grade), nitric acid (HNO3, 67%−70%, tracemetal grade), sodium hydroxide (NaOH, 
97+ %), and agarose (low EEO) were purchased from Fisher Scientific. All chemicals were used 
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without further purification. 
4.13.2 Characterization 
The morphology and diameters of nanoparticles were characterized by transmission electron 
microscopy (TEM, Tecnai T12) with an operating voltage of 120 kV. MSNs or MSNs-APTS were 
dispersed in ethanol at a low concentration (0.1 mg/mL). The suspension (10 µL) of the 
nanoparticles was dropped onto a 200 mesh carbon-coated copper grid and dried at room 
temperature. The dynamic light-scattering (DLS) size and zeta potential values of nanoparticles 
were determined by a laser particle analyzer LPA-3100 at room temperature (23 °C). MSNs 
showed the characteristic zeta potential of −27.2 mV in deionized H2O at pH 7, which was shifted 
to +37.9 mV after APTS modification (Figure 4.2b). After PEGylation, the zeta potential dropped 
to +7.3 mV, which was the result of charge screening by the formed amide bonds. The functional 
groups on the surface of MSNs were characterized by Fourier transform infrared spectroscopy 
(FT-IR, JASCO FT/IR-420) spectrometer in the range of 4000−400 cm−1. The successful APTS 
modification was supported by the new absorption peaks at ν = 1512 cm−1 (N−H bending) and the 
two bands at ν = 3717 cm−1 and ν = 3727 cm−1 (N−H stretching) in the FT-IR spectrum (Figure 
4.2c). PEGylation was confirmed by the new absorption peak at ν = 1555 cm−1 (amide II), 
supporting the formation of secondary amide bond. Stronger absorption peaks at ν = 1464 cm−1 
(C−H bending), and ν = 2880 cm−1 and ν = 2927 cm−1 (C−H stretching) of MSNs-PEG compared 
with MSNs-APTS also supported the successful PEGylation. Thermogravimetric analysis (TGA) 
was carried out using a PerkinElmer Pyris Diamond TG/DTA under air flow (200 mL/min). MSNs, 
MSNs-APTS, and MSNs-PEG (5−10 mg) were loaded in aluminum pans, and the data were 
recorded during a temperature scan from 30 to 550 °C at a scan rate of 10 °C/min. The plotted 
values are normalized to the weight at 100 °C. An empty aluminum pan was used as a reference. 
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The weight loss of MSNs, MSNs-APTS, and MSNs-PEG were 8%, 11%, and 29%, respectively, 
confirming the presence of organic matter in MSNs-APTS and MSNs-PEG (Figure 4.2d). The 
surface area, pore diameter, and pore volume of MSNs, MSNs-APTS, MSNs-PEG, or 
Gd(DTPA)2−-loaded MSNs-PEG were determined by N2 adsorption−desorption isotherm 
measurement at 77 K (Autosorb-iQ, Quantachrome Instruments). Nanoparticles were degassed at 
120 °C for 20 h before the measurement. The surface area and pore diameter distribution of the 
nanoparticles were determined by Brunauer−Emmett−Teller (BET) and Barrett−Joyner−Halenda 
(BJH) methods. The loading capacity and release efficiency of Gd(DTPA)2− from MSNs-PEG 
were quantified by inductively coupled plasma optical emission spectrometry (ICP-OES) using a 
Shimadzu ICPE-9000. The calibration curve was created from 0 to 10 ppm of gadolinium in 2% 
HNO3. 
4.13.3 Synthesis of Mesoporous Silica Nanoparticles (MSNs) 
Mesoporous silica nanoparticles were synthesized using a sol−gel reaction in the presence of 
cationic surfactant templates. In general, CTAB (250 mg) was dissolved in a mixture of 120 mL 
of deionized H2O and 875 µL of NaOH solution (2 M) in a 250 mL round-bottom flask with 
vigorous stirring. The solution was heated to 80 °C in an oil bath and kept at this temperature for 
30 min followed by the dropwise addition of 1.25 mL of TEOS. The reaction was stirred for 
another 2 h for the formation of MSNs. Afterward, the solution was cooled to room temperature, 
centrifuged, and washed with ethanol three times to remove unreacted precursors and free 
surfactants. 
4.13.4 Synthesis of Amine-Functionalized MSNs (MSNs-APTS) 
To functionalize amine groups on the surface of MSNs, MSNs (180 mg) were dispersed in a 
mixture of 50 mL of anhydrous toluene and 150 µL of APTS. The reaction mixture was heated to 
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110 °C and refluxed for 12 h with vigorous stirring. After the reaction, APTS-modified MSNs 
(MSNs-APTS) were washed with ethanol two times. To remove the surfactant template, MSNs-
APTS were dispersed in a mixture of 100 mL of ethanol and 2 g of NH4NO3 in a 250 mL round-
bottom flask. The reaction mixture was heated to 78 °C and refluxed for 1 h. The surfactant 
removal process by extraction was repeated twice. After the extraction, MSNs-APTS were 
centrifuged and further washed with deionized H2O and ethanol twice. Finally, MSNs-APTS were 
stored in ethanol for further usage. 
4.13.5 Gd(DTPA)2− Loading and PEG Capping 
Before loading Gd(DTPA)2− in the mesopores of MSNs-APTS, MSNs-APTS were first 
washed with deionized H2O. The loading of Gd(DTPA)2− was carried out by soaking MSNs-APTS 
(20 mg) in 1 mL of gadopentetate dimeglumine solution (500 mM Gd(DTPA)2−). The solution was 
stirred overnight to let Gd(DTPA)2− diffuse into the pores of MSNs-APTS. The Gd(DTPA)2−-
loaded MSNs-APTS were then conjugated with HOOC-PEG-COOH (Mw= 2000 Da) to seal the 
pores. EDC-HCl (15.3 mg) and sulfo-NHS (8.7 mg) coupling agents were dissolved in 240 µL of 
MES solution (100 mM, pH= 6.0). So that both carboxylic acids on COOH-PEG-COOH could be 
activated, the PEG polymer (20 mg) dissolved in 200 µL of MES buffer solution was stepwise 
added into the solution of coupling agents every 10 min. Afterward, the activated PEG was 
stepwise added into the Gd(DTPA)2−-loaded MSNs-APTS solution every 10 min to enable both 
ends of the activated PEG to react with the primary amines on the surface of MSNs-APTS. The 
mixture was reacted overnight and then washed thoroughly with deionized H2O to remove the 
unloaded Gd(DTPA)2−, the excess EDC-HCl and sulfo-NHS, and PEG. The resulting PEG-capped 
nanoparticles are denoted as MSNs-PEG. Finally, Gd(DTPA)2−-loaded MSNs-PEG were stored in 
10 mL of deionized H2O for further ultrasound-stimulated release studies. 
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4.13.6 Ultrasound-Stimulated Release of Gd(DTPA)2− by a Probe Sonicator 
Gd(DTPA)2−-loaded MSNs-PEG solution (3 mg/mL) was prepared in deionized H2O in an 
Eppendorf tube. The tip of the probe sonicator (VCX 130, Sonics & Materials, Inc., Newtown, CT) 
was placed in the center of the solution. The ultrasound parameter was set with the frequency of 
20 kHz and output power of 21 W (power density: 75 W/cm2). After various ultrasound stimulation 
time durations (2, 5, 8, 10, or 30 min) with the probe sonicator, the solution was centrifuged (14000 
rpm, 10 min) to separate the particles and the supernatant containing released Gd(DTPA)2−. The 
supernatant and pellet were collected for further quantification of Gd(DTPA)2− loading capacity 
and release efficiency by ICP-OES. 
4.13.7 Quantification of Gd(DTPA)2− Loading Capacity and Gd-(DTPA)2− Release Efficiency 
after Ultrasound or HIFU Stimulation 
Gd(DTPA)2−-loaded MSNs-PEG solution stimulated by ultrasound or HIFU was centrifuged 
(7830 rpm, 15 min) to separate the pellet and the supernatant. The particle-containing pellet was 
dispersed in 10 mL of aqua regia at 95 °C for 12 h to be fully digested into powder. The resulting 
powder was then dissolved and diluted by 2% HNO3. The supernatant containing the released 
Gd(DTPA)2− was diluted by 2% HNO3. The concentration of Gd ions was measured by ICP-OES 
and quantified based on the Gd ion calibration curve (0, 0.01, 0.05, 0.1, 0.5, 1, 5, and 10 ppm). 
The definition of loading capacity is (mass of Gd(DTPA)2− loaded in pores/mass of MSNs-PEG) 
× 100%. The definition of release efficiency is (mass of released Gd(DTPA)2−/mass of 
Gd(DTPA)2− loaded in pores) × 100%. 
4.13.8 Preparation of Agarose Phantom 
An agarose gel “phantom” (i.e., test object) was prepared and used as the sample holder for 
Gd(DTPA)2−-loaded MSNs-PEG during MRgHIFU experiments. The concentration of the agarose 
 149 
used was 3.5 wt %. First, deionized H2O (500 mL) was added into a 1000 mL flask. Agarose 
powder (17.5 g) was then added slowly to the flask during vigorous stirring. The solution was 
heated to boiling and maintained at that temperature for 5 min. Subsequently, the hot solution was 
poured into a plastic container with a diameter of 10 cm and the sample wells were molded by 
glass test tubes with a diameter of 1.3 cm (Figure 4.24). Finally, the solution was cooled to 4 °C 
for the gel formation. 
4.13.9 Preparation of Methylcellulose Gel or Mixture of Methylcellulose Gel and Milk 
To prepare methylcellulose gel (2.5 wt %), methylcellulose powder (1.25 g) was slowly added 
to 15 mL of boiling water in a flask under vigorous stirring to dissolve the powder. After stirring 
for 3 min, 35 mL of room-temperature water was rapidly added to the solution and mixed until the 
mixture was homogeneous. The solution was then cooled at 4 °C overnight to complete the 
gelation process. 
To prepare a mixture of methylcellulose gel (2.5 wt %) and milk (v/v = 1/1), methylcellulose 
(1.25 g) was slowly added to 15 mL of boiling water in a flask under vigorous stirring to dissolve 
the powder. After the mixture was stirred for 3 min, 10 mL of room-temperature water and 25 mL 
of concentrated milk were rapidly added to the solution and mixed until the mixture was 
homogeneous. The solution was then cooled at 4 °C overnight to complete the gelation process. 
4.13.10 MRI-Guided High-Intensity Focused Ultrasound (MRgHIFU)-Stimulated Release of 
Gd(DTPA)2− 
All MRgHIFU experiments were conducted using a research HIFU system (Image Guided 
Therapy, Bordeaux, France) integrated with a whole-body 3 T MRI scanner (Prisma, Siemens 
Healthineers, Erlangen, Germany). The HIFU system had a 128-element transducer array with a 
diameter of 9 cm, frequency of 1 MHz, a focal point of 1 × 1 × 7 mm3 in size, and a peak electrical 
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power output of 1200 W. The electrical power output used ranged from 9 to 290 W. Gd(DTPA)2−-
loaded MSNs-PEG dispersed in deionized H2O (1 mg/mL, 3 mL), methylcellulose gel (2.5 wt %, 
3 mL), or methylcellulose gel (2.5 wt %)/milk mixture (v/v = 1/1) (3 mL) were placed in sample 
wells (1.3 × 1.3 × 5 cm3) in the agarose phantom (10 × 10 × 11.5 cm3). The agarose phantom was 
placed on top of the HIFU transducer, which was secured on the patient table of the 3 T MRI 
scanner. Through both mechanical and electronic steering of the HIFU transducer, the focal point 
was placed at the center of the sample well. The samples were stimulated by HIFU at a fixed 
electrical power level (74 W, power density: 7400 W/cm2) with different durations (3, 5, or 10 
cycles of 1 min), or at different electrical power levels (9, 74, or 290 W, power density: 900, 7400, 
or 29000 W/cm2) for three cycles of 1 min. The cooling period between each cycle was 10 s. T1-
weighted MR images were acquired before and after the HIFU stimulation using a 3D turbo-
spin−echo protocol (see Section 4.13.11 T1-Weighted and T2-Weighted Images and T1 and T2 
Mapping) to compare the image intensity. The ΔT1-weighted images were obtained by subtracting 
post-T1-weighted images from pre-T1-weighted images. The temperature of the solution during 
the HIFU stimulation was measured by a 2D gradient-echo MRI temperature mapping sequence 
every 1.8 s. To quantify the released amount of Gd(DTPA)2−, the HIFU-stimulated water-
suspended samples were removed from the phantom and spun down to separate the pellet and 
supernatant. The particle-containing pellet was dispersed in 10 mL of aqua regia at 95 °C for 12 h 
to be fully digested into powder. The powder was then dissolved and diluted by 2% HNO3. The 
supernatant containing the released Gd(DTPA)2− was diluted by 2% HNO3. The concentration of 
Gd ions was measured by ICP-OES. 
4.13.11 T1-Weighted and T2-Weighted Images and T1 and T2 Mapping 
T1-weighted and T2-weighted images of water-suspended Gd(DTPA)2−-loaded MSNs-PEG 
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before and after the stimulation by a probe sonicator or MRgHIFU were acquired using a 3 T MRI 
scanner (Prisma, Siemens Healthineers, Erlangen, Germany) with gradient-echo or turbo-
spin−echo (TSE) protocols respectively. The 1 mL samples with and without HIFU stimulation 
were mixed with 3 mL of methylcellulose (2.5 wt %) in 15 mL Falcon plastic tubes placed in a 
water bath. Acquisition parameters for gradient-echo T1-weighted images were as follows: field 
of view (FOV) = 350 × 350 × 60 mm3; matrix size = 256 × 256 × 20; echo time (TE) = 1.89 ms; 
repetition time (TR) = 20 ms; flip angle = 30°. Acquisition parameters for TSE T2-weighted images 
were the following: FOV= 350 × 350 × 60 mm3; matrix size = 256 × 256 × 20; TE = 118 ms; TR 
= 8 s; flip angle = 90°. 
Parameters for the T1 mapping protocol were as follows: inversion−recovery TSE sequence; 
FOV = 350 × 350 × 60 mm3; matrix size = 256 × 256 × 20; TE = 13 ms; TR = 8 s; inversion times 
(TIs) = 50, 100, 200, 300, 500, 750, 1000, 1500, 2500 ms; excitation pulse flip angle = 90°; 
inversion pulse flip angle = 180°. Parameters for the T2 mapping protocol were the following: 
multiple-TE TSE sequence; FOV = 350 × 350 × 60 mm3; matrix size = 256 × 256 × 20; TEs = 12, 
24, 35, 47, 59, 83, 94, 118 ms; TR = 8 s; excitation pulse flip angle = 90°; refocusing pulse flip 
angle = 180°. T1 and T2 were calculated using a monoexponential fitting algorithm as described 
below. 
The standard inversion-recovery MR signal model was used to calculate T1 maps. Images 
acquired with different inversion times (TIs) were fit pixel-wise to the equation	𝑀 = 𝑀*(1 −2𝑒/0/23), where M0 is the magnetization at thermal equilibrium, M is the signal intensity of images 
acquired at TI = τ. Similarly, the standard Car-Purcell-Meiboom-Gill (CPMG) signal model was 
used to calculate T2 maps, where images acquired with different echo times (TEs) were fit pixel-
wise to the equation 𝑀 = 𝑀*𝑒/0/24, with M0 being the magnetization at thermal equilibrium, M 
being the signal intensity of images acquired at TE =	𝜏. 
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4.13.12 T1 and T2 Relaxivity (r1 and r2) Measurement 
Different concentrations of Gd(DTPA)2−, G Gd(DTPA)2−-loaded MSNs-PEG, or ultrasound 
or HIFU-stimulated Gd(DTPA)2−-loaded MSNs-PEG were mixed with 2.5 wt % methylcellulose. 
T1 and T2 relaxation times were acquired by the 3 T MRI scanner using the above 
inversion−recovery TSE sequence and multiple-TE TSE sequence, respectively. r1 or r2 were 
calculated as the ratio of 1/T1 or 1/T2 to the concentration of Gd(III) determined by ICP-OES. 
4.13.13 Molecular Weight Measurement of PEG by Matrix-Assisted Laser 
Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) 
HOOC-PEG-COOH (average Mn = 2000 Da) dissolved in 3 mL of deionized H2O (3 mg/mL) 
was added to the sample well in the agarose phantom. HIFU stimulation was focused at the center 
of the sample solution. After being stimulated for three cycles of 1 min or two cycles of 5 min (1 
MHz, 74 W), the samples were collected and diluted (1.8 mg/mL) for the MALDI-TOF 
measurement. Sodium trifluoroacetate in deionized H2O (10 mg/mL) was prepared as a cationizing 
agent. Dithranol dissolved in THF (20 mg/mL) was used as a matrix. PEG sample solution (5 µL), 
matrix solution (15 µL), and the cationizing agent (0.5 µL) were mixed well in an Eppendorf tube. 
A 1 µL portion of the mixture was spotted on a stainless steel target plate. Data were acquired in 
a reflection mode using a Bruker Ultraflex MALDI TOF/TOF mass spectrometer with the 
accelerating voltage at 25 kV. 
4.13.14 Ex Vivo MRgHIFU-Stimulated Gd(DTPA)2− Release and MRI Contrast Change 
The ex vivo experiments were conducted using the research HIFU system (Image Guided 
Therapy, Bordeaux, France) integrated with the whole-body 3 T MRI scanner (Prisma, Siemens 
Healthineers, Erlangen, Germany). The same HIFU system also had an 8-element annular 
transducer array with a diameter of 25 mm, frequency of 2.5 MHz, a focal point 0.7 × 0.7 × 3 mm3 
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in size, and a peak electrical power output of 200 W. Gd(DTPA)2--loaded MSNs-PEG (0.5 mg) 
dispersed in 2.5% methylcellulose gel (0.5 mL) were injected in a sample of boneless chicken 
breast tissue (3 × 6 cm2) that was about 1 cm thick. The HIFU transducer was placed under the 
chicken breast tissue sample and secured on the patient table of the 3 T MRI scanner. The HIFU 
focal point was positioned in the chicken breast tissue close to the sample injection site, and the 
sample was stimulated with HIFU for 3 cycles of 3 min (8 W). Control groups including the 
samples (0.5 mg of Gd(DTPA)2−-loaded MSNs-PEG in 0.5 mL of 2.5% methylcellulose gel) 
injected into chicken breast tissue without HIFU stimulation and 2.5% methylcellulose gel (0.5 
mL) injected into chicken breast tissue with HIFU stimulation (2 cycles of 3 min) were also 
included. T1-weighted MR images were acquired before and after each HIFU stimulation cycle 
using the turbo-spin−echo protocol. The difference in T1-weighted image intensity was obtained 
by subtracting post-T1-weighted images from pre-T1-weighted images, resulting in ΔT1-weighted 
images. The temperatures of the chicken breast tissue during the HIFU stimulation were measured 
by a 2D gradient-echo MRI temperature mapping protocol before and right after the stimulation. 
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4.15 Scheme, Figures and Tables 
 
 
Scheme 4.1. Scheme of the synthesis and HIFU-stimulated release of Gd(DTPA)2- from PEGylated 
mesoporous silica nanoparticles (MSNs-PEG). After HIFU stimulation, PEG undergoes bond cleavage and 
vibration to release Gd(DTPA)2-.  
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Figure 4.1. Size distribution of 91.6 ± 15.1 nm mesoporous silica nanoparticles (MSNs). 
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Figure 4.2. Characterizations of MSNs, MSNs-APTS, and MSNs-PEG. (a) TEM images of MSNs (left), 
MSNs-APTS (middle) and MSNs-PEG (right). (b) Zeta potential values, (c) FT-IR spectra, and (d) TGA 
results of MSNs, MSNs-APTS, and MSNs-PEG. (e) N2 adsorption/desorption isotherms of MSNs (curve 
(I)), MSNs-APTS (curve (II)), MSNs-PEG (curve (III)), and Gd(DTPA)2--loaded MSNs-PEG (curve (IV)). 
Solid: adsorption; hollow: desorption. (f) DLS size of MSNs, MSNs-APTS, and MSNs-PEG in deionized 
H2O, and MSNs-APTS and MSNs-PEG in PBS, respectively. 
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Figure 4.3. Pore diameter distribution of MSNs, MSNs-APTS, MSNs-PEG, and Gd(DTPA)2--loaded 
MSNs-PEG measured at 77 K. 
 
 
 
 
Figure 4.4. The colloidal stability of MSNs-PEG (left tube) and MSNs-APTS (right tube) in PBS after 
being kept undisturbed for (a) 30 min, (b) 1 day, and (c) 3 days at room temperature. 
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Figure 4.5. Ultrasound-stimulated Gd(DTPA)2- release using a probe sonicator. Time-dependent release 
profile of Gd(DTPA)2- from MSNs-PEG after probe sonication (black), or immersed in a 23 °C (pink), 37 
°C (blue) or 50 °C (red) water bath. The loading capacity of Gd(DTPA)2- in MSNs-PEG was 24.1 ± 2.1 %. 
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Figure 4.6. TEM image of MSNs-PEG after 30 min of probe sonication. 
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Figure 4.7. (a)(b) Set-up of the MRgHIFU system. The agarose phantom was placed on top of the water-
cooled HIFU transducer, which was secured on the patient bed in a 3T whole-body MRI scanner. (c) Top 
view of the HIFU transducer without cooling water and cap. 
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Figure 4.8. HIFU-stimulated Gd(DTPA)2- release in a tissue-mimicking agarose phantom and the resulting 
observable MRI contrast changes. (a) Different views of the agarose phantom and the HIFU transducer. 
The agarose phantom was placed on top of the HIFU transducer. The agarose phantom (10 cm in diameter) 
was molded with six sample wells (1.3 cm in diameter, 5 cm in height). The cigar-shaped HIFU focal point 
(1 × 1 × 7 mm3 in size) was positioned close to the center of the sample well. (b) T1-weighted images before 
(left) and after (middle) HIFU stimulation (3 cycles of 1 min, 74 W) focused on water-suspended 
Gd(DTPA)2--loaded MSNs-PEG (sample 1, with the focal point indicated). The Δ T1-weighted image is 
shown on the right. Unstimulated control groups included: water-suspended Gd(DTPA)2--loaded MSNs-
PEG (control 2), Gd(DTPA)2--loaded MSNs-PEG mixed in methylcellulose gel/milk (controls 3-5), and 
methylcellulose gel/milk (control 6). Control 7 was the agarose phantom. 
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Figure 4.9. The percentage of T1-weighted image intensity changes of the MRgHIFU-stimulated water-
dispersed Gd(DTPA)2--loaded MSNs-PEG (sample 1), unstimulated water-dispersed Gd(DTPA)2--loaded 
MSNs-PEG (control 2), unstimulated Gd(DTPA)2--loaded MSNs-PEG mixed in methylcellulose (2.5 wt %) 
and concentrated milk (v/v = 1/1) (controls 3 to 5), the mixture of methylcellulose (2.5 wt %) and 
concentration milk (v/v = 1/1) (control 6), and agarose phantom background (control 7). The amount of 
Gd(DTPA)2- release of HIFU-stimulated sample 1 was quantified by ICP-OES. 
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Figure 4.10. (a) Schematic illustration showing the shortening and lengthening effect of loaded and released 
Gd(DTPA)2- on T1 relaxation time. The loaded Gd(DTPA)2- inside the pores of MSN-PEG interacts 
electrostatically with the positively-charged pore wall and acts like an adsorbed agent. This leads to a slower 
tumbling rate and a shorter T1 relaxation time of the loaded Gd(DTPA)2-. On the contrary, the released 
Gd(DTPA)2- acts like a free agent and leads to a faster tumbling rate and a longer T1 relaxation time of the 
released Gd(DTPA)2-. (b) T1 relaxivity (r1) values of free Gd(DTPA)2- (blue), and Gd(DTPA)2--loaded 
MSNs-PEG before (red) and after HIFU stimulation (3 cycles of 1 min, 74 W) (black). 
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Figure 4.11. Ultrasound-stimulated Gd(DTPA)2- release using a probe sonicator. (a) T1 relaxivity (r1) values 
of free Gd(DTPA)2- (blue), and Gd(DTPA)2--loaded MSNs-PEG without (black) and with (red) 30 min of 
ultrasound stimulation by the probe sonicator. (b) T1-weighted images of each sample in (a) at different 
Gd(III) concentrations.  
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Figure 4.12. (a) r1 and (b) r2 values of Gd(DTPA)2- with or without HIFU stimulation (3 cycles of 1 min, 
74 W). 
 
 
 
Figure 4.13. (a) r1 and (b) r2 values of Gd(DTPA)2- with or without 30 min of probe sonication. 
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Figure 4.14. (a) Temperature increase profiles of Gd(DTPA)2--loaded MSNs-PEG in deionized H2O and in 
methylcellulose gel/milk mixture during the HIFU stimulation (74 W) measured by dynamic MRI 
temperature mapping acquired using a 2D gradient-echo protocol (For sample in water: TE= 20 ms, TR= 
30 ms, spatial resolution of 1 × 1 × 3 mm3, and temporal resolution of 2.8 s; for sample in gel/milk: TE= 
10 ms, TR= 20 ms, spatial resolution of 1 × 1 × 3 mm3, and temporal resolution of 1.8 s). (b) MALDI-TOF 
spectra of PEG (Mn 2,000 Da) without HIFU stimulation (top), after 3 cycles of 1 min HIFU stimulation 
(middle), and 2 cycles of 5 min HIFU stimulation (bottom). The intensity ratios, calculated as the highest 
intensity of the peak around m/z 1,000/the highest intensity of the peak around m/z= 2,000, were determined 
to be 0.11, 0.20, and 0.71, respectively. 
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Figure 4.15. The colloidal stability of HIFU-stimulated MSNs-PEG (left tube) and unstimulated MSNs-
PEG (right tube) in deionized H2O after being kept undisturbed for 30 min. The HIFU-stimulated tube has 
aggregation at the bottom due to loss of colloidal stability after disruption of PEG caps.  
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Figure 4.16. Dose control of released Gd(DTPA)2- and MRI contrast enhancement with different HIFU 
stimulation parameters. The percentage changes of T1-weighted image intensity of Gd(DTPA)2--loaded 
MSNs-PEG is shown in (a) after 3, 5, or 10 min of HIFU stimulation (1 MHz, 74 W), and in (b) after 3 min 
of HIFU stimulation at electrical power levels of 9 W, 74 W, or 290 W. (c) The Δ T1-weighted images of 
each HIFU-stimulated sample in (a) and (b). (d)(e) Correlations between T1 relaxation times and the release 
efficiencies of Gd(DTPA)2- from HIFU-stimulated samples in (a) and (b), respectively. 
  
 169 
 
Figure 4.17. Ultrasound-stimulated Gd(DTPA)2- release using the probe sonicator and the resulting T1 
changes. (a) T1 of Gd(DTPA)2--loaded MSNs-PEG after 2, 5, 8, 10, and 30 min of probe sonication. Inset 
shows the corresponding T1-weighted images. (b) Positive correlation between T1 and the release 
efficiencies of Gd(DTPA)2-.  
 
 
 
 
 
Figure 4.18. The percentage of T1-weighted image intensity changes of the methylcellulose gel/milk-mixed 
Gd(DTPA)2--loaded MSNs-PEG (a) after 1, 3, 5, or 10 min of HIFU stimulation (74 W); (b) after 3 min of 
HIFU stimulation at electrical power levels of 9 W, 74 W, or 290 W. (c) Time-dependent T1-weighted image 
intensity of Gd(DTPA)2--loaded MSNs-PEG with multiple HIFU stimulations (3 cycles of 1 min, 74 W) 
(shown in black). T1-weighted image intensity of agarose background is shown in red. The yellow boxes 
show the ON time (3 min) of each HIFU stimulation. The OFF times between each ON time were 67 min 
and 57 min.  
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Figure 4.19. TEM image of MSNs-PEG after 3 min of HIFU stimulation. 
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Figure 4.20. 3-D control of the MRgHIFU focal point and stimulated cargo release. (a) The axial, sagittal 
and coronal cross sections of the sample well of interest in the agarose phantom. Gd(DTPA)2--loaded 
MSNs-PEG were mixed in methylcellulose and placed in a 3 cm-in-depth sample well. The agarose 
phantom was place on top of the HIFU transducer and the HIFU beam was focused to a cigar-shaped focal 
point (1 × 1 × 7 mm3) near the center of the sample well. The color-coded Δ T1-weighted images in three 
orientations are shown in (b). The zoomed-in images showed a sharply defined region of image change in 
3-D space. 
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Figure 4.21. Ex vivo MRgHIFU-stimulated Gd(DTPA)2- release and the controllable MRI contrast changes. 
(a) T1-weighted image before HIFU stimulation of the 3 × 6 cm2 chicken breast tissue injected with 
methylcellulose gel containing Gd(DTPA)2--loaded MSNs-PEG. The location of the HIFU focal point is 
indicated by a circle. The color-coded Δ T1-weighted images of the HIFU-stimulated sample, unstimulated 
sample, and tissue background after each cycle of HIFU stimulation (3 min, 2.5 MHz, 8 W) are shown. 
Total number of cycles= 3. (b) The percentage of T1-weighted image intensity changes of the background, 
unstimulated sample, and HIFU-stimulated sample after each cycle of HIFU stimulation. Error bars were 
calculated from six analyzed locations within the region of interest. Only the HIFU-stimulated sample 
showed substantial and progressively increasing T1-weighted image intensity change. 
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Figure 4.22. Ex vivo MRgHIFU-stimulated Gd(DTPA)2- release and the controllable MRI contrast changes 
in three-dimensional space. A piece of 3 ×	6 cm2 chicken breast tissue was injected with methylcellulose 
gel containing Gd(DTPA)2--loaded MSNs-PEG and stimulated with HIFU for 3 cycles of 3 min (2.5 MHz, 
8 W). The T1-weighted image of the chicken breast before the HIFU stimulation was shown in (a) axial, (b) 
sagittal, and (c) coronal orientations. The color-coded Δ T1-weighted images, acquired by subtracting the 
T1-weighted images before from the one after 3 cycles of HIFU stimulation, were shown in three-
dimensional space. 
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Figure 4.23. Ex vivo MRgHIFU control experiment. (a) A piece of chicken breast tissue (3 cm × 5 cm) 
was injected with methylcellulose gel only. (b) The percentage of T1-weighted image intensity changes of 
the tissue background and the HIFU-stimulated gel after each cycle of HIFU stimulation (3 min, 2.5 MHz, 
8 W). Total number of cycles= 2. (c) Color-coded Δ T1-weighted images of the chicken tissue after each 
cycle of HIFU stimulation. The position of HIFU-stimulated gel and tissue background was indicated.  
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Figure 4.24. Preparation of the agarose phantom. (a) Before the removal of the glass test tubes, and (b) 
after the removal of the glass test tubes. Five sample wells were molded in the agarose phantom. 
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Table 4.1. Brunauer-Emmett-Teller (BET) surface area, total pore volume, and average pore diameter of 
MSNs, MSNs-APTS, MSNs-PEG, and Gd(DTPA)2--loaded MSNs-PEG analyzed from the N2 
adsorption/desorption isotherms. 
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Table 4.2. Summary of the Gd(DTPA)2- release efficiency and temperature increase using various HIFU 
parameters (power levels and stimulation times). 
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CHAPTER 5 
Facile Strategy Enabling Both High Loading and High 
Release Amounts of the Water-Insoluble Drug Clofazimine 
Using Mesoporous Silica Nanoparticles 
This chapter of the dissertation was adapted and reprinted with permission from Wei Chen#, Chi-
An Cheng#, Bai-Yu Lee, Daniel L. Clemens, Wen-Yen Huang, Marcus A. Horwitz, Jeffrey I. 
Zink ACS Applied Materials & Interfaces 2018, 10, 31870-31881. Copyright 2018 American 
Chemical Society. Co-author contributions: Chen W.#, Cheng C. A.# (co-first authors), and Huang 
W. Y. designed and performed the synthesis and characterization of material, and all the chemistry 
related studies. Lee B. Y., and Clemens D. L. performed the cell and bacteria studies. Marcus A. 
Horwitz, and Jeffrey I. Zink were the P.Is. 
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5.1 Abstract 
The use of nanocarriers to deliver poorly soluble drugs to the sites of diseases is an attractive 
and general method, and mesoporous silica nanoparticles (MSNs) are increasingly being used as 
carriers. However, both loading a large amount of drugs into the pores and still being able to release 
the drug is a challenge. In this work, we demonstrate a general strategy based on a companion 
molecule that chaperones the drug into the pores and also aids it in escaping. A common related 
strategy is to use a miscible co-solvent dimethyl sulfoxide (DMSO), but although loading may be 
efficient in DMSO, this co-solvent frequently diffuses into an aqueous environment, leaving the 
drug behind. We demonstrate the method by using acetophenone (AP), an FDA-approved food 
additive as the chaperone for clofazimine (CFZ), a water-insoluble antibiotic used to treat leprosy 
and multidrug-resistant tuberculosis. AP enables a high amount of CFZ cargo into the MSNs and 
also carries CFZ cargo out from the MSNs effectively when they are in an aqueous biorelevant 
environment. The amount of loading and the CFZ release efficiency from MSNs were optimized; 
4.5 times more CFZ was loaded in MSNs with AP than that with DMSO and 2300 times more 
CFZ was released than that without the assistance of the AP. In vitro treatment of macrophages 
infected by Mycobacterium tuberculosis with the optimized CFZ-loaded MSNs killed the bacteria 
in the cells in a dose-dependent manner. These studies demonstrate a highly efficient method for 
loading nanoparticles with water-insoluble drug molecules and the efficacy of the nanoparticles in 
delivering drugs into eukaryotic cells in aqueous media. 
 
5.2 Introduction 
Poor water solubility of drug molecules is a significant problem because almost 40% of the 
newly discovered drug molecules are hydrophobic which reduces their bioavailability and thus 
suppresses their efficacy.1 Great effort has been devoted to solving the problem of getting them to 
 188 
the site of the disease. One important strategy is to use nanomaterials as carriers to deliver insoluble 
drugs.2 Mesoporous silica nanoparticles (MSNs) have aroused much attention in this regard 
because their  properties include high surface area (about 1000 m2/g), large pore volume (1 cc/g), 
tunable pore sizes (2-20 nm), easy surface functionalization, and high biocompatibility.3–12 These 
excellent intrinsic properties enable MSNs to carry a wide variety of cargos, including drugs,13–17 
genes,18–21 proteins,22,23 and other biomolecules for in vitro or in vivo biomedical applications.24,25 
Additionally, MSNs can incorporate fluorescence and magnetic properties, and simultaneously 
serve as image contrast agents by integrating the relevant functional materials for diagnostics and 
therapeutics.26–28 Accordingly, these preeminent “theranostic” (therapeutic plus diagnostic) 
nanoparticles, serving as the excellent nanocarriers, are being broadly explored in biomedical 
applications.29–35 
The major challenges are to get the insoluble drug into the pores and then allow the drugs to 
escape. One of the most widely-used methods to load the poorly water-soluble drugs in MSNs is 
to dissolve the drugs in dimethyl sulfoxide (DMSO).14 The loading step is done by soaking MSNs 
in the DMSO solution which allows the drug molecules to diffuse into the channels of MSNs 
efficiently. After the loading step, the drug-loaded MSNs are washed with water or buffer solutions 
thoroughly to remove DMSO from the pores. However, during this washing step, some of drugs 
may be removed as well considering weak interactions between the hydrophobic drug molecules 
and the hydrophilic porous surface, thus decreasing the loading weight percent of drugs (defined 
as (weight of drugs / weight of MSNs) x 100%).2,14 To attempt to solve this problem of low drug 
loading, the channels of MSNs were functionalized with hydrophobic groups to increase the 
hydrophobic interactions between the drugs and the channels.36,37 However, those further surface 
modifications complicate the delivery systems and lead to colloidal instability in aqueous 
environment. Another critical challenge that remains is that the amount of the hydrophobic drug 
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released from the carriers into an aqueous environment is poor, even though MSNs are able to 
carry the drugs to the location of a disease.36–38 Consequently, the bioavailability of the drugs may 
be reduced to a level insufficient for effective treatment, or an extremely high dosage of the 
particles may be required to achieve a sufficient local concentration of free drug for it to be 
effective. Hence, to enhance the bioavailability of the drug, it is essential to improve its release 
efficiency from the nanocarriers.  
Hydrotropy is a technique that increases the water solubility of water insoluble molecules by 
adding a second solute (i.e. hydrotrope).39,40 Hydrotropes are short chain amphiphilic molecules, 
usually containing both the hydrophobic and hydrophilic moieties in their chemical structures, in 
which the hydrophobic part interacts with water-insoluble drugs through hydrophobic interactions, 
and the hydrophilic part helps solubilize the drug-hydrotropes complexation structure in water. 
The hydrotrope-assisted solubilization of water-insoluble drugs in water possesses a signature 
feature of a sigmoidal solubility curve.41,42 At low concentration of hydrotropes, the solubility of 
water-insoluble drugs hardly increases. The solubility of water-insoluble drugs significantly 
increases above a certain hydrotrope concentration, usually called a minimum hydrotrope 
concentration (MHC), when self-aggregation of the hydrotropes happens.42,43 Other mechanisms 
may also involve in the hydrotrope-assisted solubilization of water-insoluble drugs.44–47 Two 
advantages of using hydrotropy are that it obviates the need for chemical modification of the drugs, 
which may interfere with pharmaceutical activity; and it does not require a specific formulation 
for emulsification. The water solubility of water-insoluble drugs could be enhanced from several 
folds to several orders of magnitude by the hydrotrope-assisted solubilization especially if the 
hydrotropes associate well with the drugs.40,41,48 
In this study, we choose clofazimine (CFZ) as an example of a water-insoluble drug (defined 
as having water solubility of less than 100 µg/mL) to demonstrate our strategy for hydrophobic 
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drug delivery. CFZ has an extremely low (0.2 µg/mL) water solubility. The motivation for 
improving the delivery of CFZ lies in the fact that it has good efficacy against multidrug-resistant 
Tuberculosis (TB).49–52 TB is a serious contagious disease caused by the bacterium Mycobacterium 
tuberculosis (M. tuberculosis) and has becoming a global health problem; in 2016, there were 
approximately 10.4 million new TB cases and 1.3 million TB deaths worldwide.53 However, the 
extremely low water solubility of CFZ complicates its delivery by nanoparticles or other novel 
approaches e.g. via inhalation. 
In this work, we developed a facile “chaperone-assisted” delivery strategy which improves the 
loading of CFZ and delivers a large amount of CFZ with MSNs into an aqueous environment 
(Figure 5.1). First, we found acetophenone (AP) is the most promising chaperone among 9 
candidate molecules tested. Then, we compared the efficacy of AP and DMSO as non-aqueous 
solvents for CFZ loading and release. Next, we measured the effect of CFZ loading concentration 
on CFZ release and AP release and determined the optimized CFZ loading concentration. The 
effect of the location of AP relative to MSNs on CFZ was also explored. Finally, using the 
optimized AP/CFZ loaded MSNs, we investigated the antibacterial effect of this hydrotropy-based 
delivery strategy on intracellular M. tuberculosis to further validate their potential use in medicine 
and biomedical research. To the best of our knowledge, this is the first work to demonstrate 
appropriate chaperone for CFZ and to apply the strategy to the construction of nanoparticles with 
enhanced CFZ loading and release efficiency. 
 
5.3 Synthesis and Characterization of MSNs 
MSNs were synthesized by a sol-gel synthetic strategy in the presence of cationic surfactant 
template.15,55 By transmission electron microscopy (TEM) (Figure 5.2a), MSNs have a well-
ordered hexagonal mesoporous structure and the average size is 100 nm in diameter. The diameter 
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of MSNs measured by dynamic light scattering (DLS) is 165.7 nm (Figure 5.2b), which implies 
that MSNs are well-suspended in deionized (D.I.) H2O. The zeta potential value of MSNs is –21.2 
mV in D.I. H2O. Nitrogen adsorption/desorption isotherms of MSNs were measured at 77 K. The 
surface area, pore volume, and pore size are 1060 m2/g, 1.12 cm3/g, and 2.8 nm, respectively 
(Figure 5.2c and 5.2d). The high surface area, characteristic of MSNs,8,18 provides an advantage 
for loading cargos such as clofazimine (CFZ) and acetophenone (AP). 
 
5.4 Clofazimine Solubility Enhancement 
To enhance the water solubility of CFZ, we applied the concept of “hydrotropy” to the 
MSNs platform. During the past decades, the successful application of hydrotropy to the delivery 
of hydrophobic drugs by nanocarriers has been demonstrated by several research groups. For 
instance, Koo et al. used hydrotropic oligomer-conjugated glycol chitosan nanoparticles for 
paclitacxel (PTX) delivery.56 Wang, et al. used 70 nm hydrotropic polymer-based nanocarriers to 
load and deliver PTX in in vitro studies.57 Most of their work involved anticancer drugs, especially 
PTX, whose water solubility is 5.6 µg/mL.40,58,59 To the best of our knowledge, no application of 
hydrotropy to the delivery of water-insoluble antibiotics from nanocarriers has been demonstrated. 
It is known that highly effective hydrotropes frequently have either a phenyl ring or pyridine in 
their structures.59,60 For example, sodium benzoate and nicotinamide, with either a phenyl ring or 
pyridine in their structures, are effective hydrotropes for PTX.60 Therefore, sodium benzoate, 
nicotinamide, and other molecules with similar structures, including isoniazid, pyrazinamide, 2-
hydroxyacetophenone, benzoic acid, and AP were considered candidates for hydrotropes to 
enhance the water solubility of CFZ. Figure 5.3 shows the solubility enhancement of CFZ in H2O 
in the presence of the various hydrotropes mentioned above. The solubility of CFZ was determined 
from UV-Vis spectra where the maximum absorbance is at 490 nm. It is surprising that neither 
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sodium benzoate nor nicotinamide is a good hydrotrope; compared with the control, the CFZ 
solubility enhancement is only 1.3-and 1.5-fold in 1 M of sodium benzoate and nicotinamide 
solution, respectively. The results indicate that isoniazid and pyrazinamide are also not effective 
hydrotropes for CFZ (1.7-fold in 1 M isoniazid and 1.4-fold in 1 M pyrazinamide solution). The 
poor hydrotropic performance of these four molecules may due to their relatively high water 
solubility (629 mg/mL for sodium benzoate, 500 mg/mL for nicotinamide, 140 mg/mL for 
isoniazid, and 50 mg/mL for pyrazinamide) as shown in Table 5.1. It is very difficult to provide 
the hydrophobic interaction between the possible hydrotropes and CFZ. In this case, the strong 
intermolecular force of CFZ (mainly from the hydrophobic interaction of the phenyl rings of CFZ) 
is much stronger than the interaction between possible hydrotropes and CFZ. Such hydrophilicity 
of these molecules makes them unable to associate well with the hydrophobic CFZ molecules, and 
thus the water solubility of CFZ was only slightly enhanced effectively. 
On the other hand, the water solubility enhancement of CFZ is 1.6-fold, 1.7-fold, 2.0-fold, 
and 2.6-fold for 2-hydroxyacetophenone, hexanoic acid, benzoic acid, and 2-heptanone 
hydrotropes, respectively. Benzoic acid and 2-heptanone have better water solubility enhancement 
than 2-hydroxyacetophenone or hexanoic acid. This is due to the fact that the water solubility of 
benzoic acid and 2-heptanone – only 3.4 mg/mL and 4.3 mg/mL, respectively – is lower than that 
of 2-hydroxyacetophenone and hexanoic acid – 20.0 mg/mL and 10.8 mg/mL, respectively. Thus, 
these hydrotropes may associate better with the hydrophobic CFZ molecules and enhance the water 
solubility of CFZ. In addition, the presence of the phenyl rings in the structure of hydrotropes 
could also contribute to improvement in the water solubility of CFZ because of the hydrophobic 
interactions exists between the phenyl rings of the hydrotropes and hydrophobic moiety (phenyl 
rings) of CFZ. For example, the solubility enhancement of CFZ in the presence of benzoic acid or 
hexanoic acid is 2.0 or 1.7-fold, respectively. By using benzoic acid, the solubility enhancement is 
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higher than that of hexanoic acid due to the presence of the phenyl ring in benzoic acid. 
Additionally, the solubility enhancement of CFZ in the presence of 2-heptanone or AP is 2.6 or 
10.1-fold. By using AP as the hydrotrope, the solubility enhancement is about four times greater 
than that with 2-heptanone. Therefore, the phenyl ring could effectively enhance the water 
solubility of CFZ because either AP or benzoic acid could provide the hydrophobic interaction 
between their phenyl ring and the phenyl ring of CFZ. 
The hydrogen bonding between water molecules and CFZ is not strong enough to solvate 
CFZ since the intermolecular hydrophobic interaction between the phenyl rings of CFZ is strong. 
Therefore, the water solubility of CFZ is low (only 0.2 µg/mL), or water-insoluble by definition. 
However, for AP or 2-heptanone, there exists both a hydrophobic phenyl ring or alkyl chain and a 
polar carbonyl group in their chemical structures. These molecules could provide both the 
hydrophobic interaction between the hydrophobic phenyl ring or alkyl chain of AP or 2-heptanone 
and the hydrophobic moiety of CFZ, and hydrogen bonding between the carbonyl group of AP or 
2-heptanone and amine hydrogen in CFZ. Therefore, the presence of carbonyl group in AP or 2-
heptanone could provide stronger interaction between the possible hydrotropes and CFZ, e.g. the 
CFZ solubility enhancement is 10.1 or 2.6-fold by using AP or 2-heptanone as the hydrotrope, 
higher than those of benzoic acid (2.0-fold) or hexanoic acid (1.7-fold). In terms of polarity of the 
possible hydrotropes, a carboxylic acid group has larger polarity than a ketone. Therefore, if we 
compare 2-heptanone with hexanoic acid, the solubility enhancement of CFZ is 2.6 or 1.7-fold in 
the presence of 2-heptanone or hexanoic acid, respectively. The higher polarity of hexanoic acid 
has less hydrotropic effect to increase the water solubility of CFZ. This could also be proved that 
the solubility enhancement of CFZ is 10.1 or 2.0-fold in the presence of AP or benzoic acid, 
respectively, since benzoic acid has higher polarity. Based on the above observations, AP, with 
good association with CFZ and both a phenyl ring and a ketone in its structure, was chosen as a 
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promising hydrotrope for CFZ in this study. The hydrotropic efficacy of AP was examined in more 
detail in below Section 5.4.1. 
5.4.1 Hydrotropic Efficacy of AP on CFZ Solubility 
The hydrotropic efficacy of AP was examined in more detail using UV-Vis spectra to 
determine the CFZ solubility enhancement as a function of AP concentration in H2O (Figure 5.4a). 
When the AP concentration was below 2.2 mM, the absorbance at 490 nm was almost equal to that 
of the control (0 mM), whereas the absorbance rapidly increased as the AP concentration rose to 
more than 2.2 mM. The result shows that the water solubility of CFZ dramatically increases when 
the concentration of AP reaches around 2.2 mM. Figure 5.4b displays the fold enhancement of 
CFZ solubility by AP compared with the control. The maximum solubility enhancement of CFZ 
reached 12.2-fold at an AP concentration of 60 mM, which is the saturated concentration of AP in 
H2O. Accordingly, the result indicates that the water solubility of CFZ can be enhanced from 0.2 
mg/L to about 2.4 mg/L in the presence of AP in H2O. From Figure 5.4a and 5.4b, no hydrotropic 
efficacy was observed at concentrations of AP below 2.2 mM. Below this threshold, the solubility 
enhancement of CFZ is independent of the AP concentration. In contrast, when the concentration 
of AP is more than 2.2 mM, the solubility enhancement of CFZ increases significantly with AP 
concentration. The critical AP concentration may imply that the minimum hydrotropic 
concentration (MHC) is about 2.2 mM. Above the concentration, the self-aggregation of AP 
occurred,41,42 which is similar to that the surfactant molecules form the ordered micelle structure 
above the critical micelle concentration but not identical.42 Such self-aggregation of hydrotropes 
interact the water-insoluble drugs through hydrophobic interaction between the hydrophobic 
benzene ring of AP and water-insoluble CFZ and simultaneously help the solubilization of CFZ. 
Therefore, once the concentration of AP is higher than this threshold concentration, the self-
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aggregation of AP and its’ hydrotropic effect could help the solubilization of CFZ in water. This 
behavior follows the mechanism of hydrotropy-assisted solubility enhancement of hydrophobic 
drugs which may be attributed to the preferential interaction between AP and CFZ.43 A photograph 
of serial CFZ solutions with different AP concentrations is shown in Figure 5.4c. The color of the 
solutions became darker as the AP concentration increased, indicating that AP helps dissolve CFZ 
in H2O. These results show that the water solubility of CFZ is significantly enhanced by the 
addition of the AP. 
 
5.5 Clofazimine Loading by Using Different Nonaqueous Solvents: AP and DMSO  
      To realize whether AP could also facilitate the loading of CFZ in MSNs, we compared the 
loading amount of CFZ by using AP to that of conventional method using DMSO, a widely-used 
loading solvent for dissolving poorly water-soluble drugs.2,14 We called the method of using AP 
the “chaperone-assisted” method due to the preferential interaction between AP and CFZ, making 
AP act like a chaperone carrying the CFZ with it (Figure 5.5a). CFZ loading into MSNs was 
achieved by soaking MSNs in CFZ solutions with various concentrations dissolved in AP or 
DMSO. After 24 h loading of CFZ, the CFZ-loaded MSNs were introduced back to aqueous 
solution. To calculate the loading capacity, which is defined as (the mass of loaded CFZ/the mass 
of MSNs) x 100%, the CFZ loaded MSNs with AP or DMSO were respectively washed with AP 
or DMSO several times until the supernatant after centrifugation was clear. Those supernatants 
were collected and measured by UV-Vis spectroscopy. The total amount of CFZ loaded in MSNs 
was calculated based on Beer’s law and its calibration curve (Figure 5.6). From Figure 5.5b, the 
loading capacity of 0.1, 1, and 10 mM CFZ by using DMSO as the loading solvent were found to 
be 0.2, 0.9, and 5.9 %, respectively. However, with AP as the loading solvent, the higher loading 
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capacity were achieved under all loading concentrations of CFZ, which were 0.3, 1.3, 9.6, and 26.8 
% for 0.1, 1, 10, and 50 mM CFZ, respectively. The loading capacity of CFZ increased with the 
loading concentration of CFZ. The higher loading capacity of CFZ by using AP as the loading 
solvent can be explained by two reasons: (1) the CFZ solubility in AP (>71 mg/mL) is higher than 
in DMSO (5 mg/mL), so that the saturated concentration of CFZ in AP (more than 150 mM) is 
much higher than in DMSO (only 10.5 mM); (2) DMSO is miscible with water, so most of the 
DMSO molecules were removed by water during the washing steps, leading to the release of some 
CFZ molecules from MSNs together with DMSO. However, the water solubility of AP is only 6.1 
mg/mL, so a large amount of AP was still loaded in the pores of MSNs after they were re-dispersed 
in aqueous solution (Figure 5.5a). As will be shown in the next section, the AP in the pores is 
essential for good CFZ release. 
On the basis of the significant enhancement of CFZ loading by AP, it was of interest to 
investigate the detailed relationship between the loading of AP chaperone and its cargo CFZ. 
MSNs were loaded with AP itself (no CFZ), or AP with 0.1, 1, 10, and 50 mM solubilized CFZ. 
The pore volume of MSNs is 1.12 cm3/g; hence the maximum volume for cargo loading is 1.12 
µL/mg. The density of AP is 1.03 g/cm3, and thus the maximum loading capacity would be 115.4%. 
When AP itself (0 mM CFZ), or AP with 0.1, 1, 10, and 50 mM solubilized CFZ were used as the 
loading solvents, the loading capacity of AP was found to be 100.9 %, 102.4 %, 101.1%, 97.2 %, 
and 71.4 %, respectively (Figure 5.5c). The amount of loaded AP in MSNs corresponds to 8397.8, 
8522.7, 8414.5, 8089.9, and 5942.6 nmole/mg, and the amount of loaded CFZ in MSNs was 6.3, 
27.5, 202.8, and 566.1 nmole/mg at those respective CFZ loading concentrations (Table 5.2). This 
implies that when the CFZ loading capacity is low (no higher than 1.3 %, Figure 5.5b), regardless 
of the presence of CFZ, about 88% of the pore volume of MSNs is filled with AP after loading, 
which is reasonable since the low water solubility of AP (only 6.1 mg/mL) makes a large amount 
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of AP remain in the pores of MSNs after they are re-dispersed in aqueous solution. The loading 
capacity of AP is lower at higher CFZ concentrations (10 and 50 mM), at which the loading 
capacity of CFZ was enhanced (9.6 % and 26.8 %, Figure 5.5b). This is because part of the pore 
volume of MSNs is occupied by CFZ, thus reducing the volume available for AP loading. The 
mole ratios of AP to CFZ loaded in MSNs with those CFZ loading concentrations was calculated 
to be 1352.8, 306.0, 39.9, and 10.5, respectively (Table 5.2). As CFZ loading concentrations in AP 
increase, both the amount of loaded CFZ and the mole ratio of CFZ to AP increase. 
 
5.6 CFZ Release to Aqueous Solution by Using Different Nonaqueous Solvents: AP 
and DMSO 
Before applying the methods with AP and DMSO to deliver CFZ to biological systems, we 
examined their capability for facilitating the release of CFZ into aqueous solution. MSNs loaded 
with CFZ (1 mM) either by DMSO or AP were dispersed in HEPES buffer solution (pH = 7.4) for 
1, 2, 3, or 5 days, respectively (Figure 5.5a). Figure 5.7a shows the UV-Vis spectra of the 
supernatant after CFZ released from MSNs in buffer solution with DMSO as the loading solvent. 
The absorption peak of CFZ at 490 nm is not evident, indicating that the release of CFZ is 
negligible even after 5 days. This phenomenon could be explained as a result of the water-insoluble 
property of CFZ, making the drug molecules themselves prefer to stay in the pores of MSNs. On 
the contrary, with AP as the loading solvent, the release of CFZ could be easily found in the UV-
Vis spectra with the apparent peaks at 490 nm (Figure 5.7b). The absorbance peaks at 490 nm 
increased with time between 5 days, and the absorbance is significantly different from those with 
DMSO. To quantify the release amount of CFZ, the time dependent release efficiency of CFZ 
using either DMSO or AP was calculated (Figure 5.5d) based on Beer’s law and its calibration 
curve (Figure 5.8). The release efficiency is defined as (the mass of released CFZ/the mass of 
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loaded CFZ) x 100%. By using the “chaperone-assisted” strategy with AP, the release efficiency 
of CFZ achieved 47.2%, which is 2300 times higher than that by the conventional method with 
DMSO (0.02%) (Figure 5.5d). This significant enhancement in the release efficiency of CFZ by 
AP could also be clearly observed in the photograph of the supernatant (Figure 5.5e). 
 
5.7 Effect of the CFZ Loading Concentration on CFZ Release 
To optimize the release of CFZ in aqueous environment using the “chaperone-assisted” 
delivery strategy, we explored the effect of CFZ loading concentration on the long-term release 
behavior of CFZ. The release of CFZ was confirmed by the absorbance peaks at 490 nm in the 
UV-Vis spectra measured from the supernatants collected after spinning down MSNs after 1, 2, 3, 
and 5 days (Figure 5.7b). The time-dependent release capacity of CFZ was calculated based on 
Beer’s law and its calibration curve (Figure 5.8). Release capacity is defined as: (the mass of 
released CFZ / the mass of MSNs) x 100%. Figure 5.9a shows the time-dependent release capacity 
of CFZ in HEPES buffer solution (pH = 7.4) with four different CFZ loading concentrations (0.1, 
1, 10, and 50 mM) in AP. The absorbance peaks increase with time up to 5 days. Regardless of the 
CFZ loading concentration, the amount of CFZ released gradually increases with time, until it 
levels off at about five days. The amount of CFZ released from MSNs loaded with 0.1 mM CFZ 
in AP is only 0.10 % on day 5, which is mainly due to the tiny amount of CFZ (0.3 % loading 
capacity) loaded in MSNs. For the MSNs loaded with 1 and 10 mM CFZ in AP, the CFZ release 
capacity on day 5 was 0.56 % and 0.54 %, respectively. Even though the amount of CFZ loaded 
with those two samples (1.3 % and 9.6 % CFZ loading capacity, respectively) differed by 7-fold, 
the amount of CFZ released was nearly the same. However, the CFZ release capacity of the MSNs 
loaded with 50 mM CFZ in AP on day 5 is only 0.27 %, lower than those loaded with 1 and 10 
mM CFZ in AP. This low CFZ release capacity at this high CFZ loading concentration may be due 
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to a small amount of AP in the pores of MSNs that contain a large amount of CFZ (26.8 % CFZ 
loading capacity) as referred to Table 5.2, which shows the mole ratio of AP/CFZ to be only 10.5. 
This less amount of AP renders the environment inside the pores much more hydrophobic and thus 
reducing the “chaperone-assisted” effect or the hydrotropic effect. The time-dependent release 
efficiency of CFZ with four different CFZ loading concentrations (0.1, 1, 10, and 50 mM) was also 
calculated (Figure 5.9b). Release efficiency is defined as: (the mass of released CFZ / the mass of 
loaded CFZ in MSNs) x 100%. The time-dependent release efficiency on day 5 for MSNs loaded 
with 0.1, 1, 10, and 50 mM CFZ in AP is 42.3 %, 47.2 %, 4.6 %, and 0.1%, respectively. The 
lowest release efficiency, observed when MSNs were loaded with 50 mM CFZ in AP, indicates 
that most of the loaded CFZ remains in the pores of MSNs, which again may be due to the small 
amount of loaded AP and the enhanced hydrophobicity in the pores of MSNs as described above. 
 
5.8 Effect of the CFZ Loading Concentration on AP Release 
After the “chaperone-assisted” strategy was successfully demonstrated, we studied the effect 
of CFZ cargo loading concentration on the release of AP chaperone (Figure 5.9c and 5.9d). The 
release efficiency of AP was calculated based on Beer’s law and its calibration curve (Figure 5.10). 
The time-dependent release capacity of AP from MSNs loaded with 0.1, 1, 10, and 50 mM CFZ in 
AP is lower than from MSNs not loaded with CFZ on day 1 (Figure 5.9c). Nevertheless, the release 
capacity of AP from MSNs loaded with CFZ substantially increases on day 2. Finally, the release 
capacity of AP on day 5 reaches 94.2, 90.0, 77.8, and 53.6 % from MSNs loaded with 0.1, 1, 10, 
and 50 mM CFZ in AP, respectively. For the release efficiency of AP from MSNs loaded with 0.1, 
1, 10, and 50 mM CFZ, only 22, 11, 12, and 13 % were found on day 1, much lower than without 
loaded CFZ (33%) (Figure 5.9d). However, on day 2, the release efficiency of AP from MSNs 
loaded with 0.1, 1, 10, and 50 mM CFZ in AP achieves 60, 61, 59, and 57 %, respectively, which 
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is close to that without loaded CFZ (58%). Finally, on day 5, the release efficiency of AP reaches 
about 92, 89, 80, and 75 % for MSNs loaded with 0.1, 1, 10, and 50 mM CFZ in AP, respectively, 
and reaches about 95% for the MSNs loaded with AP itself (0 mM CFZ). Interestingly, the result 
on day 5 shows that the release efficiency of AP decreases as the loading concentration of CFZ 
increases. This finding together with the lower loading capacity of AP at 10 and 50 mM CFZ 
loading concentration (Figure 5.5c) adequately explain the much lower release capacity of AP 
when MSNs are loaded with 10 mM or 50 mM CFZ than when MSNs are loaded with AP without 
any CFZ (95.9%) (Figure 5.9c). 
The sigmoidal release profiles of both CFZ and AP loaded in MSNs are characterized by 
slow release during the first day followed by increased release at later time points, and a final 
leveling off (Figure 5.9b and 5.9d). In the presence of both CFZ and AP in MSNs, almost all of 
the CFZ (Figure 5.9b) as well as the greater part of AP (Figure 5.9d) remain inside the pores on 
day 1, especially for the MSNs loaded with 1, 10, and 50 mM CFZ in AP. This supports that there 
may exist an interaction between CFZ and AP in the pores of MSNs, and that this association 
favors most of the AP molecules residing in the pores of MSNs, reducing the AP release on day 1. 
The loaded CFZ molecules may sterically block the release of AP from MSNs as well. The better 
AP release compared to that of CFZ on day 1 could be explained by the higher water solubility of 
AP than CFZ, so that the release of AP in aqueous environment can occur in a short period of time. 
For MSNs loaded with 0.1 and 1 mM CFZ in AP, the release efficiency of AP increases 
significantly after day 1 (Figure 5.9d), which corresponds to the substantial increase in CFZ 
release efficiency on day 2 (Figure 5.9b). This feature is due to the high mole ratio of AP/CFZ in 
the pores of MSNs with 0.1 and 1 mM CFZ (Table 5.2). The abundant AP chaperone in the pores 
carry CFZ out of MSNs and thus facilitates CFZ release into an aqueous environment. Interestingly, 
for particles loaded with 10 and 50 mM CFZ, the CFZ release efficiency shows no significant 
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increase during those five days compared with the dramatic increase in AP release efficiency after 
day 1. This is because the mole ratio of AP/CFZ is low at those CFZ loading concentrations (Table 
5.2), and thus the interaction between AP and CFZ is not strong enough to carry CFZ out of MSNs 
and into the aqueous environment. In other words, when the mole ratio of AP/CFZ is low, even 
though the interaction between CFZ and AP in the pores retards the release of AP, the high water 
solubility of AP dominates such that more AP is released into an aqueous environment as the 
release time increases. 
The “chaperone-assisted” delivery strategy makes use of the interaction between CFZ 
cargo and AP chaperone which provides the mechanism for the release of CFZ from MSNs, and 
thus significantly enhances the water solubility of CFZ. By carefully tuning the mole ratio of 
AP/CFZ, we can control the dosage and the release profile of CFZ over time. This would be 
favorable in terms of improving the bioavailability and the efficacy of CFZ, as well as reducing 
the side-effect causing by the overdose of CFZ. 
 
5.9 Effect of External AP on CFZ Release 
As the chaperone, AP is supposed to be stayed together with its CFZ cargo in the pores of 
MSNs to bring its assistance into full play. To further confirm the idea of “chaperone-assisted” 
delivery, we studied the release of CFZ in a buffer solution with or without the addition of 
dissolved AP. Instead of using AP as the loading solvent, DMSO was used for loading CFZ to 
prevent AP from being present in the pores of MSNs. Release buffer with or without the addition 
of AP was used for CFZ release. With DMSO as the loading solution, the release efficiency of 
CFZ released in HEPES buffer solution (10 mM, pH = 7.4) without the addition of AP is only 
0.02% after 120 h, which indicates that almost all of the CFZ stays in the pores of MSNs (Figure 
5.11). The release efficiency of CFZ released in HEPES buffer solution with the addition of AP, 
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on the other hand, is only 4.3% after 120 h. Both of these CFZ release efficiencies are significantly 
lower than that with AP as the loading solvent and HEPES buffer solution as the release buffer 
(47.2%). This result suggests that the CFZ release efficiency is significantly enhanced by the AP 
loaded inside the pores of MSNs together with CFZ, of which the interaction between CFZ cargo 
and AP chaperone inside the pores contributes substantially to the significant improvement of CFZ 
release. On the other hand, AP outside of the MSNs that doesn't have good interaction with CFZ 
only contributes to about 1/10th of the CFZ release. This slightly greater CFZ release could be 
explained by the increased hydrophobicity of the environment causing by the AP located in 
solution outside of MSNs. This study further strengthens the idea of “chaperone-assisted” delivery, 
where MSNs act like a primary vehicle carrying both a secondary vehicle – the AP chaperone – 
and the CFZ cargo inside. As the chaperone, AP carries the CFZ and brings it out and away from 
MSNs effectively. 
 
5.10 Antibacterial Effect of AP-Assisted CFZ Delivery by MSNs  
To explore the antibacterial effect of the developed “chaperone-assisted” delivery strategy shown 
in Figure 5.12a, we examined the treatment efficacy of the CFZ loaded MSNs using a macrophage 
model of Mycobacterium tuberculosis (M. tuberculosis) infection. The mole ratio of AP/CFZ was 
tuned and the optimized CFZ loading concentration was found to be 10 mM considering both the 
loading capacity and release capacity of CFZ (Figure 5.5b and 5.9a). The M. tuberculosis-infected 
macrophages were treated with MSNs loaded with 10 mM CFZ in AP (AP/CFZ-MSN) for 4 days 
(Figure 5.12a). As controls, the macrophages were untreated or treated with MSNs loaded with 
AP only (AP-MSN), or with free CFZ dissolved in a mixture of DMSO and H2O (CFZ/DMSO). 
All of the infected macrophages were lysed at day 4 post-infection and the lysates were plated for 
viable M. tuberculosis. The number of M. tuberculosis colony forming units (CFUs) recovered 
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from the macrophages was enumerated to determine bacterial viability under each treatment. As 
shown in Figure 5.12b, treatment with AP-MSN (11 and 22 µg/mL) for 4 days without CFZ had 
little effect on M. tuberculosis because the number of bacteria in macrophage monolayers (6.29, 
and 6.25 log CFU, respectively) was similar to and not statistically different from the number in 
untreated macrophages (6.51 log CFU). In contrast, AP/CFZ-MSN killed the intracellular bacteria 
in a dose-dependent manner. AP/CFZ-MSN at concentrations of 5.5, 11, and 22 µg/mL correspond 
to 0.5, 1, and 2 µg/mL of free CFZ dissolved in DMSO. The number of viable bacteria after 
treatment with those concentrations of AP/CFZ-MSN was 5.97, 5.82, and 5.50 log CFU, 
respectively, suggesting that 90% of bacteria was killed (the number of bacteria decreased by 1 log 
CFU) in macrophages treated with 22 µg/mL of AP/CFZ-MSN. We also compared the effect of 
free CFZ with that of the MSN-encapsulated CFZ. The treatment efficacy of AP/CFZ-MSN 
dispersed in culture medium was similar to that of an equivalent amount of CFZ dissolved in the 
mixture of DMSO and culture medium without MSNs. This comparison shows that with the help 
of the AP chaperone, most of the CFZ loaded inside MSNs is efficiently released in the 
macrophages and kill the bacteria effectively and selectively (Figure 5.12a). 
To investigate if the “chaperone-assisted” delivery strategy with AP, an FDA approved food 
additive, has any cytotoxicity to the macrophages, we examined the viability of the infected 
macrophages after the treatment with AP-MSN and AP/CFZ-MSN for 4 days. No significant 
decrease in macrophage viability was detected (Figure 5.12c) at the concentrations studied. No 
adverse effect on the morphological appearance of the macrophages treated with AP-MSN or 
AP/CFZ-MSN was observed. Taken together, these results show that the “chaperone-assisted” 
CFZ delivery strategy via MSNs has no evident toxicity to macrophages but can selectively and 
efficiently kill the bacteria residing inside them due to the significant release of CFZ from MSNs. 
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5.11 Summary 
In this study, we have developed a novel “chaperone-assisted” strategy based on mesoporous 
silica nanoparticles (MSNs) to both load water-insoluble drugs into MSN carriers and release them 
into aqueous biological environment. First, we utilized the concept of “hydrotropy” to explore the 
nine candidate small molecules for their utility to enhance the water solubility of a water-insoluble 
antibiotics — clofazimine (CFZ), who has good efficacy against multidrug-resistant Tuberculosis 
(TB). Acetophenone (AP) was selected as the most efficacious solvent to enhance 10.1-fold of the 
water solubility of CFZ. Acting as a chaperone, AP not only brought a great amount of CFZ cargos 
(26.8% loading capacity of CFZ) into the MSN nanocarriers, but carried a significant amount of 
CFZ cargos (47.2% release efficiency of CFZ) out from MSNs into the aqueous solution. This 
release efficiency of CFZ achieved is 2300 times higher than that by conventional method using 
DMSO (0.02%). This considerable increase in CFZ release is mainly driven by the release of AP 
chaperone from the chaperone-rich pores of MSNs, which allows CFZ cargo to be carried together 
into the aqueous solution, and can be supported by our three findings: (1) a lower loading 
concentration of CFZ (1 mM) gave a higher release efficiency of CFZ (47.2%) compared with a 
higher loading concentration of CFZ (0.1%); (2) AP in the solution outside of MSNs only 
minimally increased the release efficiency of CFZ (4.3%); (3) without AP, the release efficiency 
of CFZ was only 0.02%. We examined this delivery strategy in a macrophage model of 
Mycobacterium tuberculosis (M. tuberculosis) infection using MSNs loaded with the optimized 
ratio of CFZ and AP (10 mM CFZ in AP). M. tuberculosis residing inside macrophages were 
efficiently killed (reduced by 1 log CFU) by the high amount of the released CFZ, which is 
comparable to that with the same amount of CFZ dissolved in a mixture of DMSO and culture 
medium. No adverse effect on the morphological appearance of the macrophages treated with 
either MSNs loaded with AP or MSNs loaded with CFZ and AP was observed. This novel 
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“chaperone-assisted” delivery strategy for CFZ could also be applied to other hydrophobic drugs 
with their suitable loading solvents (chaperone), opening up opportunities to apply this drug 
delivery strategy for further use in medicine and biomedical research. 
 
5.12 Methods 
5.12.1 Materials and Chemicals 
Hexadecyltrimethylammonium bromide (CTAB, 99+%), tetraethyl orthosilicate (TEOS, 
98%), clofazimine (CFZ, 98+%), acetophenone (AP, 99%), 2-heptanone (98%), 2-
hydroxyacetophenone (98%), sodium benzoate (99%), pyradinamide (97.5+%), nicotinamide 
(99.5+%), isoniazid (99+%), hexanoic acid (99+%), benzoic acid (99.5+%), sodium hydroxide 
(NaOH) (97+%), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, 99.5+%), and 
ammonium nitrate (NH4NO3, 98+%) were purchased from Sigma-Aldrich. Dimethyl sulfoxide 
(DMSO, 99.9+%) was purchased from Fisher Chemical. Absolute ethanol (200 proof) was 
purchased from Decon Labs, Inc. All chemicals were used without further purification. 
5.12.2 Characterization 
The size and morphology of mesoporous silica nanoparticles (MSNs) were investigated by 
transmission electron microscopy (TEM, Tecnai T12). MSNs were dispersed in ethanol at a very 
low concentration (0.2 mg/mL). Ten microliters of the suspension were dropped onto the carbon-
coated copper grid and dried at room temperature. The N2 adsorption-desorption isotherms of 
MSNs were obtained at liquid N2 temperature (77K) on a Autosorb-iQ (Quantachrome Instruments) 
apparatus. MSNs were degassed at 110 °C for 12 h before the measurement. The surface area and 
pore size distribution of MSNs were determined by Brunauer-Emmett-Teller (BET) and Barrett-
Joyner-Halenda (BJH) methods. The dynamic light scattering (DLS) size and zeta potential value 
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of MSNs were examined by a laser particle analyzer LPA-3100 at room temperature. The loading 
capacity, release capacity, and release efficiency of CFZ or AP were determined by UV-Vis 
Spectroscopy (Cary 5000). The absorbance of the peaks was used for quantification by Beer-
Lambert Law. 
5.12.3 Synthesis of MSNs 
CTAB (250 mg) was dissolved in a mixture of deionized water (120 mL) and 2 M NaOH (875 
µL) under vigorous stirring. The solution was heated to 80 °C and tetraethyl orthosilicate (TEOS) 
(1.25 mL) was then added dropwise to the solution for about 20 seconds. The reaction was kept at 
80 °C for 2 h. Subsequently, the solution was cooled to room temperature and MSNs were 
centrifuged and washed 3 times with ethanol. MSNs were then dispersed in 100 mL of ethanol 
containing 2 g of NH4NO3 and the reaction was refluxed for 1 h to remove the surfactant. The 
surfactant removal procedures were repeated twice and MSNs were washed thoroughly with 
ethanol and D.I. water to obtain the surfactant-free MSNs. 
5.12.4 Screening of Possible Hydrotropes for CFZ 
Nine different small molecules – nicotinamide, sodium benzoate, pyradinamide, isoniazid, 2-
hydroxyacetophenone, benzoic acid, hexanoic acid, 2-heptanone, and acetophenone – were 
screened to investigate their hydrotropic ability for CFZ in H2O. For the control lacking a 
hydrotrope, 1 µmol of CFZ and 1 mL of H2O were added into a 20 mL of glass vial and sonicated 
for 10 min to suspend CFZ in H2O. The undissolved CFZ was removed by centrifugation at 14000 
rpm for 15 min. Then, the supernatant was collected and measured by UV-Vis spectroscopy. For 
experimental samples with hydrotropes, 1 µmol of CFZ, 1 mL of H2O, and the respective 
hydrotrope [sodium benzoate (50 µmol, 500 µmol, or 1 mmol), pyrazinamide (50 µmol, 500 µmol, 
or 906 µmol), nicotinamide (50 µmol, 500 µmol, or 1 mmol), isoniazid (50 µmol, 500 µmol, 1 
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mmol), 2-hydroxyacetophenone (50 µmol), hexanoic acid (50 µmol), benzoic acid (28 µmol), 2-
heptanone (38 µmol), or acetophenone (50 µmol)] were added into 20 mL glass vials and sonicated 
for 10 min. The undissolved CFZ was removed by centrifugation as described above. Finally, the 
supernatant was collected and measured by UV-Vis spectroscopy. The solubility enhancement was 
determined by the change in absorbance at 490 nm. 
5.12.5 Concentration Dependent Hydrotropy Effect of AP 
To investigate the hydrotropic effect of AP in more detail, we prepared concentrations ranging 
from 0 to 60 mM of AP in H2O to dissolve CFZ. Similarly, 1 µmol of CFZ, 1 mL of H2O, and the 
respective concentration of AP were added into 20 mL glass vials and sonicated for 10 min. The 
undissolved CFZ was removed by centrifugation as described above. The solubility enhancement 
was determined by the change in absorbance at 490 nm. 
5.12.6 Creation of Calibration Curve of CFZ in AP, CFZ in Ethanol-Water Mixture, and AP 
in Ethanol-Water Mixture 
To determine the loading capacity, release efficiency, and release capacity of CFZ, the 
calibration curves were created by dissolving CFZ in AP. The concentration of CFZ in AP ranged 
from 0 to 50 µM. The absorption spectra of the solutions were measured by UV-Vis spectroscopy, 
and the absorbance maximum (490 nm for CFZ and 244 nm for AP) was used to plot the calibration 
curve. The calibration curves ranging from 0 to 25 µM of CFZ dissolved in a mixture of ethanol 
and HEPES buffer solution (10 mM, pH = 7.4) (v/v = 1/1) were also generated. To determine the 
release capacity and release efficiency of AP, the calibration curve of AP was generated by 
dissolving AP in a mixture of ethanol and HEPES buffer solution (10 mM, pH = 7.4) (v/v = 1/1). 
The concentration of AP ranged from 0.25 to 66 µM. 
5.12.7 Loading Capacity Analysis of Clofazimine (CFZ) 
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The loading of CFZ was studied using DMSO or AP as loading solvents. In general, 10 mg 
of MSNs were dispersed in AP or DMSO with 0.1, 1, 10, or 50 mM CFZ, respectively. After 24 h 
stirring, the CFZ loaded MSNs were centrifuged at 14000 rpm for 10 min and the pellets were 
washed three times with H2O under sonication to remove the excess CFZ. Then, the CFZ loaded 
MSNs with AP or DMSO were washed with AP or DMSO, respectively, and pelleted by 
centrifugation. The washing steps were repeated several times until the supernatant was clear. The 
supernatants were collected and measured by UV-Vis spectroscopy. The loading capacity of CFZ 
was calculated using the maximum absorbance at 490 nm based on Beer’s law, its calibration curve, 
and the following definition of loading capacity: (mass of loaded CFZ/mass of MSNs) x 100%. 
5.12.8 Release of CFZ and AP in HEPES Buffer 
The release of CFZ and AP from MSNs was carried out in HEPES buffer solution (pH = 7.4, 
10 mM). In general, 10 mg of MSNs loaded with 0.1, 1, 10, or 50 mM CFZ in AP were dispersed 
in 1 mL of HEPES buffer solution and stirred for 1, 2, 3, or 5 days, respectively. Afterwards, the 
CFZ loaded MSNs were spun down at 14000 rpm for 10 min. The supernatant was collected and 
mixed homogeneously with ethanol, which was then diluted and measured by UV-Vis spectroscopy. 
The release efficiency of CFZ and AP were calculated using their maximum absorbance at 490 nm 
and 244 nm, respectively, based on Beer’s law, their calibration curves, and the definition of release 
efficiency: (mass of released CFZ/mass of loaded CFZ) x 100%. 
5.12.9 Release of CFZ in HEPES Buffer with Addition of AP 
To gain insight into whether the AP residing outside of the pores of MSNs would affect CFZ 
release, we added AP into the release buffer. After MSNs were loaded with 1 mM CFZ in DMSO, 
10 mg of MSNs were dispersed in 1 mL of HEPES buffer (10 mM, pH = 7.4) with the addition of 
10 µL of AP. The solution was stirred for 24 h and then centrifuged at 14000 rpm for 10 min. The 
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supernatant was collected and measured by UV-Vis spectroscopy; the pellet of CFZ loaded MSNs 
was resuspended by sonication in 1 mL of HEPES buffer with the addition of 10 µL of AP and 
stirred for another 24 h. Again, the supernatant was collected as described above and measured by 
UV-Vis spectroscopy. The same procedures were repeated and the supernatant was collected and 
analyzed at 72 h and 120 h as described above. 
5.12.10 Assay for killing of M. tuberculosis in macrophages 
Human monocytic THP-1 cells (ATCC TIB202) were maintained in RPMI-1640 
supplemented with 10% fetal bovine serum, GlutaMAX, and Penicillin-Streptomycin (100 IU-100 
μg/mL). Prior to infection, the cells were treated with phorbol 12-myristate 13-acetate (PMA) for 
3 days to differentiate them into macrophage-like cells. M. tuberculosis virulent strain Erdman 
(ATCC 35801) was cultured on Middlebrook 7H11 plates for 10 days. Lawns of bacteria were 
scraped from the plates, suspended in RPMI with 20 mM HEPES, and a single bacterial suspension 
was prepared by sonication and repeated centrifugation to remove bacterial clumps. After 
opsonization with human serum type AB containing active complement, the bacteria were used to 
infect PMA-differentiated THP-1 macrophages at a multiplicity of infection of 1:1 
(bacterium:macrophage). The bacteria were incubated with macrophages for 1 hour at 37 °C, after 
which MSNs loaded with AP (AP-MSN), MSNs loaded with 10 mM CFZ in AP hydrotrope 
(AP/CFZ-MSN), or free CFZ were added to the culture of the M. tuberculosis infected 
macrophages. The concentrations of AP-MSN were 11 and 22 µg/mL. The concentrations of 
AP/CFZ-MSN were 5.5, 11, and 22 µg/mL, corresponding to 0.5, 1, and 2 µg/mL of CFZ, 
respectively. Free CFZ was dissolved in DMSO first, and then added to M. tuberculosis infected 
macrophages at concentrations of 0.5, 1, and 2 µg/mL, those concentrations of free CFZ had 
0.005%, 0.01%, and 0.02% DMSO, respectively. The cells were incubated for 4 days at 37 °C, 5% 
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CO2-95% air, lysed with 0.1% SDS, serially diluted in Middlebrook 7H9 broth supplemented with 
ADC enrichment and 0.05% Tween 80, and plated on Middlebrook 7H11 agar plates. The number 
of bacterial colonies on the plates was enumerated after incubation for 2.5 weeks at 37 °C, 5% 
CO2-95% air.32,54 
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5.14 Figures and Tables 
 
 
Figure 5.1. Chaperone-assisted delivery strategy for water-insoluble drugs. Clofazimine (CFZ) was chosen 
as an example of a water-insoluble antibiotic. Acetophenone (AP) acts like a chaperone bringing CFZ cargo 
into the vehicle — mesoporous silica nanoparticles (MSNs) and then carrying CFZ cargo out from the 
MSNs effectively. 
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Figure 5.2. (a) TEM image of mesoporous silica nanoparticles (MSNs). Inset shows the enlarged image. 
(b) Dynamic light scattering diameter distribution of MSNs in D.I. H2O. The diameter of the MSNs is 165.7 
nm. (c) Nitrogen adsorption-desorption isotherms of MSNs at 77 K. BET surface area and pore volume are 
1060 m2/g and 1.12 cm3/g, respectively. (d) Pore diameter distribution of MSNs. Average pore diameter of 
MSNs is 2.8 nm. 
  
 213 
 
Figure 5.3. CFZ solubility enhancement in the presence of (a) sodium benzoate, (b) nicotinamide, (c) 
isoniazid, (d) pyrazinamide, (e) 2-hydroxyacetophenone, (f) hexanoic acid, (g) benzoic acid, (h) 2-
heptanone, and (i) acetophenone. The solubility of CFZ in deionized water without the addition of any 
molecule served as a control. 
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Figure 5.4. (a) UV-Vis spectra of CFZ dissolved in H2O in the presence of different concentrations of AP. 
(b) CFZ solubility enhancement (fold increase compared with no AP) in the presence of different 
concentrations of AP in H2O. (c) Photograph of CFZ dissolved in H2O in the presence of different 
concentrations of AP. 
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Figure 5.5. (a) Schematic illustration of conventional method (CFZ in DMSO) or chaperone-assisted 
method (CFZ in AP) for water-insoluble CFZ loading in MSN. By using AP as the chaperone, CFZ release 
from MSNs could be enhanced significantly. Loading capacity of (b) CFZ and (c) AP using 0.1, 1, or 10 
mM CFZ in DMSO or 0, 0.1, 1, 10, or 50 mM CFZ in AP as the loading solution. The concentration of 
MSNs was 10 mg/mL. (d) Time-dependent release efficiency of CFZ in HEPES buffer solution (10 mM, 
pH = 7.4) with 1 mM CFZ in DMSO or 1 mM CFZ in AP as loading solutions. (e) Photographs of 
supernatant after CFZ release collected at selected time points. MSNs were loaded with 1 mM CFZ in 
DMSO or 1 mM CFZ in AP. 
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Figure 5.6. (a) UV-Vis spectra of CFZ in AP as a function of concentration and (b) calibration curve of 
CFZ in AP at room temperature. (c) Photograph of CFZ dissolved in AP. 
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Figure 5.7 UV-Vis spectra of time-dependent CFZ release in HEPES buffer solution (10 mM, pH = 7.4) by 
using (a) DMSO or (b) AP as loading solvents. MSNs were loaded with 1 mM CFZ in DMSO or 1 mM 
CFZ in AP. The concentration of MSNs in both loading solution and release buffer solution were 10 mg/mL. 
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Figure 5.8. (a) Concentration dependent UV-Vis spectra and (b) calibration curve of CFZ in EtOH/HEPES 
buffer (10 mM, pH = 7.4) (v/v=1/1) solution at room temperature. (c) Photograph of CFZ dissolved in 
EtOH/HEPES buffer solution (10 mM, pH=7.4) (v/v=1/1). 
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Figure 5.9. Time-dependent release capacity of (a) CFZ and (c) AP and release efficiency of (b) CFZ and 
(d) AP in HEPES buffer solution (10 mM, pH = 7.4) with 0, 0.1, 1, 10, and 50 mM CFZ in AP as loading 
solutions. The concentration of MSNs in both loading solution and release buffer solution was 10 mg/mL 
(n=3). 
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Figure 5.10 (a) Concentration dependent UV-Vis spectra and (b) calibration curve of AP in EtOH/ HEPES 
buffer solution (10 mM, pH = 7.4) (v/v=1/1). 
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Figure 5.11. Time-dependent release efficiency of CFZ in HEPES buffer solution (10 mM, pH = 7.4) with 
or without the addition of AP to the buffer solution. After loading with 1 mM CFZ in DMSO, 10 µL of AP 
was added to the buffer solution (10 mg MSNs/mL, 1 mL) (n=3). 
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Figure 5.12. (a) Schematic illustration of applying chaperone-assisted CFZ delivery strategy to selectively 
killing M. tuberculosis in macrophage. (b) AP/CFZ loaded MSNs kill M. tuberculosis in vitro in 
macrophage cultures. M. tuberculosis-infected THP-1 macrophages were untreated, treated with MSN 
loaded with AP (AP-MSN), treated with MSN loaded with CFZ and AP (AP/CFZ-MSN), or treated with 
CFZ dissolved in a mixture of DMSO and H2O (CFZ/DMSO) for 4 days. Bacterial colony forming units 
(CFUs) were determined by spreading serially diluted lysates of the infected macrophages on agar plates. 
CFU data are shown as the mean ± standard deviation. Statistical analysis was performed using one-way 
ANOVA with Tukey’s correction for multiple comparisons. ns, not significant; *p < 0.05; **p < 0.01; ***p 
< 0.001 (c) Count of macrophage nuclei per 10x microscopic field normalized to that of the macrophage 
control wells without addition of drug. Count of macrophage nuclei per microscopic field is used as a 
surrogate of macrophage viability, as dead macrophages detach and are lost from the monolayer over the 
long incubation period. Human THP-1 macrophages were either not infected (no bacteria) or infected with 
Mycobacterium tuberculosis in the absence of nanoparticles (no drug) or in the presence of AP-MSN and 
AP/CFZ-MSN with serial two-fold increasing concentration ranging from 3.1 to 25 µg/mL, as indicated. 
At the end of a 4-day incubation, macrophages were fixed with paraformaldehyde and the nuclei were 
stained with DAPI and imaged with an ImageXpress High Content Screening system using a 10x objective 
lens. The acquired images were analyzed using the Count Nuclei module of MetaXpress software to 
quantitate numbers of nuclei per 10x field. Data shown are mean ± sem of three biological replicates. 
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Table 5.1. Chemical structures of possible hydrotropes for clofazimine (CFZ) and their water solubilities. 
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Table 5.2. Summary of the amount of loaded CFZ and AP in MSNs (nmole/mg) and the mole ratio of 
AP/CFZ loaded in MSNs. 
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CHAPTER 6 
Shortwave Infrared Imaging with J-aggregates Stabilized in 
Hollow Mesoporous Silica Nanoparticles 
This chapter of the dissertation was adapted and reprinted with permission from Wei Chen#, Chi-
An Cheng#, Emily D. Cosco#, Shyam Ramakrishnan, Jakob G. P. Lingg, Oliver T. Bruns, Jeffrey 
I. Zink, Ellen M. Sletten Journal of the American Chemical Society 2019, 141, 12475–12480. 
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publication. 
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6.1 Abstract 
Tissue is translucent to shortwave infrared (SWIR) light, rendering optical imaging superior in this 
region. However, the widespread use of optical SWIR imaging has been limited, in part, by the 
lack of bright, biocompatible contrast agents that absorb and emit light above 1000 nm. J-
aggregation offers a means to transform stable, near-infrared (NIR) fluorophores into red-shifted 
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SWIR contrast agents. Here we demonstrate that J-aggregates of NIR fluorophore IR-140 can be 
prepared inside hollow mesoporous silica nanoparticles (HMSNs) to result in nanomaterials that 
absorb and emit SWIR light. The J-aggregates inside PEGylated HMSNs are stable for multiple 
weeks in buffer and enable high resolution imaging in vivo with 980 nm excitation. 
 
6.2 Introduction 
Optical imaging with shortwave infrared (SWIR, 1000–2000 nm) light has emerged as a 
powerful method of fluorescence imaging in animals due to the superior resolution and contrast 
one can achieve with low energy light (Figure 6.1A).1 A primary challenge with SWIR imaging 
is the development of bright, biocompatible, SWIR contrast agents.2 Originally, the advantageous 
qualities of imaging in the SWIR region were showcased with carbon nanotubes,3 quantum dots,4 
and rare earth nanomaterials.5 In efforts to set the stage for clinical translation, the past three years 
have seen a focus on the synthesis of non-toxic, SWIR-emissive organic fluorophores.6 This work 
has significantly expanded the suite of fluorophores that emit above 1000 nm; however, challenges 
remain in the stability, delivery, and brightness of SWIR dyes. Consequently, we looked to explore 
an alternative avenue to create SWIR organic materials: J-aggregation.  
J-aggregation is the slip-stacked alignment of chromophores that leads to constructive 
coupling of the excited state transition dipoles (Figure 6.1B).7 The photophysical consequences 
of J-aggregation are bathochromically-shifted absorption and emission spectra, narrow absorption 
and emission bands with small Stokes shifts, enhanced absorbance coefficients (ε), and shortened 
fluorescence lifetimes which can result in enhanced quantum yields (ΦF) and cycling rates. Many 
J-aggregate characteristics are beneficial qualities for in vivo imaging: red-shifted absorption and 
emission spectra will enable significant depth penetration during both the excitation and image 
acquisition,2,8 narrow bands can facilitate multiplexed imaging, and increased ε will result in bright 
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materials. Despite the significant photophysical advantages J-aggregates typically have over the 
monomer, there are few reports of employing J-aggregates for in vivo imaging due to the difficulty 
in obtaining and stabilizing the necessary chromophore alignment in complex settings.9 
Nanostructures can sequester and protect payloads, rendering nanomaterials a promising 
approach toward stabilizing J-aggregates in vivo. In 2016, Zheng and coworkers performed image-
guided surgery with porphyrin lipids that formed J-aggregates upon self-assembly into 
nanovesicles.10 The following year, Xu and coworkers prepared pyrrolopyrrole cyanine J-
aggregate-containing polymer micelles, which could be visualized after subcutaneous injection.11 
In work recently published, Fan and coworkers reported a squaraine J-aggregate, stabilized in 
polymeric micelles, for SWIR image-guided photothermal therapy.12 Each of these reports utilizes 
self-assembled organic nanomaterials,13 which are prone to disassembly when diluted in the 
presence of hydrophobic biomolecules, leading to destabilization of the J-aggregate.14 Here, we 
employ robust, biocompatible, hollow mesoporous silica nanoparticles to stabilize and protect 
SWIR-emissive J-aggregates of IR-140 for in vivo imaging (Figure 6.1C/D).  
Hollow mesoporous silica nanoparticles (HMSNs) have 2–4 nm pores that open into a large, 
10–200 nm cavity, allowing these nanostructures to carry significant cargo.15 The surfaces of the 
HMSNs can be modified to alter the biodistribution of the nanoparticles.16 Consequently, there are 
numerous reports of HMSNs as the core scaffold of multifunctional materials.15a,16b,17 Included in 
these studies are the loading or conjugation of visible18 and near-infrared15a,19 fluorophores and 
administering the resulting nanomaterials for imaging. However, the controlled assembly of J-
aggregates in HMSNs has yet to be demonstrated. 
To realize SWIR-emissive J-aggregates inside HMSNs, we utilized the heptamethine dye IR-
140 (1). IR-140 is a commercially available NIR fluorophore (λmax,abs=826 nm, λmax, em=875 nm) 
that has been applied as a photopolymerization initiator,20 fluorescent payload,21 component of 
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plasmonic arrays,22 as well as a Raman23 and two-photon24 imaging agent. In 2016, Wang and 
Weiss reported that introduction of IR-140 to glutathione coated quantum dots results in J-
aggregate formation with two aggregates observed: J1 (λmax,abs=965 nm, non-emissive), and J2 
(λmax,abs=1040 nm, λmax,em=1047 nm).25 We envisioned that similar IR-140 J-aggregates could be 
formed on the negatively charged pores and inner surface of HMSNs. Further, once the aggregates 
were assembled inside the particles, the hydrophobic nature of IR-140 would make them unlikely 
to disassemble in aqueous environments, rendering J-aggregates stable in vivo. 
 
6.3 Result and Discussion 
We prepared HMSNs by synthesizing a mesoporous silica coating on a Stöber sphere core 
that was subsequently removed via etching with sodium carbonate (Scheme 6.1, Figure 6.2). The 
HMSNs were treated with varying amounts of IR-140 in different solvents (Figure 6.3A). J-
aggregate formation was assayed by UV/Vis/NIR spectroscopy evaluating loss of monomeric IR-
140 at 826 nm and formation of the J-aggregates at 965 nm (J1) and 1040 nm (J2). Upon 
optimization, we found that SWIR J-aggregates could be obtained when IR-140 dissolved in 
dimethyl sulfoxide (DMSO) was combined with HMSNs and washed. The washing procedure 
proved essential for obtaining the desired J2 aggregate formation (Figure 6.3B and 6.4), with 
gentle PBS washes yielding the largest amount of the desired J2 aggregate (dark blue, Figure 
6.3B). When these optimized conditions were repeated on Stöber spheres that did not have pores 
or an inner surface for IR-140 to associate with, only a small J-band was observed (Figure 6.3B, 
gray line, Figure 6.5). Similar results were obtained when loading was performed on mesoporous 
silica coated Stöber spheres (Figure 6.4). These control experiment (Figure 6.6) suggests that the 
majority of IR-140 is protected inside the HMSN cavity. Through analysis of IR-140 collected 
after the washing procedures, we calculated the loading of IR-140 to be ~103 molecules/particle 
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(Figure 6.7, Note 6.5.13.1). 
The HMSNs were further characterized through transmission electron microscopy (TEM), 
indicating ~85 nm particles with a distinct cavity and pores (Figure 6.3C). The pore size was 
quantified to be 3.2 nm through nitrogen adsorption experiments (Figure 6.8). While the pores are 
clearly visible in the TEM of the empty HMSNs, they are darkened after treatment with IR-140 
(Figure 6.3D), suggesting the presence of IR-140. Control experiments in which HMSNs were 
subjected to PBS washing procedures but no IR-140 show no change in contrast of the pores upon 
TEM analysis (Figure 6.9). 
After confirming that the HMSNs could facilitate J-aggregation of IR-140, we modified the 
surface with poly(ethylene glycol) (PEG) such that they could be suspended in aqueous media. 
This was accomplished by loading HMSNs that had undergone surface silanization with (3-
aminopropyl)triethoxysilane (APTS) prior to Stöber sphere and surfactant removal (Scheme 6.2). 
This procedure resulted in HMSNs that were positively charged on the outside but still contained 
a negatively charged interior to associate with the cationic IR-140.26 Nitrogen adsorption data 
(Figure 6.8) also suggests that the pores are not modified with APTS.27 The introduction of IR-
140 into the HMSNs-APTS proceeded similarly to the HMSNs, yielding analogous loading of IR-
140 and a higher ratio of J2:J1 (Figure 6.10). Control experiments performed with Stöber spheres 
treated with APTS support that IR-140 is protected on the interior of the HMSNs (Figures 6.5 and 
6.6). After loading, a 23kDa PEG-carboxylate was conjugated to the amines present on the outer 
surface of the HMSNs-APTS using carbodiimide chemistry (Scheme 6.2). Successful PEG 
conjugation was verified by changes in hydrodynamic diameter and zeta potential (Figures 6.11 
and 6.12). 
We evaluated the photophysical properties of the PEGylated HMSNs (HMSNs-PEG) 
containing IR-140 in comparison to IR-140 in solution as the monomer and J-aggregate (Figure 
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6.13A). Monomeric IR-140 has been well-characterized;28 however, the solution J-aggregate of 
IR-140 had previously not been reported.29 After screening numerous conditions (Figure 6.14), 
we found that 35% DMSO/0.9% NaCl in water afforded formation of the desired SWIR J-
aggregate with a lmax,abs=1042 nm, lmax,em=1043 nm, e=3.9 x 105 M-1cm-1, and FF =0.01% (Table 
6.1, Notes 6.5.13.2 and 6.5.13.3). The IR-140-containing HMSNs-PEG had similar spectral 
properties with a lmax,abs=1038 nm, lmax,em=1047 nm, although the absorbance was considerably 
broader, which we attribute to the presence of other non-emissive aggregate states. When solutions 
of IR-140 in DMSO, IR-140 in 35% DMSO/0.9% NaCl in water, and IR-140 loaded HMSNs-PEG 
in PBS were excited with a 980 nm laser, the wavelength to be used for in vivo imaging 
experiments, the IR-140 J-aggregate in solution and in the particles were similarly emissive, while 
the monomer was not excited by 980 nm light (Figures 6.13B and 6.15).30 Thus, J-aggregation is 
essential for SWIR imaging with low energy excitation. 
Next, we analyzed the role of the HMSNs in stabilizing IR-140 J-aggregates. Over two weeks 
in PBS at room temperature, we observed only a ~10% decrease in absorbance from the IR-140 
loaded HMSNs-PEG and no evidence that the packing of the IR-140 within the nanoparticles was 
changing (Figures 6.13C, blue; Figure 6.16). Comparatively, only ~8% of the J-aggregate in 
solution remained after 1 day (Figure 6.13C, red; Figure 6.16). Not only do the HMSNs stabilize 
the assembly of the J-aggregate, but they also enhance the photostability. The fluorescence of 
solutions containing IR-140 J-aggregate in 35% DMSO/0.9% NaCl in water and HMSNs-PEG 
containing IR-140 J-aggregate in PBS were continually irradiated with a 980 nm laser (97 mW/cm2) 
and the fluorescence intensity was measured with an InGaAs camera. The photostability of 
monomeric IR-140 in DMSO was also evaluated via excitation at 785 nm (97 mW/cm2). As shown 
in Figure 6.13D, the J-aggregates within the HMSNs-PEG are 4-fold more stable than the J-
aggregates in solution and ~60-fold more stable than the monomer (Table 6.2, Note 6.5.13.4). This 
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result is consistent with the use of silica shells to overcome the poor photostability that is 
characteristic of J-aggregates by limiting the amount of reactive oxygen species that can access 
the aggregate.31 Photobleaching experiments in deoxygenated solvents support that the HMSNs 
protect the IR-140 J-aggregate from reactive oxygen species (Figure 6.17). Taken together, our 
data show that the HMSNs are critical for stabilizing J-aggregates to light and solution. 
Finally, with bright SWIR-emissive nanoparticles prepared and characterized, we evaluated 
their biocompatibility and in vivo imaging performance. In vitro studies showed no cytotoxicity of 
the IR-140 loaded HMSNs-PEG over 6 h at concentrations up to 200 µg/mL (Figure 6.18). These 
data are consistent with other studies regarding mesoporous silica, which is generally considered 
non-toxic to animals.26,32 We performed in vivo imaging experiments using the IR-140 loaded 
HMSNs-PEG with excitation at 980 nm and collection from 1000–1700 nm. The SWIR-emissive 
HMSNs-PEG were intravenously injected into nude mice and the mice were immediately imaged 
(Figure 6.19). The HMSNs-PEG rapidly clear from the blood stream and intense signal can be 
seen in the lungs, liver, and spleen. Fifty minutes after injection, the signal intensity within these 
organs remained constant (Figure 6.20). 
 
6.4 Summary 
In summary, we have presented J-aggregation as an approach to prepare biocompatible, 
SWIR contrast agents and demonstrated this concept by stabilizing J-aggregates of the NIR 
fluorophore IR-140 inside HMSNs. The bathochromically-shifted absorption and emission and 
small Stokes shifts of the IR-140 J-aggregate allow imaging with 980 nm excitation and 1000–
1700 nm acquisition, providing high resolution in vivo images. The modularity of the HMSNs will 
enable facile exchange of the imaging agent as well as the addition of targeting agents and/or 
therapeutics, poising these materials to become SWIR theranostics.33 While we did not observe an 
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enhanced ΦF with the IR-140 J-aggregate, likely due to disorder or intermolecular vibrations,34 
work is ongoing to access a SWIR J-aggregate that exhibits the superradience phenomena 
predicted by Kasha.35 Collectively, the use of J-aggregates stabilized in HMSNs as SWIR imaging 
agents has the potential to overcome the stability, toxicity, and brightness challenges of contrast 
agents for this compelling region of the electromagnetic spectrum. 
 
6.5 Methods 
6.5.1 Materials and Chemicals 
IR-140 (95%), cetyltrimethylammonium chloride (CTAC, 25 wt% in water), 
cetyltrimethylammonium bromide (CTAB, 99+%), tetraethyl orthosilicate (TEOS, 98%), (3-
aminopropyl)triethoxysilane (APTS, 99%), ammonium nitrate (NH4NO3, 98+%), triethanolamine 
(TEA, 99+%), 2-(N-morpholino)ethanesulfonic acid hydrate (MES hydrate, 99.5+%), and 
phosphate buffer saline (X10) were purchased from Sigma-Aldrich. Sodium carbonate anhydrous 
(99.5+%) was purchased from EMD Millipore. Alpha-methoxy-omega-carboxylic acid 
poly(ethylene glycol) (MeO-PEG-COOH, Mw = 23,000 Da) was purchased from Iris Biotech 
GmbH. Ethanol (200 proof) was purchased from Decon Laboratories, Inc. 1-Ethyl-3-(-3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC-HCl, 99+%), and N-
hydroxysulfosuccinimide sodium salt (sulfo-NHS, 99+%) were purchased from CovaChem. 
Dimethyl sulfoxide (DMSO, 99.9+%), sodium hydroxide (NaOH, 97+%), and ammonium 
hydroxide (NH4OH) purchased from Fisher Scientific. Dulbecco’s modified Eagle’s medium 
(DMEM) with high glucose, fetal bovine serum (FBS), antibiotics (10,000 U/mL penicillin, 10,000 
µg/mL streptomycin, and 29.2 mg/mL L-glutamine), trypsin-ethylenediaminetetraacetic acid 
(trypsin-EDTA) (0.05 %), and Dulbecco’s phosphate-buffered saline (DPBS) were purchased from 
Gibco. Cell counting kit-8 (CCK-8) was purchased from Dojindo Molecular Technologies, Inc. 
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All chemicals were used without further purification. 
6.5.2 Instrumentation 
Bath sonication was performed using a Branson 3800 ultrasonic cleaner or an Elma S15 
Elmasonic. Masses for analytical measurements were taken on a Sartorius MSE6.6S-000-DM or 
MSA6.6S-000-DM Cubis Micro Balance. Absorbance spectra were collected on a JASCO V-770 
UV-Visible/NIR spectrophotometer with a 2000 nm/min scan rate after blanking with the 
appropriate solvent, on a Cary 5000 UV-Vis-NIR spectrophotometer or on a Shimadzu UV-1800 
UV-Visible Scanning Spectrophotometer. Photoluminescence spectra were obtained on a Horiba 
Instruments PTI QuantaMaster Series fluorometer. Quartz cuvettes (10 mm, 3 mm and 2 mm) were 
used for absorbance and photoluminescence measurements. The dynamic light scattering (DLS) 
measurements were performed on a ZETAPALS instrument with a 660 nm red diode laser 
(Brookhaven Instruments Corporation). Zeta potential value was measured on a Malvern Zetasizer 
Nano at room temperature. Nitrogen adsorption/desorption isotherms were acquired at 77 K on a 
Autosorb-iQ, Quantachrome Instruments. Transmission electron microscopy was performed on a 
Tecnai T12 instrument with an operating voltage of 120 kV. Animal imaging was performed on 
custom instrumentation described below. 
6.5.3 Synthesis of Stöber Silica Spheres 
Stöber silica spheres were synthesized by a sol-gel reaction in basic solution as reported 
previously.36 Briefly, NH4OH (1.6 mL) was dissolved in a mixture of ethanol (71.4 mL) and D.I. 
water (10 mL) in a 250 mL flask with vigorous stirring. After stirring for 10 min at room 
temperature, TEOS (2 mL) was rapidly added to the solution which was further stirred for 1 h at 
room temperature for the formation of Stöber silica nanoparticles. Afterwards, the solution 
containing Stöber silica spheres was centrifuged (7830 rpm, 7197 g, 20 min) and washed with 
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ethanol and D.I. water twice, respectively. The Stöber silica spheres were finally dispersed in 40 
mL of D.I. water for further use. 
6.5.4 Synthesis of Hollow Mesoporous Silica Nanoparticles (HMSNs) 
The synthesis of hollow mesoporous silica nanoparticles (HMSNs) was carried out by using 
Stöber silica spheres as the hard templates which were later removed by selective etching in a basic 
solution. First, CTAC (2 g, 25 wt% in water solution) and TEA (20 mg) were dissolved in D.I. 
water (20 mL) in a 100 mL round-bottom flask with vigorous stirring at 80 °C. The reaction 
mixture was stirred for 5 min followed by the addition of 10 mL of Stöber silica sphere solution 
prepared as described above, and stirred for 20 min. To coat mesoporous silica on the surface of 
Stöber silica spheres, TEOS (150 µL) was added dropwise to the solution with vigorous stirring. 
The nanoparticles were designated as dSiO2@MSNs (Scheme 4.1). After 1 h, the solution was 
cooled to 50 °C and sodium carbonate (1.89 g) dissolved in D.I. water (3 mL) was added to 
selectively etch the Stöber silica sphere template in the mesoporous silica shell. The etching 
process was carried out at 50 °C for 2 h. Afterwards, the solution containing HMSNs were 
centrifuged (7830 rpm, 7197 g, 15 min) and washed with ethanol 3 times (3 x 50 mL) to remove 
the unreacted impurities. To remove the CTAC surfactant templates, HMSNs were dispersed in 50 
mL of ethanol containing NH4NO3 (1 g). The solution was brought to 60 °C with vigorous stirring. 
After 1 h, the solution was cooled to room temperature, centrifuged (7830 rpm, 7197 g,15 min), 
and washed once with ethanol (50 mL). The surfactant removal process was repeated two more 
times. Finally, surfactant free HMSNs were washed with D.I. water (2 x 50 mL) and ethanol (2 x 
50 mL) twice, respectively and stored in 10 mL of absolute ethanol for further use. 
6.5.5 Synthesis of APTS Functionalized HMSNs (HMSNs-APTS) 
APTS functionalized HMSNs (HMSNs-APTS) were synthesized by procedures similar to 
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those of HMSNs. First, CTAC (2 g, 25 wt% in water solution) and TEA (20 mg) were dissolved 
in D.I. water (20 mL) in a 100 mL round-bottom flask with vigorous stirring at 80 °C. The reaction 
solution was stirred for 5 min followed by the addition of 10 mL of Stöber silica sphere solution 
prepared as described above. After stirring for 20 min, TEOS (150 µL) was added dropwise to the 
solution with vigorous stirring. After 1 h, a mixture of APTS (40 µL) and ethanol (120 µL) was 
added to the solution followed by stirring for another 1 h at 80 °C to conjugate APTS on the surface 
of HMSNs. The Stöber silica sphere etching and surfactant removal processes were the same as 
described in the synthesis of HMSNs section. The resulting nanoparticles were dispersed in ethanol 
and designated as HMSNs-APTS. 
6.5.6 Synthesis of APTS Functionalized Stöber Silica Spheres 
The Stöber silica spheres (80 mg) were dispersed in a mixture of ethanol (20 mL) and APTS 
(10 µL). The solution was stirred at room temperature for 5 min and was brought to 78 °C. Then, 
the solution was refluxed for 12 h with vigorous stirring. Subsequently, the solution was cooled to 
room temperature, and APTS functionalized Stöber silica spheres (Stöber silica spheres-APTS) 
were washed twice (2 x 20 mL) with ethanol and stored in 10 mL of absolute ethanol for further 
use. 
6.5.7 Loading of IR-140 in HMSNs, HMSNs-APTS, or dSiO2@MSNs 
HMSNs, HMSNs-APTS, or dSiO2@MSNs (2 mg) dispersed in ethanol were centrifuged 
(14000 rpm, 16873 g, 15 min) and washed with DMSO (3 x 1 mL) before IR-140 loading. HMSNs 
or HMSNs-APTS were then dispersed in 200 µL of a DMSO solution containing 5, 10, or 20 mM 
IR-140 by sonication in a bath sonicator for 10 min. For dSiO2@MSNs, the nanoparticles were 
dispersed in 200 µL of a DMSO solution containing 5, or 20 mM IR-140 by sonication in a bath 
sonicator for 10 min. After stirring the solution for 20 h to make IR-140 diffuse into the pores and 
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cavity of HMSNs, HMSNs-APTS, or dSiO2@MSNs, the solution containing the particles was 
centrifuged (14000 rpm, 16873 g, 15 min) and the supernatant was kept for loading capacity 
calculations. Then, IR-140 loaded HMSNs were washed with three different methods: (a) washed 
with PBS (1 mL) using a water bath sonication, (b) gently washed with PBS (1 mL) by using 
plastic transfer pipettes, and (c) washed with water (1 mL) by using plastic transfer pipettes, 
respectively, to remove free DMSO and DMSO loaded in the pores. IR-140 loaded HMSNs-APTS, 
or IR-140 loaded dSiO2@MSNs were washed only by method (b). Afterwards, IR-140 loaded 
nanoparticles were centrifuged (8000 rpm, 5510 g, 3 min) to remove the supernatant. The washing 
steps were repeated 5 times. Finally, IR-140 loaded HMSNs, HMSNs-APTS, or dSiO2@MSNs 
were re-dispersed in PBS (1 mL) solution by sonication. 
6.5.8 PEG Conjugation on the Surface of IR-140 Loaded HMSNs-APTS  
To increase the colloidal stability, PEG was conjugated on the surface of IR-140 loaded 
HMSNs-APTS via amide bond formation. After IR-140 was loaded in HMSNs-APTS, the 
nanoparticles were gently washed with PBS (5 x 1 mL), D.I. water (2 x 1 mL), and MES buffer 
solution (pH = 6.0, 10 mM) (1 x 1 mL), respectively. Finally, IR-140 loaded HMSNs-APTS (2 mg) 
were dispersed in MES buffer (1 mL) by sonication. Alpha-methoxy-omega-carboxylic acid 
poly(ethylene glycol) (MeO-PEG-COOH, CAS No. 92450-99-2) (10 mg) was dissolved in MES 
buffer (200 µL) followed by the addition of EDC-HCl (5 mg) and sulfo-NHS (2.5 mg) pre-
dissolved in MES buffer (300 µL). The solution was stirred for 30 min. Then, the MES buffer 
solution containing the activated MeO-PEG-COOH (500 µL) was added to 1 mL of 2 mg/mL IR-
140 loaded HMSNs-APTS MES solution. The solution was further mixed and stirred for 20 h to 
conjugate PEG on the surface of IR-140 loaded HMSNs-APTS. Then, IR-140 loaded HMSNs-
PEG were centrifuged (10000 rpm, 8609 g, 10 min) and washed with D.I. water (2 x 1 mL) and 
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PBS (1 x 1 mL) to remove the excess MeO-PEG-COOH, EDC-HCl, sulfo-NHS, and MES buffer 
solution. Finally, IR-140 loaded HMSNs-PEG were dispersed in PBS buffer (1 mL) solution for 
UV-Vis-NIR or photoluminescence measurements. 
6.5.9 Cell Culture Procedures 
HeLa cells, a cervical cancer cells line, were cultured in T-75 flasks (Corning) with vented 
caps in a high glucose Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10 % 
fetal bovine serum (FBS), and 1 % antibiotics (100 U/mL penicillin and 100 µg/mL streptomycin) 
in a humidity-controlled incubator at 37 °C with 5% CO2. The HeLa culture media were daily 
changed and the cells were harvested by trypsinization with 0.05% trypsin-
ethylenediaminetetraacetic acid (EDTA) for passaging every 2–3 days. 
6.5.10 Animal Procedures  
Animal experiments were conducted in accordance with the approved institutional protocols 
of Helmholtz Zentrum München. Non-invasive whole mouse imaging was performed on two six-
week old female CD-1 nude mice (22.4 g, 19.1 g), purchased from Charles River Laboratories. 
Mice were anesthetized with an i.p. injection of a ketamine/xylazine mixture. Tail vein injections 
were performed with a catheter assembled from a 30 ga needle connected through plastic tubing 
to a second 30 ga needle with syringe prefilled with isotonic saline solution. The bevel of the 
needle was then inserted into the tail vein and secured using tissue adhesive. 
6.5.11 SWIR imaging apparatus  
For whole mouse imaging, we used a custom-built setup. A 35 W 980 nm laser (Lumics 
LU0980D350-D30AN) was coupled in a fiber (600 µm core, Thorlabs BF46LS01) The output 
from the fiber was fixed in an excitation cube and reflected off of a mirror (Thorlabs BBE1-E03), 
and passed through a positive achromat (Thorlabs AC254-050-B), 1000 nm shortpass filter 
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(Thorlabs FESH 1000), and an engineered diffuser (Thorlabs ED1-S20-MD) to provide uniform 
illumination over the working area. The excitation flux at the object was adjusted to be close to 
100 mWcm-2 with an error of ± 3% (power density used is defined separately in each experiment). 
The working area was covered by a heating mat coated with blackout fabric (Thorlabs BK5). A 4-
inch square first-surface silver mirror (Edmund Optics, 84448) was used to direct the emitted light 
through a custom filter set (Thorlabs NF980-41, 3x FELH1000, 2x FGL1000) to an Allied Vision 
Goldeye G-032 Cool TEC2 camera at -30 °C, equipped with a C-mount camera lens (Navitar, 
SWIR-35). The assembly was partially enclosed to avoid excess light while enabling manipulation 
of the field of view during operation. The image acquisition toolbox of MATLAB programming 
environment is used in combination with a custom MATLAB script to preview and collect the 
required image data. The prepared MATLAB script allows users to access basic functionalities of 
the image acquisition device by establishing a packet jitter free data streaming link between the 
desktop computer and the acquisition device. 
6.5.12 Experimental Procedures of Figures  
Figure 6.2 
Stöber silica spheres, dSiO2@MSNs, or HMSNs were dispersed in ethanol at a concentration 
of 0.1 mg/mL. The suspension (5 µL) of the nanoparticles was dropped onto the carbon-coated 
copper grid and dried at room temperature. Transmission electron microscopy was measured on a 
Tecnai T12 instrument with an operating voltage of 120 kV. 
Figure 6.3 B 
Refer to 6.5.7 “Loading of IR-140 in HMSNs, HMSNs-APTS, or dSiO2@MSNs”. 10 mM 
IR-140 was used as the loading solution. Then, IR-140 loaded HMSNs were washed by methods 
(a), (b), or (c) to compare the extent of IR-140 aggregate by using the above washing methods. 
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The washing steps were repeated 5 times and finally IR-140 loaded HMSNs were re-dispersed in 
1 mL of PBS solution by sonication. 
Stöber silica spheres dispersed in ethanol were centrifuged (14000 rpm, 15 min) and washed 
with DMSO 3 times before IR-140 loading. Afterwards, Stöber silica spheres were dispersed in 
200 µL of DMSO solution containing 10 mM IR-140 by sonication in a bath sonicator for 10 min. 
Then, the solution was stirred for 20 h After the IR-140 loading, the solution containing the 
particles was centrifuged (14000 rpm, 15 min) to get IR-140 loaded Stöber silica spheres. Then, 
IR-140 loaded Stöber silica spheres were washed with 1 mL of PBS by gently washing with plastic 
transfer pipettes to remove free DMSO. After each washing step, IR-140-loaded Stöber silica 
spheres were centrifuged (8000 rpm, 3 min) to remove the supernatant. The washing steps were 
repeated for 5 times and finally IR-140-loaded Stöber silica spheres were re-dispersed in PBS 
solution (1 mL) by sonication. The absorbance spectra of IR-140 loaded HMSNs or IR-140 loaded 
Stöber silica spheres were measured with 10 mm quartz cuvettes at a concentration of 0.25 mg 
nanoparticles/mL PBS on a Cary 5000 UV-Vis-NIR spectrophotometer at room temperature. 
Absorbance traces were corrected for the non-linearity between gratings. Absorbance traces were 
corrected for the non-linearity between gratings. 
For the prewash spectrum: after the IR-140 (10 mM) loading, the particles solution (10 
mg/mL) was diluted 1:350 with DMSO for measurement. The absorbance spectrum of the prewash 
sample was measured with 3 mm quartz cuvettes on a JASCO V-770 UV-Vis-NIR 
spectrophotometer at room temperature. 
Figure 6.3 C/D 
HMSNs and IR-140 loaded HMSNs were dispersed in ethanol and D.I. water, respectively at 
a concentration of 0.1 mg/mL. The suspension (5 µL) of the nanoparticles was dropped onto the 
carbon-coated copper grid and dried at room temperature. Transmission electron microscopy was 
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measured on a Tecnai T12 instrument with an operating voltage of 120 kV. 
Figure 6.4 
Refer to 6.5.7 “Loading of IR-140 in HMSNs, HMSNs-APTS, or dSiO2@MSNs”. 5 or 20 
mM IR-140 was used as the loading solution. Then, IR-140 loaded HMSNs were washed by 
methods (a), (b), or (c). In addition, IR-140 loaded dSiO2@MSNs were washed by method (b). 
The washing steps were repeated 5 times and finally IR-140 loaded HMSNs or IR-140 loaded 
dSiO2@MSNs were re-dispersed in 1 mL of PBS solution by sonication. The absorbance spectra 
of IR-140 loaded HMSNs or IR-140 loaded dSiO2@MSNs were measured with 10 mm quartz 
cuvettes at a concentration of 0.25 mg nanoparticles/mL PBS on a Cary 5000 UV-Vis-NIR 
spectrophotometer at room temperature. Absorbance traces were corrected for the non-linearity 
between gratings. 
Figure 6.5 
Stöber silica spheres or Stöber silica spheres-APTS were prepared and described in synthetic 
procedures. Stöber silica spheres or Stöber silica spheres-APTS (2 mg for each) dispersed in 
ethanol were centrifuged (14000 rpm, 16873 g, 15 min) and washed with DMSO 3 times before 
IR-140 loading. Afterwards, Stöber silica spheres or Stöber silica spheres-APTS were dispersed in 
200 µL of DMSO solution containing 20, 10, or 5 mM IR-140 by sonication in a bath sonicator 
for 10 min. Then, the solution was stirred for 20 h After the IR-140 loading, the solution containing 
the particles was centrifuged (14000 rpm, 16873 g, 15 min) to get IR-140 loaded Stöber silica 
spheres or Stöber silica spheres-APTS. Then, IR-140 loaded Stöber silica spheres or Stöber silica 
spheres-APTS were washed with 1 mL of PBS by gently washing with plastic transfer pipettes to 
remove free DMSO and DMSO loaded in the pores. After each washing step, IR-140 loaded Stöber 
silica spheres or Stöber silica spheres-APTS were centrifuged (8000 rpm, 5510 g, 3 min) to remove 
the supernatant. The washing steps were repeated for 5 times and finally IR-140 loaded Stöber 
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silica spheres or Stöber silica spheres-APTS were re-dispersed in PBS solution (1 mL) by 
sonication. The absorbance spectra of Stöber silica spheres or Stöber silica spheres-APTS were 
measured with 10 mm quartz cuvettes at a concentration of 0.25 mg nanoparticles/mL PBS on a 
Cary 5000 UV/Vis/NIR Spectrophotometer at room temperature. Absorbance traces were 
corrected for the non-linearity between gratings. 
For zeta potential measurement, Stöber silica spheres or Stöber silica spheres-APTS were 
dispersed in D.I. water (2 mL) at a concentration of 50 µg/mL. The measurement was performed 
on a Malvern Zetasizer Nano at room temperature. 
Figure 6.6 
 HMSNs, Stöber silica spheres, Stöber silica spheres-APTS, or dSiO2@MSNs (2 mg for each) 
dispersed in ethanol were centrifuged (14000 rpm, 16873 g, 15 min) and washed with DMSO 3 
times before IR-140 loading. Afterwards, HMSNs, Stöber silica spheres, Stöber silica spheres-
APTS, or dSiO2@MSNs were dispersed in 200 µL of DMSO solution containing 10 mM IR-140 
by sonication in a bath sonicator for 10 min. Then, the solution was stirred for 20 h. After the IR-
140 loading, the solution containing the particles was centrifuged (14000 rpm, 16873 g, 15 min) 
to get IR-140 loaded nanoparticles. Then, IR-140 loaded nanoparticles were washed with 1 mL of 
PBS by gently washing with plastic transfer pipettes to remove free DMSO and DMSO loaded in 
the pores. After each washing step, IR-140 loaded nanoparticles were centrifuged (8000 rpm, 5510 
g, 3 min) to remove the supernatant. The washing steps were repeated for 5 times and finally IR-
140 loaded nanoparticles were re-dispersed in PBS solution (1 mL) by sonication. The absorbance 
spectra of IR-140 loaded HMSNs, Stöber silica spheres, Stöber silica spheres-APTS, or 
dSiO2@MSNs were measured with 10 mm quartz cuvettes at a concentration of 0.25 mg 
nanoparticles/mL PBS on a Cary 5000 UV/Vis/NIR Spectrophotometer at room temperature. 
Absorbance traces were corrected for the non-linearity between gratings. 
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Figure 6.7 
The loading capacity of IR-140 in HMSNs or HMSNs-APTS was calculated based on the 
absorbance difference between the IR-140 DMSO solution before and after loading. After loading 
with IR-140 for 20 h, HMSNs or HMSNs-APTS were centrifuged (14000 rpm, 16873 g, 15 min) 
and the supernatant was collected for absorbance measurements. The loading capacity of IR-140 
was calculated using the difference of maximum absorbance at 831 nm and the following definition 
of loading capacity (%): (mass of loaded IR-140/mass of particles) x 100. 
Figure 6.8 
HMSNs (A/B) and HMSNs-APTS (C/D), and dSiO2@MSNs (E/F) were prepared as 
described in the synthetic procedures and degassed at 120 °C under vacuum for 16 h before the 
measurement. The surface area and pore diameter distribution of HMSNs, HMSNs-APTS, and 
dSiO2@MSNs were determined by Brunauer-Emmett-Teller (BET) and Barrett-Joyner-Halenda 
(BJH) methods, respectively. 
Figure 6.9 
(A) HMSNs were dispersed in ethanol at a concentration of 0.1 mg/mL. (B) The control 
HMSNs were subjected to washing by method (b) in the Section II “Loading of IR-140 in HMSNs, 
HMSNs-APTS, or dSiO2@MSNs” but without the loading of IR-140. The particles were dispersed 
in PBS at a concentration of 0.1 mg/mL. (C) Refer to Section II “Loading of IR-140 in HMSNs, 
HMSNs-APTS, or dSiO2@MSNs”. 10 mM IR-140 was used as the loading solution. IR-140 
loaded HMSNs were dispersed in PBS at a concentration of 0.1 mg/mL. (D) The mixed samples 
were prepared by mixing 50 µL of HMSNs in PBS solution (0.2 mg/mL) and 50 µL of IR-140 
loaded HMSNs in PBS solution (0.2 mg/mL) and were sonicated in a water bath sonicator for 20 
s. The suspension (5 µL) of each of the nanoparticles was dropped onto the carbon-coated copper 
grid and dried at room temperature. Transmission electron microscopy was measured on a Tecnai 
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T12 instrument with an operating voltage of 120 kV. 
Figure 6.10 
HMSNs-APTS (2 mg) dispersed in ethanol were centrifuged (14000 rpm, 16873 g, 15 min) 
and washed with DMSO (3 x 1 mL) before IR-140 loading. Afterwards, HMSNs-APTS was 
dispersed in 200 µL of DMSO solution containing 5, 10, or 20 mM IR-140 by sonication in a bath 
sonicator for 10 min. Then, the solution was stirred for 20 h to let IR-140 diffuse into the pores 
and cavity of HMSNs-APTS. After the IR-140 loading, the solution containing the particles was 
centrifuged (14000 rpm, 16873 g, 15 min) to get IR-140 loaded HMSNs-APTS. Then, IR-140 
loaded HMSNs-APTS were washed with PBS (1 mL) by gently washing with plastic transfer 
pipettes to remove free DMSO and DMSO loaded in the pores. After each washing step, IR-140 
loaded HMSNs-APTS were centrifuged (8000 rpm, 5510 g, 3 min) to remove the supernatant. The 
washing steps were repeated 5 times and finally IR-140 loaded HMSNs-APTS were re-dispersed 
PBS (1 mL) by sonication. The absorbance spectra of IR-140 loaded HMSNs-APTS were 
measured with 10 mm quartz cuvettes at a concentration of 0.25 mg nanoparticles/mL PBS on a 
Cary 5000 UV/Vis/NIR Spectrophotometer at room temperature. Absorbance traces were 
corrected for the non-linearity between gratings. 
Figure 6.11 
Refer to 6.5.7 “Loading of IR-140 in HMSNs, HMSNs-APTS, or dSiO2@MSNs”. 20 mM 
IR-140 was used as the loading solution. The loading concentration of HMSNs-APTS was 10 
mg/mL. Then, IR-140 loaded HMSNs-APTS were washed by method (b). The washing steps were 
repeated 5 times and finally IR-140 loaded HMSNs-APTS were re-dispersed in PBS (1 mL) by 
sonication. The synthetic procedures of PEGylation of IR-140 loaded HMSNs-APTS can be 
referred to Section II “PEG conjugation on the surface of IR-140 loaded HMSNs-APTS”. For 
dynamic light scattering size measurement, HMSNs-APTS, HMSNs-APTS containing IR-140, 
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and HMSNs-PEG containing IR-140 were dispersed in PBS (2 mL) at a concentration of 50 µg/mL. 
The measurement was performed on a ZETAPALS instrument with a 660 nm red diode laser at 
room temperature. 
Figure 6.12 
Refer to 6.5.7 “Loading of IR-140 in HMSNs, HMSNs-APTS, or dSiO2@MSNs”. 20 mM 
IR-140 was used as the loading solution. The loading concentration of HMSNs-APTS was 10 
mg/mL. Then, IR-140 loaded HMSNs-APTS were washed by method (b). The washing steps were 
repeated 5 times and finally IR-140 loaded HMSNs-APTS were re-dispersed in 1 mL of PBS 
solution by sonication. The synthetic procedures of PEGylation of IR-140 loaded HMSNs-APTS 
can be referred to Section II “PEG conjugation on the surface of IR-140 loaded HMSNs-APTS”. 
For zeta potential measurement, HMSNs, HMSNs-APTS, HMSNs-APTS containing IR-140, and 
HMSNs-PEG containing IR-140 were dispersed in D.I. water (2 mL) at a concentration of 50 
µg/mL. The measurement was performed on a Malvern Zetasizer Nano at room temperature. 
Figure 6.13A 
All absorbance and emission traces were baseline corrected and normalized. Absorbance 
traces were acquired on a JASCO V-770 UV-Visible/NIR spectrophotometer. The slit widths used 
in fluorescence spectra were 5.76 mm for excitation and 11.52 mm for emission. The step size was 
1.0 nm, integration time 0.1 s, and traces were acquired after an automatic detector background 
subtraction. 
IR-140 monomer was dissolved in DMSO and diluted to an O.D. of ~ 0.7 for absorbance and 
less than 0.1 for fluorescence spectroscopy (ex. 785 nm) in a 1 cm path length cuvette. The 
monomer absorption trace was corrected for the non-linearity between gratings before baseline 
subtraction and normalization. 
The IR-140 J-aggregate in 35% DMSO/0.9% NaCl was prepared by dissolving 0.02 mg of 
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IR-140 in 350 µL DMSO, vortexing briefly, adding 650 µL 0.9% aqueous NaCl, and shaking 
briskly. The solution becomes warm and immediately loses the blue color. Absorbance and 
emission traces of the J-aggregate in solution were obtained with a 2 mm path length cuvette. For 
the fluorescence trace, a 10 mm path length was used on the excitation side and a 2 mm path length 
on the emission side. A reabsorption correction was performed on the emission trace analogous to 
that described in Note 6.5.13.2.  
The IR-140 loaded HMSNs-PEG were prepared as described in the synthetic procedures, 
section VI. The absorbance was collected without dilution in a 10 mm cuvette. The fluorescence 
spectrum was obtained by diluting the sample to an O.D. of less than 0.1 in a 3 mm path length 
square quartz cuvette, and exciting at 885 nm with a shortpass filter (Thorlabs, FES0900).  
Figure 6.13B 
Samples consisted of IR-140 monomer: 0.01 mg/mL IR-140 in DMSO (left); IR-140 J-
aggregate in solution: 0.01 mg/mL IR-140 in 35% DMSO/0.9% NaCl in water (center); IR-140 
HSMNs-PEG: 1 mg/mL in PBS (right). Vials were excited with 980 nm light (with Thorlabs 
FESH1000) with an average power density of 99 ± 3 mWcm-2. Power densities over the three 
samples were not identical due to varying distance from the excitation cube. See Figure 4.15 for 
images with consistent distances from the excitation cube. Collection was from 1000–1700 nm 
(1000 nm LP, Edmund Optics 84-776). The custom lens system consists of a 4f configuration with 
a f=750.0mm lens (Thorlabs LB1247-C) and two f=200.0mm lenses (Thorlabs LB1199-C). For 
ergonomic reasons a 2’’ protected silver-coated elliptical mirror (PFE20-P01) mounted to a 
kinematic mount (Thorlabs KCB2EC/M) was used. Images were acquired at 35 ms exposure time, 
16.65 fps. Displayed image was background subtracted and averaged over 6 frames.  
Figure 6.13C 
Stability of IR-140 in HMSNs-PEG over time. IR-140 loaded HMSNs-PEG were dispersed 
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in PBS at 0.25 mg/mL. The absorbance spectra were taken in a 3 mm path length cuvette 
immediately (day 0) and after 14 days (day 14) on a JASCO V-770 UV-Visible/NIR 
spectrophotometer. The absorbance was normalized, relative to spectrum (1). Results of the 
triplicate experiment are presented in Figure 4.16. 
Stability of IR-140 in solution over time. IR-140 J-aggregate was prepared in DMSO as 
described in Figure 6.11A. The aggregate absorbance in a 2 mm path length cuvette was obtained 
immediately (day 0) and after 17 h storage in the dark (day 1) on a JASCO V-770 UV-Visible/NIR 
spectrophotometer. The absorbance was normalized, relative to spectrum at day 0. Results are 
reproduced in triplicate in Figure 6.16.  
Figure 6.13D 
Three solutions were prepared: (a) 1 mg/mL solution of HMSNs-PEG containing IR-140 (b) 
0.01 mg/mL IR-140 in 35% DMSO/0.9% NaCl solution, and (c) 0.01 mg/mL IR-140 in DMSO. 
Each solution (400 µL) was irradiated with 97 ± 3 mWcm-2 of 980 nm (a and b) and 785 nm (c) 
light and their emission was monitored by a SWIR camera. Acquisition settings were 2 fps and (a) 
25 ms, (b) 15 ms, and (c) 0.3 ms. Excitation and emission settings were identical to Figure 6.13B. 
Error represents the standard deviation of three measurements.  
Figure 6.14 
Samples were prepared as by dissolving 0.02 mg IR-140 in DMSO, and then adding to the 
appropriate aqueous phase (either MilliQ water, 1x PBS, or 0.9% NaCl in water) and shaking 
vigorously. The appropriate volumes of DMSO and aqueous phase were used to sum to 2.0 mL for 
each listed percentage. For the 0% DMSO traces, IR-140 is at its solubility limit, after sonicating 
0.02 mg IR-140 in 1.0 mL of the appropriate solvent for 4 hours. Absorbance traces were measured 
in a 3.0 mm cuvette with blanking to the appropriate solvent mixture on a JASCO V-770 UV-
Visible/NIR spectrophotometer. 
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Figure 6.15 
Samples were prepared and excitation and acquisition was performed as described in Figure 
6.13B. Absorbance traces were acquired on a Shimadzu UV-1800 UV-Visible Scanning 
Spectrophotometer. 
Figure 6.16 
IR-140 loaded HMSNs-PEG, obtained as described in 6.5.8 “PEG conjugation on the surface 
of IR-140 loaded HMSNs-APTS,” were dispersed in PBS (0.25 mg/mL). The absorbance spectra 
were taken in a 3 mm path length cuvette immediately (day 0) and after 14 days storage in the dark. 
IR-140 J-aggregate in solution was prepared by dissolving 0.02 mg IR-140 in 700 µL DMSO, and 
subsequently adding 1.3 mL 0.9% NaCl and briskly shaking. The aggregate absorbance in a 2 mm 
path length cuvette was obtained immediately and after 24 h storage in the dark. 
Figure 6.17A 
Deoxygenated IR-140 solution J-aggregates were prepared by adding 1.4 mL DMSO to 0.04 
mg IR-140 in a purged dram vial, followed by 2.6 mL 0.9% NaCl solution in water and shaking. 
Solvents were deoxygenated by purging with N2 for at least one hour. Oxygenated IR-140 solution 
J-aggregates were prepared analogously, but with solvents which had been exposed to air. 
Solutions (4 mL), sealed with septa, were irradiated for 20 min. The optical parameters for 
experiment in (A) consisted of the following: a 4-inch square first-surface silver mirror (Edmund 
Optics, 84448) was used to direct the emitted light through a custom filter set (Edmund optics #84-
776, TL) to an Allied Vision Goldeye G-032 Cool TEC2 camera at -20 °C, equipped with a C-
mount camera lens (Navitar, SWIR-35). Excitation light was passed through a positive achromat 
(Thorlabs AC254-050-B), 1000 nm shortpass filter (Thorlabs FESH 1100), and an engineered 
diffuser (Thorlabs ED1-S20-MD) to provide uniform illumination over the working area. 
Exposure time used was 100 ms, with 2 fps. 
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Figure 6.17B 
IR-140 containing HMSNs-PEG were prepared according to 6.5.7 “Loading of IR-140 in 
HMSNs, HMSNs-APTS, or dSiO2@MSNs” and 6.5.8 “PEG conjugation on the surface of IR-140 
loaded HMSNs-APTS”. Deoxygenated solutions were purged with N2 for at least 30 min, while 
oxygenated were left open to air. Both sample types (1 mg/L, 0.40 mL), sealed with septa, were 
irradiated for 20 minutes. The optical parameters for experiment in (B) consisted of the following: 
a 4-inch square first-surface silver mirror (Edmund Optics, 84448) was used to direct the emitted 
light through a custom filter set (Edmund optics #84-776, 3x FELH1000,) to an Allied Vision 
Goldeye G-032 Cool TEC2 camera at -20 °C, equipped with a C-mount camera lens (Navitar, 
SWIR-35). Excitation light was passed through a positive achromat (Thorlabs AC254-050-B), 
1000 nm shortpass filter (Thorlabs FESH 1000), and an engineered diffuser (Thorlabs ED1-S20-
MD) to provide uniform illumination over the working area. Exposure time used was 200 ms, with 
2 fps.  
Data were analyzed analogous to that discussed in Note 6.5.13.4, however only the relative 
rates between oxygenated and deoxygenated experiments were calculated and evaluated. 
Figure 6.18 
The viabilities of HeLa cells after the treatment of IR-140 loaded HMSNs-PEG were 
examined by using a cell counting kit-8 (CCK-8) assay. The cells were seeded in 96-well plates at 
a density of 5 x 103 cells per well in 200 µL DMEM supplemented with 10% FBS and 1% 
antibiotics in a humidity-controlled incubator at 37 °C for 24 h attachment. After the attachment, 
the medium was removed and the cells were incubated in 200 µL fresh DMEM containing 0, 2, 5, 
10, 15, 20, and 40 µg of IR-140 loaded HMSNs-PEG (i.e. 0, 10, 25, 50, 75, 100, and 200 µg/mL) 
for 3 or 6 h in an incubator at 37 °C. After incubation, the medium was removed and the treated 
cells were washed with DPBS 1 time (200 µL). To measure the cell viability, 100 µL of DMEM 
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and 10 µL of CCK-8 cellular cytotoxicity reagent were added to each well. Then, the plates were 
put in the incubator for 2 h at 37 °C. To measure the number of the viable cells in each condition, 
a plate reader (Tecan M1000) was used to measure the absorbance at 450 nm and 650 nm (as a 
reference). The DMEM (100 µL) mixed with CCK-8 reagent (10 µL) served as a background 
control. 
Figure 6.19 
The IR-140 HMSNs-PEG in PBS were sonicated (Elma S15 Elmasonic) for 30 mins prior to 
injection and filtered through a 40 µm nylon filter. 200 µL of the IR-140 HMSNs-PEG in PBS 
were injected via the tail vein and immediately imaged. The excitation flux (980 nm) had an 
average power density of 91 ± 3 mWcm-2 over the field of view. Images were acquired at 60 ms 
exposure time and 16.65 fps, in 8-bit format. Displayed images were background subtracted with 
an average of 10-frames from the pre-injection time points, outliers were removed, and the stills 
were averaged over 5 frames. 
Figure 6.20 
Refer to Figure 6.19 experimental procedures. 
6.5.13 Supplementary Notes 
Note 6.5.13.1: Estimation of The Amount of Dye Molecules in a Single HMSN and HMSN-
PEG 
In order to calculate how many IR-140 molecules loaded in a single HMSN or HMSN-APTS, 
we need to estimate the mass of a single HMSN or HMSN-APTS using the equation: 
mamorphous silica  = 𝑉89:;<=:>?	?@A@B8	 ×	𝜌89:;<=:>?	?@A@B8          (1) 
Amorphous silica is defined as the silica in HMSNs shell excluding mesopores. The density 
(ρ) of amorphous silica is known to be 2.5 (g/cm3 amorphous silica). There are several ways to 
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estimate the volume of a single MSNs, as we have published previously.37 Here, we started to 
determine the shell volume of a single HMSN (𝑉?=DAA) from the equation below:  
𝑉?=DAA 	= EFG ×	"𝑅IG −	𝑅JG# = 𝑉9D?:<:;D + 𝑉89:;<=:>?	?@A@B8     (2) 𝑉?=DAA 	of the HMSNs used here (Figure 6.21) was calculated to be 141961 nm3 based on equation 
(2). 𝑉9D?:<:;D  was determined to be 0.94 (cm3/g amorphous silica) from N2 adsorption-
desorption isotherm analysis.  
Although we cannot directly calculate  𝑉89:;<=:>?	?@A@B8  from the equation (2) at this point 
because 𝑉9D?:<:;D  is a function of the mass of amorphous silica, we can first determine the ratio 
( 𝑎 ) between 𝑉9D?:<:;D  and 𝑉89:;<=:>?	?@A@B8  which would facilitate determination of 𝑉89:;<=:>?	?@A@B8 .  𝑉	9D?:<:;D 	÷ 𝑉	89:;<=:>?	?@A@B8 	= 	𝑎            (3) 
From the density of amorphous silica, 1 g of amorphous silica has a volume of 0.4 cm3, and 
thus 𝑎 = 2.35, which is derived from 𝑉	9D?:<:;D/𝑉	89:;<=:>?	?@A@B8 	=	 0.94 cm3/0.4 cm3. Now, 
plug the ratio in equation (2): 𝑉?=DAA = 	𝑉	9D?:<:;D 	+ 𝑉	89:;<=:>?	?@A@B8 = 2.35	𝑉	89:;<=:>?	?@A@B8 + 𝑉	89:;<=:>?	?@A@B8	 																																																																							= 3.35	𝑉	89:;<=:>?	?@A@B8          (4) 
From above, we determine that the percentage (𝑏) of 𝑉	89:;<=:>?	?@A@B8 occupying 𝑉?=DAA  is: 
(𝑉	89:;<=:>?	?@A@B8 	÷ 	𝑉?=DAA) 	× 	100	% = 𝑏       (5) 𝑏  was calculated to be 30%. Since we already calculated 𝑉?=DAA  to be 141961 nm3, 𝑉	89:;<=:>?	?@A@B8 was then determined to be 42446 nm3 from (5). The mass of a single HMSN 
(mamorphous silica) was then calculated by plugging in 𝑉	89:;<=:>?	?@A@B8 in the equation (1), which 
was determined to be 1.06	× 	10/IT (g). 
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To estimate the amount of dye molecules in a single HMSN, the average loading capacities 
of IR-140 in HMSNs (5.9	± 1.2 %, 8.9 ± 1.1 %, and 22.9 ± 2.8 % with 5 mM, 10 mM, and 20 
mM IR-140 as the loading solution, respectively) were used to determine the mass of IR-140 
loaded in a single HMSN. Then, the number of IR-140 molecules loaded in a single HMSN could 
be calculated as: 
number of IR-140 molecules loaded in a single HMSN = [(the loading capacity of IR-140 in 
HMSNs)	× mamorphous silica  ÷ molecular weight of IR-140] ×	𝑁W                  (6) 
where 𝑁W is the Avogadro’s constant. For example, using equation (6), with 5 mM IR-140, the 
number of IR-140 molecules loaded in a single HMSN was then determined to be 4.87 × 10G ± 
0.99 × 10G molecules. The number of IR-140 molecules loaded in a single HMSN with 10 and 
20 mM IR-140 were 7.35 × 10G ± 0.91 × 10G and 1.89 × 10E ± 0.23 × 10E, respectively. 
By applying the above calculation to HMSNs-APTS, we can also estimate how many IR-140 
molecules were loaded in a single HMSN-APTS. Given that 𝑉	9D?:<:;D	of HMSNs-APTS is 0.73 
cm3/g, the mass of a single HMSN-APTS is calculated to be 1.26 × 10/IT g. 
Given that the loading capacity of IR-140 in HMSN-APTS is 6.6 ± 2.5 %, 10.2 ± 1.8 %, 
and 21.6	± 1.5 % with 5, 10, and 20 mM IR-140, respectively, the number of IR-140 molecules 
loaded in a single HMSN-APTS were estimated to be 6.43 × 103	± 2.44 × 10G, 9.94 × 103 ± 1.76 × 10G, and 2.10 × 104 ± 0.15 × 10E, respectively. 
Note 6.5.13.2: Absorption Coefficients 
Absorption coefficients were calculated according to the Lambert - Beer-Lambert law,  𝐴 = 	𝜀𝑙𝑐  (7) 
where A represents absorbance (unitless), 𝜀  the absorption coefficient (M-1cm-1), 𝑙  the path 
length (cm), and c the concentration (M). Masses were determined on a microbalance and diluted 
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using Hamilton microsyringes to concentrations within the linear range of the UV-Vis-NIR 
spectrophotometer. Four concentrations were obtained for each experiment and the reported error 
represents the standard deviation of three measurements.  
The monomer absorption coefficient was straightforward as only one species is present in 
solution. These data were collected using a 10 mm quartz cuvette in DMSO. The raw data was 
corrected for non-linearity between gratings, and baseline corrected to 478 nm. The absorption 
coefficient at all relevant wavelengths is displayed below in Figure 6.22. The absorption 
coefficient at λmax,abs = 826 nm was 1.7 ± 0.1 x 105 M-1cm-1.  
The J-aggregate absorption coefficient is more complex due to the requirement of high 
concentrations for selective formation of the J-aggregate over the monomer. As a result, to use 
higher concentrations, yet stay in the linear range of the spectrometer, these data were collected 
using a 3 mm cuvette. The raw data were baseline corrected to 449 nm and are included below in 
Figure 6.23. The uncorrected absorption coefficient (εraw) at λmax,abs = 1043 nm was 3.3 ± 0.3 x 105 
M-1cm-1.  
Despite the higher concentrations, some monomer remained in solution. The uncorrected data 
can be corrected for the remaining monomer in solution using the absorption coefficient of the 
monomer at its λmax,abs and making the assumption that the absorption coefficient of the monomer 
does not change significantly between 100% DMSO and 35% DMSO/0.9% NaCl in water. We 
used the equation: 𝛼9 + 𝑎] = 1  (8) 
where αm represents the mole fraction of monomer and αj the mole fraction of J-aggregate. The 
value αm for each absorbance trace was obtained using the Beer-Lambert law from the absorption 
coefficient of the monomer and the known concentration of total dye. The value 𝑎] was then used 
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as a multiplicative factor to correct the concentration of J-aggregate in solution. The absorption 
coefficient was then recalculated with the corrected concentration values. The corrected absorption 
coefficient at λmax,abs = 1043 nm was 3.9 ± 0.4 x 105 M-1cm-1. Error was taken as the standard 
deviation of the three replicates. The corrected absorption coefficient is displayed below in Figure 
6.24.  
Note 6.5.13.3: Quantum Yield 
The photoluminescence quantum yield (Φ_)	of a molecule or material is defined as follows, Φ_ = `a	`b   (9) 
where PE and PA are the number of photons absorbed and emitted, respectively. To determine the 
quantum yield, we either use a relative method with a known standard in the same region of the 
electromagnetic spectrum, or an absolute method, in which the number of photons absorbed and 
emitted are measured independently. Here, due to the limits of our petite integrating sphere (Horiba 
KSPHERE-Petite with InGaAs detector Horiba Edison DSS IGA 020L), we use a relative method, 
with IR-26 as the known standard.  
The quantum yield was measured at three different excitation wavelengths, 885 nm, 900 nm, 
and 915 nm and the results were averaged to obtain the value reported.  
To compare an unknown to a reference with a known quantum yield, the following 
relationship was used:  Φ_,d = 	Φ_,;(𝑚d 𝑚f⁄ )(𝜂dJ 𝜂;J⁄ )  (10) 
Where m represents the slope of the line (y = mx + b) obtained from graphing integrated 
fluorescence intensity versus optical density across a series of samples, 𝜂 is the refractive index 
of the solvent, and the subscripts x and r represent values of the unknown and reference, 
respectively. 
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The (Φ_,;) of IR-26 was taken to be 0.05 ± 0.03%, as we have previously measured38, and 
which agrees with several recent measurements.[6,9]   
To obtain a plot of integrated fluorescence intensity versus absorbance for the reference and 
unknown, five solutions and a solvent blank were prepared and their absorbance and emission 
spectra were acquired. IR-26 was diluted in dichloroethane to concentrations with optical densities 
less than 0.1 to minimize effects of reabsorption. The baseline corrected (to 1500 nm) fluorescence 
traces were integrated from 950 – 1500 nm, and the raw integrals were corrected by subtracting 
the integral over an identical range from fluorescence traces of the blank solvent (Figure 6.25A). 
The methods employed here were validated with comparison of IR-26 to IR-1061, giving a Φ_ value of 0.3 ± 0.2 %, which is in agreement with our prior absolute quantum yield 
measurement,[8] but with lower precision due to the uncertainty in IR-26 absolute Φ_ . 
The IR-140 J-aggregate was prepared as described in Figure 6.13A, in 35% DMSO/0.9% 
NaCl in water. Due to the necessity of using concentrated samples for IR-140 to remain in the J2 
aggregate state, high concentrations of IR-140 J-aggregate were used for quantum yield 
measurements (the OD with a 2 mm path length at the relevant excitation wavelengths ranged from 
0.07 – 0.16). The baseline corrected (to 1400 nm) fluorescence traces of the optically dense IR-
140 J-aggregate samples were corrected for reabsorption by the relationship,  
𝐼(𝜆) = 𝐼:(𝜆)[−ln	(10/no(p)) (1 − 10/no(p))⁄ ]  (11) 
where 𝐼(𝜆)  and 𝐼:(𝜆)  are the corrected and experimental fluorescence intensities at each 
wavelength, and 𝑂𝐷(𝜆) is the optical density of the sample at the corresponding wavelength. The 
corrected fluorescence traces were then integrated from 965 nm – 1400 nm, and the raw integrals 
were corrected by subtracting the integral over an identical range from fluorescence traces of the 
blank solvent.  
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The integrated fluorescence intensities were then plotted against the baseline corrected 
absorbance values at the relevant wavelength, and the slope and error in slope were obtained (R2 
> 0.95 for all traces) (Figure 6.25B).   
The refractive index for DCE was taken as 1.44039, while that of the 35% DMSO/0.9% NaCl 
solution in water was approximated as a binary mixture of 35% DMSO in water and taken to be 
1.383.40 Both values were designated to have a precision to ± 0.001. 
The average quantum yield value (over 885 nm, 900 nm, and 915 nm excitations) was 
calculated to be 0.012 ± 0.007. Errors were propagated from the error in IR-26 Φ_	(± 0.03)[8], 
slope of the integrated fluorescence intensity versus optical density plot (unique for each trace, but 
ranged from 7-10% of the slope value), and refractive indices (± 0.001).  
For quantum yield measurements, fluorescence traces were acquired with ex. 885 nm, 900 
nm, and 915 nm with a 950 nm shortpass filter (Thorlabs FESH0950) and collection from 950–
1400 nm for IR-140 J-aggregate and 950–1500 for IR-26. The slits were 5.76 mm for excitation 
and 11.52 mm for emission. The step size used was 1.0 nm, integration time 0.1 s, and traces were 
acquired after an automatic detector background subtraction, and with the default excitation 
correction. All absorbance and fluorescence traces were taken in a 10 mm x 2 mm path length 
cuvette. For absorbance traces, the 2 mm path length was used, while emission traces were 
acquired with 10 mm at the excitation side and 2 mm on the emission side, with emission detection 
occurring at 90° from excitation. 
Note 6.5.13.4: Photobleaching Rates 
All photobleaching data were fit to a mono-exponential decay and the rate constants were 
obtained from the first order reaction equation:  ln[𝐴] = 	−𝑘𝑡 + ln	[𝐴]:	  (12) 
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where A and Ao represent the emission collected at time t and the initial emission collected, 
respectively. All R2 values were > 0.96. Error bars represent the standard deviation of three 
measurements. If a change in slope occurred in the ln[A] values (i.e. in the IR-140 J-aggregate 
bleaching in 35% DMSO/0.9% NaCl in water solution), the rate was taken as the initial rate and 
the lines were fit only to the linear region (Figure 6.26). This analysis conservatively estimates 
the photobleaching rate of the solution phase aggregate as slower than it appeared in subsequent 
time points (see Figure 6.13D).  
To compare photobleaching rates between samples irradiated at distinct wavelengths, it is 
necessary to consider the relative number of photons absorbed by each species. This requires 
corrections for (1) the difference in photon energy between the two wavelengths, and (2) the 
difference in photons absorbed by the two samples. 
To account for photons of different energy, we go back to the common unit of number of 
photons per second per surface unit Np, (cm-2s-1). This value can be obtained by first calculating 
energy of a photon Ep, (J) at the wavelength of irradiation: 
𝐸< = =Bp   (13) 
where h is Planck’s constant, and c the speed of light. The Np can then be found from the irradiance 
I (Wcm-2) and Ep by the following equation:  
𝑁< = wxy  (14) 
The Np for 980 nm and 785 nm light is 4.8 x 1017 and 3.8 x 1017 cm-2s-1, respectively.  
To account for the difference in photons absorbed, we use the absorption coefficients at the 
wavelength of irradiation, 𝜆ex. For the IR-140 J-aggregate, the corrected absorption value was 
used. The absorption coefficient of IR-140 in HMSNs-PEG was taken to be that of the J-aggregate 
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in solution. The relative values of 𝑁<	 × 	𝜀	can then be compared to obtain a ratio, X for each 
wavelength,   X{|} = (𝑁<,{|} 	×	ε9) (𝑁<,|* 	×	ε]⁄ )  (15) X|* = (𝑁<,|* 	×	ε]) (𝑁<,|* 	×	ε]⁄ )  (16) 
where ε9  and ε]  represent the aborbance coefficient of the monomer and J-aggregate, 
respectively, at their appropriate excitation wavelength, 𝜆ex. The ratio X785 was calculated to be 
0.998, providing a correction factor for the relative number of photons absorbed per second in the 
785 nm experiment compared to the 980 nm experiments, while the ratio X980 is 1.000. These 
values can be related to the relative rate, krel by the equation:  𝑘;DA =  	 	 (17)	
The relative rates with intermediate values used in the calculations are listed below in Table 6.3. 
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6.7 Schemes, Figures and Tables 
 
 
Scheme 6.1. Synthesis of hollow mesoporous silica nanoparticles (HMSNs). 
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Scheme 6.2. Synthesis of IR-140-loaded HMSN-PEG. A) Overall synthesis starting from Stöber spheres. 
B) Detailed schematic of conjugation of PEG to the surface of HMSN-APTS. Note that we believe the 
APTS modification is only on the outer surface due to the Stöber silica sphere blocking the inner surface 
and the CTAC surfactant blocking the pores. 
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Figure 6.1. (A) Regions of the electromagnetic spectrum employed for optical imaging. For further details 
on contrast and resolution within regions of the SWIR see references 1bc; 8b-c. (B) J-aggregation and 
characteristic photophysical properties. (C) IR-140. (D) Work reported herein: the stabilization of IR-140 
J aggregates in hollow mesoporous silica nanoparticles (HMSNs) to result in biocompatible SWIR-emissive 
contrast agents. 
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Figure 6.2. TEM images of (A) Stöber silica spheres, (B) dSiO2@MSNs, and (C) HMSNs. The 
nanoparticles were dispersed in ethanol at a concentration of 0.1 mg/mL. TEM images were measured on 
a Tecnai T12 instrument with an operating voltage of 120 kV. 
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Figure 6.3. (A) Schematic of loading IR-140 into HMSNs. (B) Washing conditions facilitate J-aggregation. 
10 mg/mL HMSNs were combined with 10 mM IR-140 in DMSO and washed with PBS with (green) and 
without (dark blue) sonication. Pre-wash spectrum, diluted 1:350 is shown in orange. Loading control for 
solid, non-porous Stöber spheres is shown in gray. (C/D) Transmission electron microscopy images of 
HMSNs with (D) and without (C) IR-140 treatment. 
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Figure 6.4. UV/Vis/NIR spectra of HMSNs or dSiO2@MSNs containing IR-140. The loading 
concentrations of IR-140 were (A) 20 mM and (B) 5 mM; HMSNs or dSiO2@MSNs were loaded at 10 
mg/mL. The HMSNs particles were washed by methods (a, PBS with sonication, teal), (b, PBS, blue), or 
(c, water, gray) (5x, 1 mL), or the dSiO2@MSNs were washed by method (b, PBS, magenta) (see Section 
II, synthetic procedures). The absorbance spectra were measured with 10 mm quartz cuvettes at 0.25 mg 
nanoparticles/mL in PBS. 
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Figure 6.5. Control experiment with Stöber silica spheres. (A) The zeta potential of Stöber silica spheres 
(black), and Stöber silica spheres-APTS (red) in D.I. water at 0.05 mg/mL at room temperature. In the case 
of the APTS-modified Stöber spheres, we believe the surface is saturated with APTS as higher 
concentrations of APTS did not significantly change the zeta potential. (B/C/D) UV/Vis/NIR spectra of 
Stöber silica spheres (black) or Stöber silica spheres-APTS (red) containing IR-140. The loading 
concentrations of IR-140 were (B) 20 mM, (C) 10 mM, or (D) 5 mM; Stöber silica spheres or Stöber silica 
spheres-APTS were loaded at 10 mg/mL. After the loading, the particles were washed with PBS (5x, 1 mL). 
The absorbance spectra were measured with 10 mm quartz cuvettes at 0.25 mg nanoparticles/mL PBS. 
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Figure 6.6. UV/Vis/NIR spectra of IR-140 loaded HMSNs, Stöber silica spheres, Stöber silica spheres-
APTS, or dSiO2@MSNs. The loading concentrations of IR-140 were 10 mM; HMSNs, Stöber silica spheres, 
Stöber silica spheres-APTS, or dSiO2@MSNs were loaded at 10 mg/mL. After the loading, the particles 
were gently washed with PBS (5x, 1 mL). The absorbance spectra were measured with 10 mm quartz 
cuvettes at 0.25 mg nanoparticles/mL in PBS. 
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Figure 6.7. The loading capacity, defined as (grams IR-140/grams HMSNs or HMSNs-APTS) x 
100%, of IR-140 in HMSNs (black) or HMSNs-APTS (red) at different IR-140 loading 
concentrations. The loading concentration of HMSNs or HMSNs-APTS was 10 mg/mL. Error 
represents the standard deviation of three replicates. 
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Figure 6.8. Nitrogen adsorption (black)/desorption (red) isotherms of (A) HMSNs, (C) HMSNs-APTS, and 
(E) dSiO2@MSNs. The BET surface areas of HMSNs, HMSNs-APTS, and dSiO2@MSNs are 969 m2/g, 
831 m2/g, and 340 m2/g, respectively. The total pore volumes of HMSNs, HMSNs-APTS, and 
dSiO2@MSNs are 1.40 cc/g, 1.01 cc/g, and 0.39 cc/g, respectively. Pore diameter distributions of (B) 
HMSNs, (D) HMSNs-APTS, and (F) dSiO2@MSNs. The average pore diameters are 3.2 nm, 3.1 nm, and 
3.1 nm, respectively. 
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Figure 6.9. TEM images of HMSNs with (C) and without (A) IR-140 treatment. (A) HMSNs were 
dispersed in ethanol at a concentration of 0.1 mg/mL. (C) The loading concentration of IR-140 was 10 mM; 
HMSNs were loaded at 10 mg/mL. After loading, the particles were washed with PBS (5x, 1 mL) and 
dispersed in PBS at a concentration of 0.1 mg/mL. (B) As a control, HMSNs were washed with PBS (5x, 
1mL) but without the loading of IR-140. After washing, HMSNs were dispersed in PBS at a concentration 
of 0.1 mg/mL. (D) Mixture of HMSNs with and without IR-140 treatment. The mixed particles were 
prepared by mixing HMSNs in PBS solution (50 µL, 0.2 mg/mL) with IR-140 loaded HMSNs in PBS 
solution (50 µL, 0.2 mg/mL) at the mass ratio of 1:1. TEM images were measured on a Tecnai T12 
instrument with an operating voltage of 120 kV. 
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Figure 6.10. UV/Vis/NIR spectra of HMSNs-APTS containing IR-140 for dye loading concentrations of 
20 mM (black), 10 mM (red), or 5 mM (blue) in PBS, after washing the particles with PBS (5 x 1 mL). The 
loading concentration of HMSNs-APTS was 10 mg/mL. The absorbance spectra were measured with 10 
mm quartz cuvettes at 0.25 mg nanoparticles/mL. 
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Figure 6.11. The dynamic light scattering size distribution of HMSNs-APTS (black), HMSNs-APTS 
containing IR-140 (red), and HMSNs-PEG containing IR-140 in PBS (blue) measured at 0.05 mg/mL at 
room temperature in PBS. Note that the HMSNs-APTS are not soluble in water and significant aggregation 
is observed in the DLS until after conjugation of PEG. 
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Figure 6.12. The zeta potential of HMSNs (black), HMSNs-APTS (red), HMSNs-APTS containing IR-140 
(blue), and HMSNs-PEG containing IR-140 (pink) in D.I. water at 0.05 mg/mL at room temperature.  
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Figure 6.13. (A) Normalized absorption and emission of IR-140 J-aggregate in HMSNs-PEG (blue), J-
aggregate in solution (red), and monomer (yellow). (B) Emission (1000–1700 nm) of IR-140 monomer 
(left), J-aggregate in solution (middle) and J-aggregate in HMSNs-PEG (right) upon 980 nm excitation. (C) 
Normalized relative absorption of IR-140 J-aggregate in 35% DMSO/0.9% NaCl in water (red) and in 
HMSNs-PEG in PBS (blue) on day zero (solid) and day 1 or 14 (dotted). (D) Photostability under laser 
irradiation (97 mW/cm2) at 980 nm for IR-140 J-aggregate in HMSNs-PEG (blue) and IR-140 J-aggregate 
in 35% DMSO/0.9% NaCl in water (red), and at 785 nm for monomer in DMSO (yellow). 
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Figure 6.14. UV-Vis-NIR characterization of IR-140 J-aggregate formation in solution at 0.01 mg/mL in 
(A) DMSO/water, (B) DMSO/1xPBS, and (C) DMSO/0.9% NaCl in water. 
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Figure 6.15. Emission of monomer and J-aggregate states of IR-140 under 980 nm excitation. (A) 
Absorbance traces of samples (10 mm path length) used in vial images in B and in Figure 4.13B, baseline 
corrected to 521 nm. (B) Images of IR-140 monomer in DMSO (left), IR-140 J-aggregate in solution (center) 
and J-aggregate in HMSNs-PEG (right) under 980 nm irradiation (99 ± 3 mWcm-1). All Eppendorf tubes 
are placed in the same location, such that laser intensity across all samples is identical. See Figure 4.13B 
experimental procedure for sample preparation and acquisition settings. Displayed images were background 
subtracted, averaged over 10 frames and the contrast was set to identical values for comparison. 
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Figure 6.16. Stability of J-aggregates over time, displayed as the normalized, relative absorbance remaining 
for IR-140 in HMSNs-PEG after 14 days, and IR-140 in solution after 1 day. IR-140 loaded HMSNs-PEG 
were dispersed in PBS (0.25 mg/mL), and IR-140 J-aggregate was composed of 0.01 mg/mL IR-140 in 
35% DMSO/0.9% NaCl in water. Error represents the standard deviation of three replicates. 
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Figure 6.17. Photostability of J-aggregates in the presence and absence of oxygen. (A) Raw data of IR-140 
J-aggregate in 35 % DMSO/0.9% NaCl at 0.01 mg/mL under 980 nm irradiation with 79 mWcm-2 power 
density. The relative rates of oxygenated to deoxygenated photobleaching is 7.1 to 1. (B) Raw data of 
HMSNs-PEG loaded with IR-140 at 1.0 mg/mL in 1x PBS under 980 nm irradiation with 101 mWcm-2 
power density. The relative rates of oxygenated to deoxygenated photobleaching is 1.9 to 1. Error bars 
represent the standard deviation of three replicate experiments in (A) and (B) oxygenated and two replicate 
experiments in (B) deoxygenated. Deoxygenated samples were prepared by purging with N2 for 30-60 min; 
oxygenated samples were not purged with N2. Note: The photobleaching rate of the solution IR-140 
aggregate is substantially attenuated by the removal of oxygen, (~7x) while the photobleaching of the 
HMSNs IR-140 is improved by only ~2x. These data indicate that the IR-140 loaded inside the HMSNs are 
less affected by the presence of oxygen, which may be due to a shielding of reactive oxygen species by the 
dense silica shells, as suggested previously.41   
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Figure 6.18. Cytotoxicity study of IR-140 loaded HMSNs-PEG examined by a CCK-8 assay. HeLa cells 
were incubated in 200 µL fresh DMEM containing 0, 2, 5, 10, 15, 20, and 40 µg of IR-140 loaded HMSNs-
PEG (i.e. 0, 10, 25, 50, 75, 100, and 200 µg/mL) for 3 (black) or 6 (red) hours at 37 °C. The viable cells in 
each condition was determined by the absorbance at 450 nm and 650 nm (as a reference). The DMEM (100 
µL) mixed with CCK-8 reagent (10 µL) served as a background. Error bars represent the standard deviation 
of three replicate experiments. 
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Figure 6.19. Whole-mouse imaging at 16 fps (980 nm, 91 mW/cm2 excitation; 1000–1700 nm collection) 
upon i.v. delivery of IR-140 HMSNs-PEG. Background subtracted stills were averaged over 5 frames at 3 
s (A), 8 s (B), 25 s (C), and 120 s (D) post injection. Scale bar represents 1 cm. Data are representative of 
two replicate experiments. 
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Figure 6.20. Images from the front (A/C) and left side (B/D) of a nude mouse directly after vascular 
clearance (>2 m post injection) (A/B), and after 50 minutes (C/D), showing uptake of IR-140 loaded 
HMSNs-PEG in the liver and spleen. Images were acquired with 60 ms exposure time at 16.65 fps with 
980 nm ex. (91 ± 3 mW/cm2) and 1000–1700 nm detection (see general experimental procedures, section 
I, for details of optical set up). Displayed images were background subtracted, averaged over 5 frames, 
outliers were removed, and the contrast was set to identical values for comparison. Regions of interest were 
defined and applied to quantify the intensity in the liver (A/C) and spleen (B/D) over time. Scale bar 
represents 1 cm. (E) Quantification of signal for liver and spleen showing no significant change in signal 
over 50 minutes. Error bars represent the standard deviation over the regions of interest. Data are 
representative of two replicate experiments. 
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Figure 6.21. HMSN or HMSN-APTS used in this work. 𝑅I and 𝑅J	are the outer radius and inner radius 
of HMSN or HMSN-APTS, respectively. 𝑉?=DAA is the shell volume of a single HMSN. 𝑉9D?:<:;D  is the 
volume of the mesopores in the shell. 𝑉89:;<=:>?	?@A@B8  is the volume of silica in the shell excluding 
mesopores. 
 
 
 
Figure 6.22. Absorption coefficient of IR-140 monomer in DMSO.  
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Figure 6.23. Uncorrected absorption coefficient of IR-140 J-aggregate in 35% DMSO/0.9% NaCl in water.  
 
 
 
Figure 6.24. Corrected absorption coefficient of IR-140 J-aggregate in 35% DMSO/0.9% NaCl in water.  
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Figure 6.25. Solvent corrected integrated fluorescence intensity versus absorbance plots for (A) IR-26 and 
(B) IR-140 J-aggregate, also corrected for reabsorption.  
 
 
 
Figure 6.26. Photobleaching data plotted as the ln[A] vs time and the corresponding linear fits. 
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Table 6.1. Photophysical characterization of 1 (IR-140) 
Species λmax,abs (nm) ε (M-1cm-1) λmax,em (nm) Φ (%) 
1 monomer a 826 1.7 ± 0.1 x 105 875 2042 
1 J-aggregate b 1042 3.9 ± 0.4 x 105 1043 0.012 ± 0.007 
a in DMSO 
b in 35% DMSO/0.9% NaCl in water 
 
Table 6.2. Photobleaching rates of IR-140 (1) 
Species 𝜆ex (nm) kraw (s-1) x 103 krel (s-1) x 103 Relative stability 
1 monomer 785 19.54 ± 0.04 19 ± 1 1 
1 J-aggregate 980 1.276 ± 0.008 1.28 ± 0.05 15 ± 1 
1 in HMSNs-PEG 980 0.317 ± 0.002 0.32 ± 0.01 62 ± 5 
 
Table 6.3. Photobleaching rates and values used in calculations and corrections 
Sample	
𝝀ex	
(nm)	
Fluence	
(mWcm-2)	
kraw	(s-1)	x	
103	 ε	at	λi	(M-1cm-1)	x	10-5	 Np	 krel	(s-1)	x	103	 Relative	stability	
1	monomer	 785	 97	±	3	 19.54	±	.04	 1.18 ± 0.07  3.83 x1017 19	±	1	 1	
1	J-aggregate	 980	 97	±	3	 1.276	±	0.008	 0.95	±	0.04	 4.79 x 1017 1.28	±	0.05	 15	±	1	
1	in	HMSNs-PEG	 980	 97	±	3	 0.317	±	0.002	 0.95	±	0.04	 4.79	x	1017	 0.32 ±0.01 62	±	5	
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